<html class="gs_el_sm gs_pfcs"><head><title>‪Chloe Orkin‬ - ‪Google Scholar‬</title><meta http-equiv="Content-Type" content="text/html;charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="referrer" content="origin-when-cross-origin"><meta name="viewport" content="width=device-width,initial-scale=1,minimum-scale=1,maximum-scale=2"><meta name="format-detection" content="telephone=no"><link rel="shortcut icon" href="/favicon.ico"><link rel="canonical" href="https://scholar.google.com/citations?user=OB_eiO0AAAAJ&amp;hl=en"><meta name="description" content="‪Professor of HIV Medicine , Queen Mary University of London‬ - ‪‪Cited by 10,744‬‬ - ‪HIV‬"><meta property="og:description" content="‪Professor of HIV Medicine , Queen Mary University of London‬ - ‪‪Cited by 10,744‬‬ - ‪HIV‬"><meta property="og:title" content="Chloe Orkin"><meta property="og:image" content="https://scholar.google.com/citations/images/avatar_scholar_256.png"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>html,body,form,table,div,h1,h2,h3,h4,h5,h6,img,ol,ul,li,button{margin:0;padding:0;border:0;}table{border-collapse:collapse;border-width:0;empty-cells:show;}html,body{height:100%}#gs_top{position:relative;box-sizing:border-box;min-height:100%;min-width:964px;-webkit-tap-highlight-color:rgba(0,0,0,0);}#gs_top>*:not(#x){-webkit-tap-highlight-color:rgba(204,204,204,.5);}.gs_el_ph #gs_top,.gs_el_ta #gs_top{min-width:320px;}#gs_top.gs_nscl{position:fixed;width:100%;}body,td,input,button{font-size:13px;font-family:Arial,sans-serif;line-height:1.24;}body{background:#fff;color:#222;-webkit-text-size-adjust:100%;-moz-text-size-adjust:none;}.gs_gray{color:#777777}.gs_red{color:#dd4b39}.gs_grn{color:#006621}.gs_lil{font-size:11px}.gs_med{font-size:16px}.gs_hlt{font-weight:bold;}a:link{color:#1a0dab;text-decoration:none}a:visited{color:#660099;text-decoration:none}a:hover,a:hover .gs_lbl{text-decoration:underline}a:active,a:active .gs_lbl,a .gs_lbl:active{color:#d14836}.gs_el_tc a:hover,.gs_el_tc a:hover .gs_lbl{text-decoration:none}.gs_pfcs a:focus,.gs_pfcs button:focus,.gs_pfcs input:focus,.gs_pfcs label:focus{outline:none}.gs_a,.gs_a a:link,.gs_a a:visited{color:#006621}.gs_a a:active{color:#d14836}a.gs_fl:link,.gs_fl a:link{color:#1a0dab}a.gs_fl:visited,.gs_fl a:visited{color:#660099}a.gs_fl:active,.gs_fl a:active{color:#d14836}.gs_fl{color:#777777}.gs_ctc,.gs_ctu{vertical-align:middle;font-size:11px;font-weight:bold}.gs_ctc{color:#1a0dab}.gs_ctg,.gs_ctg2{font-size:13px;font-weight:bold}.gs_ctg{color:#1a0dab}a.gs_pda,.gs_pda a{padding:7px 0 5px 0}.gs_alrt{background:#f9edbe;border:1px solid #f0c36d;padding:0 16px;text-align:center;box-shadow:0 2px 4px rgba(0,0,0,.2);border-radius:2px;}.gs_spc{display:inline-block;width:12px}.gs_br{width:0;font-size:0}.gs_ibl{display:inline-block;}.gs_scl:after{content:"";display:table;clear:both;}.gs_ind{padding-left:8px;text-indent:-8px}.gs_ico,.gs_icm{display:inline-block;background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png);background-position:-23px -161px;background-size:169px;width:21px;height:21px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_ico,.gs_icm{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);}}.gs_el_ta .gs_nta,.gs_ota,.gs_el_ph .gs_nph,.gs_oph{display:none}.gs_el_ta .gs_ota,.gs_el_ph .gs_oph{display:inline}.gs_el_ta div.gs_ota,.gs_el_ph div.gs_oph{display:block}.gs_sth_g{visibility:hidden;max-height:0;}.gs_sth_vis .gs_sth_g{max-height:1000px;}.gs_sth_vis .gs_sth_b{position:fixed;top:0;}@keyframes gs_anm_spin{0%{transform:rotate(0deg);}100%{transform:rotate(360deg);}}.gs_rimg{display:block;background-color:#e5e5e5;border-radius:50%;overflow:hidden;position:relative;z-index:1;}.gs_rimg>img{position:absolute;margin:auto;left:0;top:0;bottom:0;right:0;}.gs_in_txtw{display:inline-block;vertical-align:middle;}.gs_in_txtb{display:block;}.gs_in_txt{color:#000;background-color:#fff;font-size:16px;box-sizing:border-box;height:29px;line-height:23px;border:1px solid #d9d9d9;border-top-color:#c0c0c0;padding:3px 6px 1px 8px;border-radius:1px;outline:none;-webkit-appearance:none;-moz-appearance:none;}.gs_el_tc .gs_in_txt{font-size:18px;}.gs_in_txtb .gs_in_txt{width:100%;}.gs_in_txt:hover{border-color:#b9b9b9;border-top-color:#a0a0a0;box-shadow:inset 0 1px 2px rgba(0,0,0,.1);}.gs_in_txte .gs_in_txt{border-color:#dd4b39;}.gs_in_txt:focus{border-color:#4d90fe;box-shadow:inset 0 1px 2px rgba(0,0,0,.3);}.gs_in_txt:disabled{color:#b8b8b8;border-color:#f1f1f1;box-shadow:none;}.gs_in_txtm .gs_in_txt{font-size:13px;height:24px;line-height:16px;padding:3px 6px;}.gs_el_tc .gs_in_txtm .gs_in_txt{height:29px;line-height:21px;}.gs_in_txts{font-size:13px;line-height:18px;color:#666;}.gs_in_txte .gs_in_txts{color:#dd4b39;}button{position:relative;z-index:1;box-sizing:border-box;font-size:13px;cursor:pointer;height:29px;line-height:normal;min-width:72px;padding:0 8px;color:#444;border:1px solid rgba(0,0,0,.1);border-radius:3px;text-align:center;background-color:#f5f5f5;-webkit-user-select:none;user-select:none;}button.gs_btn_rnd{border-radius:14px;padding:0 12px;}button.gs_btn_rnd.gs_btn_rndci{padding-left:4px;}button.gs_btn_lrge{height:41px;min-width:82px;padding:0 9px;}button.gs_btn_lrge.gs_btn_rnd{border-radius:20px;padding:0 16px;}button.gs_btn_lrge.gs_btn_rnd.gs_btn_rndci{padding-left:10px;}button.gs_btn_cir{border-radius:14.5px;min-width:29px;}button.gs_btn_lrge.gs_btn_cir{border-radius:20.5px;min-width:41px;}button.gs_btn_mini{padding:0;border:0;}.gs_el_ph button.gs_btn_mph,.gs_el_ta button.gs_btn_mta{height:41px;}button .gs_wr{position:relative;display:inline-block;width:100%;height:100%;}button .gs_wr:before{content:"";width:0;height:100%;}button .gs_wr:before,button .gs_ico,button .gs_rdt,button .gs_lbl,button .gs_icm{display:inline-block;vertical-align:middle;}button .gs_wr{font-size:13px;text-transform:none;}.gs_btn_lrge .gs_wr{font-size:15px;}.gs_btn_lsb .gs_wr{font-size:11px;font-weight:bold;}.gs_btn_lsu .gs_wr{font-size:11px;text-transform:uppercase;}.gs_btn_lrge.gs_btn_lsb .gs_wr,.gs_btn_lrge.gs_btn_lsu .gs_wr{font-size:13px;}.gs_btn_half,.gs_el_ta .gs_btn_hta,.gs_el_ph .gs_btn_hph{min-width:36px;}.gs_btn_lrge.gs_btn_half,.gs_el_ta .gs_btn_lrge.gs_btn_hta,.gs_el_ph .gs_btn_lrge.gs_btn_hph,.gs_el_ta .gs_btn_mta,.gs_el_ph .gs_btn_mph{min-width:41px;}.gs_btn_slt{border-radius:3px 0 0 3px;}.gs_btn_srt{margin-left:-1px;border-radius:0 3px 3px 0;}.gs_btn_smd{margin-left:-1px;border-radius:0;}button:hover{z-index:2;color:#222;border-color:rgba(0,0,0,.2);background-color:#f8f8f8;}button.gs_sel{background-color:#dcdcdc;}button:active{z-index:2;background-color:#f1f1f1;}button:focus{z-index:2;}button::-moz-focus-inner{padding:0;border:0}button:-moz-focusring{outline:1px dotted ButtonText}.gs_pfcs button:-moz-focusring{outline:none}a.gs_in_ib{position:relative;display:inline-block;line-height:16px;padding:6px 0 7px 0;-webkit-user-select:none;user-select:none;}a.gs_btn_lrge{height:40px;padding:0;}a.gs_in_ib .gs_lbl{display:inline-block;padding-left:21px;color:#222;}a.gs_in_ib .gs_lbl:not(:empty){padding-left:29px;}button.gs_in_ib .gs_lbl:not(:empty){padding-left:4px;}a.gs_in_ib:active .gs_lbl,a.gs_in_ib .gs_lbl:active,a.gs_in_ib :active~.gs_lbl{color:#d14836;}.gs_el_ta .gs_btn_hta .gs_lbl,.gs_el_ph .gs_btn_hph .gs_lbl,.gs_el_ta .gs_btn_mta .gs_lbl,.gs_el_ph .gs_btn_mph .gs_lbl,.gs_el_ta .gs_btn_cta .gs_lbl,.gs_el_ph .gs_btn_cph .gs_lbl{display:none;}a.gs_in_ib .gs_ico{position:absolute;top:3px;left:0;}.gs_in_ib.gs_md_li .gs_ico{left:14px;}.gs_el_tc .gs_in_ib.gs_md_li .gs_ico{top:11px;}.gs_in_ib.gs_md_li.gs_md_lix .gs_ico{top:10px;left:16px;}a.gs_btn_lrge .gs_ico{top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}.gs_in_ib .gs_ico{opacity:.55;}.gs_in_ib:hover .gs_ico{opacity:.72;}.gs_in_ib:active .gs_ico,.gs_in_ib .gs_ico:active,.gs_in_ib :active~.gs_ico{opacity:1;}.gs_in_ib:disabled .gs_ico,.gs_in_ib.gs_dis .gs_ico{opacity:.28;}.gs_in_ib.gs_btn_act .gs_ico,.gs_in_ib.gs_btn_cre .gs_ico{opacity:1;}.gs_btn_act:disabled .gs_ico,.gs_btn_cre:disabled .gs_ico{opacity:.72;}.gs_rdt{position:relative;width:0;height:21px;}.gs_rdt:before{content:"";position:absolute;top:2px;right:1px;width:5px;height:5px;border-radius:50%;background-color:#dd4b39;}button.gs_btn_flat{border-color:transparent;background-color:transparent;}button.gs_btn_flat:hover{background-color:rgba(0,0,0,.05);}button.gs_btn_flat:active{background-color:rgba(0,0,0,.1);}button.gs_btn_flat.gs_btn_flact{color:#1a0dab;}button.gs_btn_act{color:#fff;-webkit-font-smoothing:antialiased;background-color:#4d90fe;}button.gs_btn_act:hover{color:#fff;background-color:#3983fe;}button.gs_btn_act.gs_sel{background-color:#2f6bcc;}button.gs_btn_act:active{background-color:#357ae8;}button.gs_btn_cre{color:#fff;-webkit-font-smoothing:antialiased;background-color:#d14836;}button.gs_btn_cre:hover{color:#fff;background-color:#c53727;}button.gs_btn_cre.gs_sel{background-color:#992b1e;}html:not(.gs_pfcs) .gs_btn_act:focus:not(:active){box-shadow:inset 0 0 0 1px rgba(255,255,255,.5);}button.gs_btn_cre:active{background-color:#b0281a;}button:disabled,button:disabled:hover,button:disabled:active{cursor:default;color:#b8b8b8;border-color:rgba(0,0,0,.05);background-color:transparent;z-index:0;}button.gs_btn_flat:disabled{color:#b8b8b8;border-color:transparent;}button.gs_btn_act:disabled{color:#fff;background-color:#a6c8ff;}button.gs_btn_cre:disabled{color:#fff;background-color:#e8a49b;}a.gs_in_ib.gs_dis{cursor:default;pointer-events:none}a.gs_in_ib.gs_dis .gs_lbl{color:#b8b8b8;text-decoration:none}.gs_ttp{position:absolute;top:100%;right:50%;z-index:10;pointer-events:none;visibility:hidden;opacity:0;transition:visibility 0s .13s,opacity .13s ease-out;}button:hover .gs_ttp,button:focus .gs_ttp,a:hover .gs_ttp,a:focus .gs_ttp{transition:visibility 0s .3s,opacity .13s ease-in .3s;visibility:visible;opacity:1;}.gs_md_tb.gs_sel .gs_ttp{transition:none;visibility:hidden;}button.gs_btn_lrge.gs_btn_cir .gs_ttp{top:75%;}.gs_ttp .gs_aro,.gs_ttp .gs_aru{position:absolute;top:-2px;right:-5px;width:0;height:0;line-height:0;font-size:0;border:5px solid transparent;border-top:none;border-bottom-color:#595959;z-index:1;}.gs_ttp .gs_aro{top:-3px;right:-6px;border-width:6px;border-top:none;border-bottom-color:white;}.gs_ttp .gs_txt{display:block;position:relative;top:2px;right:-50%;padding:4px 6px;background:#595959;color:white;font-size:11px;font-weight:bold;line-height:normal;white-space:nowrap;border:1px solid white;border-radius:3px;box-shadow:inset 0 1px 4px rgba(0,0,0,.2);}.gs_press,.gs_in_se,.gs_tan{touch-action:none;}.gs_in_se .gs_lbl:not(:empty){padding-right:14px;}.gs_in_se .gs_icm{position:absolute;top:50%;margin-top:-5.5px;right:0;width:7px;height:11px;background-position:-21px -88px;opacity:.55;}.gs_in_se:hover .gs_icm{opacity:.72;}.gs_in_se:active .gs_icm{opacity:1;}.gs_in_se:disabled .gs_icm{opacity:.28;}.gs_el_ta .gs_btn_hta .gs_icm,.gs_el_ph .gs_btn_hph .gs_icm,.gs_el_ta .gs_btn_mta .gs_icm,.gs_el_ph .gs_btn_mph .gs_icm,.gs_el_ta .gs_btn_cta .gs_icm,.gs_el_ph .gs_btn_cph .gs_icm{display:none;}.gs_btn_mnu .gs_icm{margin-top:-3.5px;height:7px;background-position:0 -110px;}.gs_in_se.gs_btn_act .gs_icm,.gs_in_se.gs_btn_cre .gs_icm{margin-top:-3.5px;height:7px;background-position:-42px -44px;opacity:1;}.gs_btn_act:disabled .gs_icm,.gs_btn_cre:disabled .gs_icm{opacity:.72;}button.gs_btnG .gs_ico{width:21px;height:21px;background-position:-92px -253px;}button .gs_bs{position:absolute;top:50%;left:50%;margin-top:-10px;margin-left:-10px;box-sizing:border-box;width:20px;height:20px;border-radius:50%;border:2px solid #eee;border-top-color:#4d90fe;visibility:hidden;animation:gs_anm_spin .8s linear infinite;}button.gs_bsp .gs_bs{visibility:visible;transition:visibility 0s .4s;}.gs_md_d{text-transform:none;white-space:nowrap;position:absolute;top:0;left:0;border:1px solid #ccc;border-color:rgba(0,0,0,.2);background:#fff;box-shadow:0 2px 4px rgba(0,0,0,.2);z-index:1100;text-align:left;visibility:hidden;max-height:0;margin-top:-1000px;opacity:0;transition:opacity .13s,visibility 0s .13s,max-height 0s .13s,margin-top 0s .13s;}.gs_md_d.gs_vis{visibility:visible;max-height:10000px;margin-top:0;opacity:1;transition:all 0s;}.gs_el_tc .gs_md_d{transform-origin:100% 0;transform:scale(1,0);transition:opacity .218s ease-out,transform 0s .218s,visibility 0s .218s,max-height 0s .218s,margin-top 0s .218s;}.gs_el_ios .gs_md_d{-webkit-backface-visibility:hidden;}.gs_el_tc .gs_md_d.gs_ttzi{transform-origin:50% 50%;transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_ttzr{transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_vis{transform:scale(1,1);transition:transform .218s ease-out;}.gs_md_r{position:relative;display:inline-block;}.gs_md_rmb>.gs_md_d{top:29px}.gs_md_rmbl>.gs_md_d{top:41px}.gs_md_ul{list-style-type:none;word-wrap:break-word;display:inline-block;vertical-align:top;}.gs_md_ul.gs_md_ul_tb{display:block;}.gs_md_li,.gs_in_cb.gs_md_li,.gs_md_li:link,.gs_md_li:visited{display:block;padding:6px 44px 6px 16px;font-size:13px;line-height:16px;color:#222;cursor:pointer;text-decoration:none;position:relative;z-index:0;}a.gs_md_li:hover .gs_lbl,a.gs_md_li:active .gs_lbl{text-decoration:none}.gs_el_tc .gs_md_li{padding-top:14px;padding-bottom:10px;}.gs_md_li.gs_md_lix{font-size:16px;line-height:20px;padding:12px 16px 8px 16px;}.gs_md_li:before{content:"";background-color:#f1f1f1;position:absolute;left:0;right:0;top:0;bottom:0;opacity:0;transition:opacity .13s;z-index:-1;}.gs_md_li:hover:before,.gs_md_li:focus:before{opacity:1;transition:all 0s;}a.gs_in_ib.gs_md_li .gs_lbl{color:#222}a.gs_in_ib.gs_md_li.gs_in_gray .gs_lbl{color:#444}.gs_md_li:active:before{background-color:#ddd}.gs_md_li.gs_sel,a.gs_in_ib.gs_md_li.gs_sel .gs_lbl{color:#d14836}.gs_md_d:focus,.gs_md_li:focus{outline:none}a.gs_md_lix .gs_lbl,a.gs_md_lix .gs_lbl:not(:empty){padding:0 0 0 40px;}a.gs_in_cb:link,a.gs_in_cb:visited,a.gs_in_cb:active,a.gs_in_cb:hover{cursor:pointer;color:#222;text-decoration:none;}.gs_in_cb,.gs_in_ra{position:relative;line-height:16px;display:inline-block;-webkit-user-select:none;user-select:none;}.gs_in_cb.gs_md_li{padding:6px 44px 6px 16px;}.gs_in_cb input,.gs_in_ra input{position:absolute;top:1px;left:1px;width:15px;height:15px;margin:0;padding:0;opacity:0;z-index:2;}.gs_in_ra input{top:0;left:0}.gs_el_tc .gs_in_cb input{top:9px}.gs_el_tc .gs_in_ra input{top:8px}.gs_in_cb.gs_in_cbj input{top:15px;left:15px}.gs_in_cb label,.gs_in_cb .gs_lbl,.gs_in_ra label{display:inline-block;padding-left:21px;min-height:16px;}.gs_in_cb label:empty:before,.gs_in_cb .gs_lbl:empty:before,.gs_in_ra label:empty:before{content:"\200b";}.gs_el_tc .gs_in_cb label,.gs_el_tc .gs_in_cb .gs_lbl,.gs_el_tc .gs_in_ra label{padding-top:8px;padding-bottom:5px;}.gs_in_cb.gs_in_cbj label,.gs_in_cb.gs_in_cbj .gs_lbl{padding:13px 0 12px 41px;}.gs_in_cbb,.gs_in_cbb label,.gs_in_cbb .gs_lbl{display:block;}.gs_in_cb .gs_cbx,.gs_in_ra .gs_cbx{position:absolute}.gs_in_cb .gs_cbx{top:2px;left:2px;width:11px;height:11px;border:1px solid #c6c6c6;border-radius:1px;}.gs_md_li .gs_cbx{top:8px;left:18px}.gs_el_tc .gs_in_cb .gs_cbx{top:10px}.gs_el_tc .gs_md_li .gs_cbx{top:16px}.gs_in_cb.gs_in_cbj .gs_cbx{top:15px;left:15px}.gs_el_tc .gs_in_ra .gs_cbx{top:8px}.gs_in_ra .gs_cbx{top:0;left:0;border:1px solid #c6c6c6;width:13px;height:13px;border-radius:7px;}.gs_in_cb:hover .gs_cbx,.gs_in_ra:hover .gs_cbx{border-color:#666;box-shadow:inset 0 1px 1px rgba(0,0,0,.1);}button.gs_in_cb:hover .gs_cbx{border-color:#c6c6c6;}.gs_in_cb :focus~label,.gs_in_ra :focus~label{outline:1px dotted #222;outline:auto -webkit-focus-ring-color;}.gs_pfcs .gs_in_cb :focus~label,.gs_pfcs .gs_in_ra :focus~label{outline:none;}.gs_in_cb:active .gs_cbx,.gs_in_ra:active .gs_cbx,.gs_in_cb .gs_cbx:active,.gs_in_ra .gs_cbx:active,.gs_in_cb :active~.gs_cbx,.gs_in_ra :active~.gs_cbx{border-color:#666;background-color:#ebebeb;}button.gs_in_cb:active .gs_cbx{border-color:#a6a6a6;}.gs_in_cb :disabled~.gs_cbx,.gs_in_ra :disabled~.gs_cbx,button.gs_in_cb:disabled .gs_cbx{border-color:#f1f1f1;box-shadow:none;}.gs_in_cb :disabled~label,.gs_in_ra :disabled~label{color:#b8b8b8;}.gs_in_cb.gs_err .gs_cbx{border-color:#eda29b;}.gs_in_cb .gs_chk,.gs_in_ra .gs_chk{position:absolute;z-index:1;top:-3px;left:-2px;width:21px;height:21px;}.gs_md_li .gs_chk{top:3px;left:14px}.gs_el_tc .gs_in_cb .gs_chk{top:5px}.gs_el_tc .gs_md_li .gs_chk{top:11px}.gs_in_cb.gs_in_cbj .gs_chk{top:10px;left:11px}.gs_in_ra .gs_chk{top:4px;left:4px;width:7px;height:7px;border-radius:4px;}.gs_el_tc .gs_in_ra .gs_chk{top:12px}.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -69px -67px;opacity:.62;}.gs_in_ra input:checked~.gs_chk{background-color:#666}.gs_in_cb.gs_par .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -21px -44px;opacity:.55;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk,.gs_in_cb.gs_par .gs_chk{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);background-size:169px;}}.gs_in_cb input:checked:disabled~.gs_chk{opacity:.22}.gs_in_ra input:checked:disabled~.gs_chk{background-color:#f1f1f1}.gs_ico_x{background-position:-113px -22px;opacity:.55;}.gs_ico_x:hover{opacity:.72;}.gs_ico_x:active{opacity:1;}.gs_ico_X{background-position:-71px 0;opacity:.55;}.gs_ico_X:hover{opacity:.72;}.gs_ico_X:active{opacity:1;}.gs_el_tc .gs_ico_Xt{background-origin:content-box;background-clip:content-box;padding:10px 6px 10px 14px;}.gs_ico_P{background-position:0 0;opacity:.55;}.gs_ico_P:hover{opacity:.72;}.gs_ico_P:active{opacity:1;}.gs_btnP .gs_ico{background-position:-21px 0;}.gs_btnC .gs_ico{background-position:0 -66px;}.gs_btnL .gs_ico{background-position:-92px -44px;}.gs_ico_LB{background-position:-50px -44px;height:16px;}.gs_btnJ .gs_ico{background-position:-92px -22px;}.gs_btnM .gs_ico{background-position:-92px 0;}.gs_btnMW .gs_ico{background-position:-21px -22px;}.gs_btnSB .gs_ico{background-position:0 -44px;}.gs_btnTSB .gs_ico{background-position:-115px -253px;}.gs_btnPL .gs_ico{background-position:-148px -66px;}.gs_btnPR .gs_ico{background-position:-21px -66px;}.gs_btnPLW .gs_ico{background-position:-0 -230px;}.gs_btnPRW .gs_ico{background-position:-23px -230px;}.gs_btnZI .gs_ico{background-position:-148px -22px;}.gs_btnZO .gs_ico{background-position:-127px -44px;}.gs_btnDE .gs_ico{background-position:-134px 0;}.gs_btnFI .gs_ico{background-position:-50px -66px;}.gs_btnAD .gs_ico{background-position:-141px -88px;opacity:.55;}.gs_btnAD:hover .gs_ico{opacity:.72;}.gs_btnAD:active .gs_ico,.gs_btnAD .gs_ico:active,.gs_btnAD :active~.gs_ico{opacity:1;}.gs_btnBA .gs_ico{background-position:-50px -22px;}.gs_btnADD .gs_ico{background-position:-92px -66px;}.gs_btnMRG .gs_ico{background-position:-113px 0;}.gs_btnLBL .gs_ico{background-position:0 -161px;}.gs_btnCNCL .gs_ico{background-position:-71px 0;}.gs_btnDWL .gs_ico{background-position:-28px -88px;}.gs_btnMNU .gs_ico{background-position:0 -88px;}.gs_btnMNT .gs_ico{background-position:-46px -161px;}.gs_btnALT .gs_ico{background-position:-92px -161px;}.gs_btnART .gs_ico{background-position:-115px -161px;}.gs_btnGSL .gs_ico{background-position:-69px -161px;}.gs_btnCLS .gs_ico{background-position:-138px -161px;}.gs_btnXBLU .gs_ico{background-position:-138px -253px;}.gs_btnSSB .gs_ico{background-position:0 -276px;}.gs_btnSSW .gs_ico{background-position:-23px -276px;}.gs_btnFLT .gs_ico{background-position:0 -184px;}.gs_btnXT .gs_ico{background-position:-46px -184px;}.gs_btnPD .gs_ico{background-position:-69px -184px;}.gs_btnPU .gs_ico {background-position:-92px -276px;}.gs_btnCP .gs_ico{background-position:-92px -184px;}.gs_btnTP .gs_ico{background-position:-138px -184px;}.gs_btnML .gs_ico{background-position:-115px -276px;}.gs_btnCHK .gs_ico{background-position:-71px -66px;}.gs_btnDNB .gs_ico{background-position:-115px -230px;}.gs_btnDNW .gs_ico{background-position:0 -207px;}.gs_btnACA .gs_ico{background-position:-23px -207px;}.gs_btnAPT .gs_ico{background-position:-46px -207px;}.gs_btnAPTW .gs_ico{background-position:-92px -230px;}.gs_btnAFL .gs_ico{background-position:-69px -207px;}.gs_btnAN .gs_ico{background-position:-46px -276px;}.gs_btnAI .gs_ico{background-position:-69px -276px;}.gs_btnPBL .gs_ico{background-position:-92px -207px;}.gs_btnUCT .gs_ico{background-position:-115px -207px;}.gs_btnVRF .gs_ico{background-position:-138px -207px;}.gs_btnLSI .gs_ico{background-position:-46px -230px;}.gs_btnLSG .gs_ico{background-position:-69px -230px;}.gs_btnMOR .gs_ico{background-position:-23px -253px;}.gs_btnADV .gs_ico{background-position:-46px -253px;}.gs_btnPRO .gs_ico{background-position:-69px -253px;}.gs_ico_star{background-position:-71px -44px;width:13px;height:13px;}.gs_btnPLSW .gs_ico{background-position:-138px -230px;}.gs_btnPDF .gs_ico{background-position:0 -253px;}.gs_btnS .gs_ico{background-position:-138px -276px;}.gs_btnUNS .gs_ico{background-position:0 -299px;}.gs_btnMORR .gs_ico{background-position:-23px -299px;}.gs_btnTW .gs_ico{background-position:-46px -299px;}.gs_btnIN .gs_ico{background-position:-69px -299px;}.gs_btnFB .gs_ico{background-position:-92px -299px;}#gs_hdr_drs,#gs_hdr_drw{position:fixed;top:0;left:0;width:100%;height:100%;z-index:1200;visibility:hidden;}#gs_hdr_drs{opacity:0;background-color:#fff;transition:opacity .15s,visibility 0s .15s;}.gs_el_ta #gs_hdr_drs,.gs_el_ph #gs_hdr_drs{background-color:#666;}#gs_hdr_drs.gs_vis{visibility:visible;opacity:.5;transition:opacity .15s,visibility 0s;}.gs_el_tc #gs_hdr_drs{transition:opacity .218s,visibility 0s .218s;}.gs_el_tc #gs_hdr_drs.gs_vis{transition:opacity .218s,visibility 0s;}#gs_hdr_drw{overflow:auto;width:228px;background-color:#fff;box-shadow:2px 2px 4px rgba(0,0,0,.15);outline:none;transform:translate(-100%,0);transition:transform .15s ease-in-out,visibility 0s .15s;}#gs_hdr_drw.gs_vis{visibility:visible;transform:translate(0,0);transition:transform .15s ease-in-out,visibility 0s;}.gs_el_tc #gs_hdr_drw{transition:transform .3s cubic-bezier(.4,0,.6,1),visibility 0s .3s;}.gs_el_tc #gs_hdr_drw.gs_vis{transition:transform .225s cubic-bezier(0,0,.2,1),visibility 0s;}#gs_hdr_drw.gs_abt,.gs_el_tc #gs_hdr_drw.gs_abt{transition:none;}#gs_hdr_drw_in{position:relative;box-sizing:border-box;min-height:100%;padding:0 0 8px 0;}.gs_el_ta #gs_hdr_drw_in,.gs_el_ph #gs_hdr_drw_in{padding:0 0 65px 0;}#gs_hdr_drw_top{position:relative;height:63px;border-bottom:1px solid #e5e5e5;margin-bottom:8px;}.gs_el_ta #gs_hdr_drw_top,.gs_el_ph #gs_hdr_drw_top{height:57px;}#gs_hdr_drw_mnu,#gs_hdr_drw_lgo{position:absolute;top:0;height:100%;}#gs_hdr_drw_mnu{left:0;width:55px;}#gs_hdr_drw_lgo{left:56px;}.gs_hdr_drw_sec:before{display:block;content:" ";height:0;border-bottom:1px solid #e5e5e5;margin:8px 0;}.gs_hdr_drw_sec:first-child:before{display:none;}#gs_hdr_drw_bot{display:none;}.gs_el_ta #gs_hdr_drw_bot,.gs_el_ph #gs_hdr_drw_bot{display:block;position:absolute;left:0;bottom:0;width:100%;height:65px;}#gs_hdr_drw_bot .gs_md_li:before{opacity:0;}#gs_hdr_drw_bot .gs_hdr_pp{display:block;position:absolute;bottom:14px;left:15px;pointer-events:none;}#gs_hdr_drw_bot .gs_lbl{display:block;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}#gs_hdr{position:relative;height:63px;background-color:#f5f5f5;border-bottom:1px solid #e5e5e5;display:flex;}.gs_el_ta #gs_hdr,.gs_el_ph #gs_hdr{height:57px;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_lgo,#gs_hdr_lgt,#gs_hdr_md,#gs_hdr_sre,#gs_hdr_act{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}#gs_hdr_md{flex:1 1 auto;}#gs_hdr .gs_hdr_mbo,#gs_hdr .gs_hdr_mbo,.gs_el_ta #gs_hdr .gs_hdr_dso,.gs_el_ph #gs_hdr .gs_hdr_dso{display:none;}.gs_el_ta #gs_hdr .gs_hdr_mbo,.gs_el_ph #gs_hdr .gs_hdr_mbo{display:inline-block;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_sre{width:55px;margin-right:1px;}#gs_hdr_lgo,#gs_hdr_drw_lgo{width:149px;background:no-repeat url('/intl/en/scholar/images/1x/scholar_logo_24dp.png') 0% 50%;background-size:149px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){#gs_hdr_lgo,#gs_hdr_drw_lgo{background-image:url('/intl/en/scholar/images/2x/scholar_logo_24dp.png');}}#gs_hdr_lgo{margin-right:31px;}.gs_el_ph #gs_hdr_lgo{margin-right:0;}#gs_hdr_lgt{min-width:164px;margin-right:16px;}#gs_hdr_lgt:empty{display:none;}#gs_hdr_md{margin-right:16px;min-width:1px;}#gs_hdr_lgt,#gs_hdr_md h1{padding:19px 0 0 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;font-size:20px;line-height:25px;font-weight:normal;color:#666;max-width:100%;text-align:left;}.gs_el_ta #gs_hdr_md h1,.gs_el_ph #gs_hdr_md h1{padding:16px 0 0 0;}#gs_hdr_srch{padding:14px 0 0 0;max-width:600px;}.gs_el_ta #gs_hdr_srch,.gs_el_ph #gs_hdr_srch{padding:10px 0 0 0;max-width:none;}#gs_hdr_frm{position:relative;padding-right:39px;}#gs_hdr_tsi{height:38px;border-radius:2px 0 0 2px;}#gs_hdr_tsi::-ms-clear{display:none;}#gs_hdr_tsc{display:none;position:absolute;top:3px;right:41px;width:21px;height:21px;padding:6px 10px 7px 10px;}.gs_in_acw[dir="rtl"]~#gs_hdr_tsc{right:auto;left:1px;}#gs_hdr_tsb{position:absolute;top:0;right:0;width:40px;height:38px;border-radius:0 2px 2px 0;}#gs_hdr_frm_ac{top:37px;right:40px;}.gs_el_ph #gs_hdr_frm_ac{right:0;}.gs_el_ph .gs_hdr_ifc #gs_hdr_mnu,.gs_el_ph .gs_hdr_ifc #gs_hdr_bck,.gs_hdr_src #gs_hdr_srch,.gs_hdr_src #gs_hdr_lgt,.gs_hdr_srx #gs_hdr_sre,.gs_hdr_srx #gs_hdr_md h1,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_mbo,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_dso,.gs_el_ta .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_mnu,.gs_el_ph .gs_hdr_srx #gs_hdr_bck{display:none;}.gs_el_ph .gs_hdr_ifc #gs_hdr_md,.gs_el_ph .gs_hdr_srx #gs_hdr_md{margin-left:16px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="ltr"]{padding-right:41px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="rtl"]{padding-left:41px;}.gs_el_tc .gs_hdr_tsc .gs_in_acw~#gs_hdr_tsc{display:block;}#gs_hdr_act{min-width:64px;max-width:200px;text-align:right;float:right;}.gs_el_ta #gs_hdr_act,.gs_el_ph #gs_hdr_act{display:none;}#gs_hdr_act_i,#gs_hdr_act_s{display:inline-block;padding:23px 24px 23px 16px;max-width:100%;box-sizing:border-box;font-size:13px;line-height:17px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;color:#444;}#gs_hdr_act_s{text-transform:uppercase;}.gs_el_sm #gs_hdr_act_i,.gs_el_sm #gs_hdr_act_s{padding:23px 16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ta #gs_hdr_act_s,.gs_el_ph #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_s{padding:20px 16px;}#gs_hdr_act_i:active,#gs_hdr_act_s:active{color:#d14836;}#gs_hdr_act_i,.gs_el_sm #gs_hdr_act_i{padding-top:15px;padding-bottom:16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_i{padding-top:12px;padding-bottom:13px;}#gs_hdr_act_i .gs_hdr_pp{vertical-align:top;}#gs_hdr_act_d{top:63px;left:auto;right:24px;min-width:288px;max-width:400px;}.gs_el_sm #gs_hdr_act_d{right:16px;}.gs_el_ta #gs_hdr_act_d{top:57px;}.gs_el_ph #gs_hdr_act_d{top:57px;min-width:280px;max-width:280px;max-width:90vw;}/* Account dialog body. */#gs_hdr_act_aw,#gs_hdr_act_ap,.gs_hdr_act_am,#gs_hdr_act_ab{display:block;padding:10px 20px;word-wrap:break-word;white-space:normal;}#gs_hdr_act_aw{background-color:#fef9db;font-size:11px;}#gs_hdr_act_ap,.gs_hdr_act_am{border-bottom:1px solid #ccc;}#gs_hdr_act_ap{padding:20px;}.gs_el_ph #gs_hdr_act_ap{padding:10px;}#gs_hdr_act_apb{margin-top:12px;}#gs_hdr_act_aa:link,#gs_hdr_act_aa:visited{float:right;margin-left:8px;color:#1a0dab;}#gs_hdr_act_aa:active{color:#d14836}.gs_hdr_act_am:link,.gs_hdr_act_am:visited{color:#222;text-decoration:none;background:#fbfbfb;}.gs_hdr_act_am:hover,.gs_hdr_act_am:focus{background:#f1f1f1;}.gs_hdr_act_am:active{background:#eee;}#gs_hdr_act_ab{background:#fbfbfb;padding:10px 0;display:table;width:100%;white-space:nowrap;}#gs_hdr_act_aba,#gs_hdr_act_abs{display:table-cell;padding:0 20px;}#gs_hdr_act_abs{text-align:right;}.gs_el_ph #gs_hdr_act_aba,.gs_el_ph #gs_hdr_act_abs{display:block;padding:10px;text-align:center;}.gs_el_ph #gs_hdr_act_aba button,.gs_el_ph #gs_hdr_act_abs button{width:100%;}#gs_hdr_act_a1,#gs_hdr_act_a2{position:absolute;top:-9px;right:7.5px;width:0;height:0;z-index:1;border:8.5px solid transparent;border-top:none;border-bottom-color:#333;border-bottom-color:rgba(0,0,0,.2);}#gs_hdr_act_a2{top:-8px;border-bottom-color:#fff;}.gs_hdr_act_mw #gs_hdr_act_a2{border-bottom-color:#fef9db;}.gs_hdr_pp{border-radius:50%;overflow:hidden;}#gs_hdr_act_ap .gs_hdr_pp,.gs_hdr_act_am .gs_hdr_pp{float:left;}#gs_hdr_act_ap .gs_hdr_pm{margin-left:116px;}.gs_hdr_act_am .gs_hdr_pm{margin:6px 0 0 58px;}#gs_ab{position:relative;height:41px;border-bottom:1px solid #e5e5e5;display:flex;white-space:nowrap;background-color:#fff;z-index:1000;}.gs_el_ta #gs_ab.gs_nta,.gs_el_ph #gs_ab.gs_nph{display:none;}#gs_ab_g{height:42px;}.gs_sth_vis #gs_ab{position:fixed;}#gs_ab_ico,#gs_ab_ttl,#gs_ab_md,#gs_ab_btns{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}.gs_el_ph #gs_ab_md{display:block;}#gs_ab_ico{width:55px;margin-right:1px;}#gs_ab_ico .gs_ico{position:absolute;top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}#gs_ab_ttl{min-width:172px;padding-right:8px;}.gs_el_sm #gs_ab_ttl{min-width:68px;}.gs_el_ta #gs_ab_ttl,.gs_el_ph #gs_ab_ttl{min-width:0;}#gs_ab_ttl,#gs_ab_ttll{font-size:18px;color:#666;text-transform:none;}.gs_el_sm #gs_ab_ttl,.gs_el_sm #gs_ab_ttll{font-size:16px;}#gs_ab_ttll{overflow:hidden;text-overflow:ellipsis;max-width:200px;}#gs_ab_md{flex:1 0 auto;}.gs_ab_st #gs_ab_md{flex:1 1 auto;font-size:13px;line-height:17px;padding:0 8px;color:#999;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gs_ab_st #gs_ab_md{visibility:hidden;padding:0;}#gs_ab_btns{margin-right:8px;}.gs_el_sm #gs_ab_btns{margin-right:0;}.gs_el_ta #gs_ab_btns,.gs_el_ph #gs_ab_btns{margin-right:4px;}#gs_ab_ttl:before,#gs_ab_md:before,#gs_ab_btns:before{content:"";display:inline-block;width:0;height:100%;vertical-align:middle;}#gs_ab_md>button,#gs_ab_btns>button,#gs_ab_md>.gs_in_ib,#gs_ab_btns>.gs_in_ib,#gs_ab_md>.gs_md_r,#gs_ab_btns>.gs_md_r,#gs_ab .gs_ab_mdw,#gs_ab .gs_ab_btw{margin:0 8px;vertical-align:middle;}#gs_ab .gs_ab_mdw,.gs_ab_btw{display:inline-block;margin:0;}#gs_ab_btns>.gs_in_ib{margin:0 16px 0 8px;}#gs_ab .gs_ab_btw{margin:0 12px 0 16px;}.gs_el_ta .gs_ab_sel #gs_ab_ico,.gs_el_ph .gs_ab_sel #gs_ab_ico,.gs_el_ta .gs_ab_sel #gs_ab_ttl,.gs_el_ph .gs_ab_sel #gs_ab_ttl,.gs_el_ta .gs_ab_sel #gs_ab_btns,.gs_el_ph .gs_ab_sel #gs_ab_btns{display:none;}#gs_bdy{display:table;table-layout:fixed;width:100%;}#gs_bdy_sb{vertical-align:top;width:228px;word-wrap:break-word;display:none;}.gs_el_sm #gs_bdy_sb{}.gs_el_ta #gs_bdy_sb,.gs_el_ph #gs_bdy_sb{}.gs_bdy_sb_sec{margin:0 40px 0 56px;}.gs_bdy_sb_sec:before{display:block;content:" ";height:0;margin:13px 0;border-top:1px solid #eee;}.gs_bdy_sb_sec:first-child:before{margin:21px 0 0 0;border:none;}#gs_bdy_sb ul{list-style-type:none;}.gs_bdy_sb_sec a:link,.gs_bdy_sb_sec a:visited{color:#222;}.gs_bdy_sb_sec a:active{color:#d14836;}.gs_bdy_sb_sel a:link,.gs_bdy_sb_sel a:visited{color:#d14836;text-decoration:none;}.gs_el_tc .gs_bdy_sb_sec li.gs_ind,.gs_el_tc .gs_bdy_sb_sec li.gs_ind a{padding-top:8px;padding-bottom:5px;}.gs_el_tc .gs_bdy_sb_sec:first-child li.gs_ind:first-child{margin-top:-8px;}#gs_bdy_sb .gs_ind,#gs_bdy_sb .gs_inw{margin-bottom:4px;}.gs_el_tc #gs_bdy_sb .gs_ind,.gs_el_tc #gs_bdy_sb .gs_inw{margin-bottom:0;}#gs_bdy_ccl{display:table-cell;vertical-align:top;padding:0 24px 0 16px;}.gs_el_sm #gs_bdy_ccl{padding:0 16px;}.gs_el_ta #gs_bdy_ccl,.gs_el_ph #gs_bdy_ccl{padding:0 16px;}.gs_el_ph #gs_bdy_ccl{padding:0;}#gs_ftr_sp{height:62px;}.gs_el_sm #gs_ftr_sp{height:57px;}#gs_ftr{position:absolute;bottom:0;left:0;width:100%;white-space:nowrap;border-top:1px solid #e4e4e4;background-color:#f2f2f2;display:flex;}#gs_ftr_rt{box-sizing:border-box;max-width:100%;overflow-x:auto;margin-left:auto;padding:0 12px;}.gs_el_sm #gs_ftr_rt{padding:0 8px;}.gs_el_ph #gs_ftr_rt:after{content:" ";position:absolute;top:0;right:0;width:16px;height:100%;background-image:linear-gradient(to right,rgba(242,242,242,0),rgba(242,242,242,1) 80%);}#gs_ftr_rt a{display:inline-block;line-height:16px;padding:12px;white-space:nowrap;}.gs_el_sm #gs_ftr_rt a{padding:12px 8px;}#gs_ftr_rt a:link,#gs_ftr_rt a:visited{color:#666}#gs_ftr_rt a:active{color:#d14836}#gsc_a_t{width:100%;table-layout:fixed;}#gsc_a_tr0,#gsc_a_trh{box-sizing:border-box;}#gsc_a_tr0 th.gsc_a_x,#gsc_a_tr0 th.gsc_a_t,#gsc_a_tr0 th.gsc_a_c,#gsc_a_tr0 th.gsc_a_y{height:0;}#gsc_a_trh{z-index:700;background-color:#f5f5f5;height:42px;}.gs_el_ta #gsc_a_trh,.gs_el_ph #gsc_a_trh,.gs_el_ta #gsc_a_t td,.gs_el_ph #gsc_a_t td{background-color:#fff;border-bottom:1px solid #e5e5e5;}#gsc_a_t th.gsc_a_x,#gsc_a_t th.gsc_a_t,#gsc_a_t th.gsc_a_c,#gsc_a_t th.gsc_a_y{box-sizing:border-box;text-transform:uppercase;vertical-align:middle;padding-top:0;padding-bottom:0;}#gsc_x_all{z-index:1;}.gsc_a_x,.gsc_a_t,.gsc_a_c,.gsc_a_y,.gsc_a_e{font-weight:normal;padding:16px 16px 0 16px;vertical-align:top;text-align:right;}.gsc_a_c{padding:16px 8px 0 8px;}.gs_el_sm .gsc_a_x,.gs_el_sm .gsc_a_t,.gs_el_sm .gsc_a_c{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_x,.gs_el_ta .gsc_a_t,.gs_el_ta .gsc_a_c,.gs_el_ph .gsc_a_x,.gs_el_ph .gsc_a_t,.gs_el_ph .gsc_a_c{padding:12px 8px;}.gs_el_sm .gsc_a_y{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_y{padding-bottom:12px;}.gsc_a_x{width:41px;padding:4px 0 0 0;}.gs_el_sm .gsc_a_x{padding:0;}.gsc_a_t{text-align:left;}.gs_el_ph .gsc_a_t{padding-left:16px;}#gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:16px;}.gs_el_ph #gsc_a_ta{display:none}.gs_el_ph .gsc_a_c{padding-right:16px;}th.gsc_a_c{width:64px;white-space:nowrap;}.gsc_art_sel #gsc_a_ta,.gsc_art_sel #gsc_a_ca,.gsc_art_sel .gsc_a_h{display:none;}.gsc_a_ac,.gsc_a_hc{margin-top:3px;}th.gsc_a_y{width:88px;white-space:nowrap;}.gs_el_sm th.gsc_a_y{width:58px;}.gs_el_ph th.gsc_a_y,.gs_el_ph td.gsc_a_y{width:0;padding:0;}.gs_el_ph .gsc_a_h{display:none}@media print{#gs_top th.gsc_a_y{width:58pt;}#gs_top #gsc_a_tr0{display:none}#gs_top #gsc_a_trh{position:static}}.gsc_a_e{padding:16px;text-align:center;}.gsc_a_a{padding:8px 0}.gsc_a_at{padding:8px 0;font-size:16px}a.gsc_a_acm{text-decoration:line-through;}a.gsc_a_acm:hover,a.gs_a_acm:active{text-decoration:underline;}.gsc_a_m{position:absolute;}.gs_el_ph .gsc_a_m{display:block;position:static;}.gsc_a_am{font-size:24px;position:absolute;top:-18px;left:-2px;padding:8px 12px 4px 8px;}.gs_el_ph .gsc_a_am{display:inline-block;position:static;padding:6px 16px;margin-bottom:-6px;}#gsc_a_sp{visibility:hidden;}#gsc_a_sp.gs_vis{visibility:visible;padding:16px 0;height:25px;border-bottom:1px solid #ccc;}#gsc_a_sp:after{display:block;height:100%;content:" ";background:url('/intl/en/scholar/images/spinner.gif') no-repeat 50% 50%;opacity:0;}#gsc_a_sp.gs_vis:after{opacity:1;transition:opacity 0s .4s;}#gsc_a_err{display:none;padding:28px 0;}#gsc_a_err.gs_vis{display:block;}#gsc_md_iad{width:800px;max-width:94%;}.gs_el_ph #gsc_md_iad{width:100%;max-width:100%;}#gsc_md_iad .gs_md_prg{min-height:400px;}.gs_el_ph #gsc_iads_res .gs_md_prg{margin:0 16px;}#gsc_iad_tart,.gsc_iad_tsel.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tart #gsc_iad_tgrp,.gsc_iad_tsel #gsc_iad_tgrp,#gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tart,#gsc_napb_hdr #gsc_iad_tgrp{display:none;}#gsc_iad_tgrp,.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tsel #gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tsel{display:inline-block;}#gsc_iad_t:not(.gsc_iad_tsel) #gsc_iad_tsel{pointer-events:none;color:#b5b5b5;}.gs_el_ph #gsc_napb #gsc_iads_frm{margin:0 16px;}#gsc_iads_res{position:relative;margin:8px 0 16px 0;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_md_iad #gsc_iads_res{margin:8px -16px 16px -16px;}.gs_el_ph #gsc_napb #gsc_iads_pp{margin-right:16px;}#gsc_iadb_hdr{display:table;table-layout:fixed;width:100%;}#gsc_iadb_hdr_cb,#gsc_iadb_hdr_instr{display:table-cell;vertical-align:middle;height:41px;}#gsc_iadb_hdr_cb{width:41px;}#gsc_iadb_hdr_cb:empty{width:0;}.gs_el_ph #gsc_iadb_hdr_cb:empty{width:16px;}#gsc_iadb_hdr_instr{font-size:16px;}.gs_el_ph #gsc_iadb_hdr_instr{padding-right:16px;}.gsc_oic{position:relative;}.gsc_oic_cb{font-weight:normal;border-top:1px solid #e5e5e5;border-bottom:1px solid #e5e5e5;background-color:#fcfcfc;padding-right:16px;}.gsc_oict{display:block;overflow:hidden;}.gsc_oict_name{display:block;font-size:16px;line-height:20px;word-wrap:break-word;}.gsc_oict_inf{display:block;float:right;margin-left:16px;white-space:nowrap;}.gsc_oict_all,.gsc_oict_prf{font-size:13px;text-transform:uppercase;line-height:20px;}.gsc_oict_all[data-a]{color:#1a0dab;cursor:pointer;}.gsc_oict_all[data-a]:hover{text-decoration:underline;}.gsc_oict_all[data-a]:active{color:#d14836;}.gsc_oict_prf{padding-left:8px;margin-left:8px;border-left:1px solid #e0e0e0;}.gsc_oict_prf:empty{display:none;}.gs_el_ph .gsc_oict_all,.gs_el_ph .gsc_oict_prf{float:right;clear:both;margin:0;padding:0;border:none;}.gs_el_ph .gsc_oict_prf{margin-top:2px;}.gsc_oic_res{margin:8px 0 12px 41px;}.gs_el_ph .gsc_oic_res{margin-right:16px;}.gsc_oic_res h4{font-size:13px;font-weight:normal;}.gsc_oic_dis .gsc_oic_name,.gsc_oic_dis .gsc_oic_all,.gsc_oic_dis .gsc_oic_prf{color:#777;}.gsc_oic_dis .gsc_oict_all[data-a]{color:#1a0dab;opacity:.66;}.gsc_oic_dis .gsc_oic_res{opacity:.5;}.gsc_iadb_art{border-top:1px solid #e5e5e5;overflow:hidden;}.gsc_iadb_art_cb{float:left;}.gsc_iadb_art_added{float:right;margin:12px;font-size:11px;text-transform:uppercase;color:#777;}.gs_el_ph .gsc_iadb_art_added{display:block;float:none;text-align:right;margin:8px 16px;}.gsc_iadb_art_added:empty{display:none;}.gsc_iadb_art_body{margin:12px 0 12px 41px;}.gs_el_ph .gsc_iadb_art_body{margin:12px 16px 12px 41px;}.gsc_iadb_art_body h3{font-size:13px;font-weight:normal;}.gsc_iadb_art_dis .gsc_iadb_art_body{opacity:.5;}#gsc_md_mopt,#gsc_md_cbyd,#gsc_md_cbym{width:600px;}.gs_el_ta #gsc_md_mopt,.gs_el_ta #gsc_md_cbyd,.gs_el_ta #gsc_md_cbym{width:500px;}.gs_el_ph #gsc_md_mopt,.gs_el_ph #gsc_md_cbyd,.gs_el_ph #gsc_md_cbym{width:100%;}.gsc_mob_art{vertical-align:top;padding:8px 0;}.gs_el_tc .gsc_mob_art>.gs_in_ra{margin-top:-8px;}.gsc_mob_cby{vertical-align:top;text-align:right;padding:8px 12px;position:relative;}.gsc_mob_ttl,.gsc_mob_pub{display:block;}.gsc_mob_pub{color:#666;}.gsc_mob_cbym{text-decoration:line-through}.gsc_mob_cbm{font-size:24px;position:absolute;padding:4px 0 0 4px;line-height:16px;}.gs_fsvg line{stroke:#222222}a:link .gs_fsvg{fill:#1a0dab;}a:link .gs_fsvg line{stroke:#1a0dab;}a:visited .gs_fsvg{fill:#660099;}a:visited .gs_fsvg line{stroke:#660099;}a:active .gs_fsvg{fill:#d14836;}a:active .gs_fsvg line{stroke:#d14836;}a .gs_fsvg{border-bottom:1px solid transparent;}a:hover .gs_fsvg,a:focus .gs_fsvg{border-bottom-color:inherit;}.gs_fsml{font-size:13px}.gs_fscp{font-variant:small-caps}.gsh_clim{display:table-row}.gsh_clil,.gsh_clic{display:table-cell;padding-bottom:8px}.gsh_clil{padding-right:8px;}.gsh_lla{list-style-type:lower-alpha}.gsh_lua{list-style-type:upper-alpha}.gsh_llr{list-style-type:lower-roman}.gsh_lur{list-style-type:upper-roman}.gsh_l>li{margin-left:32px;}.gsh_h3{font-size:inherit;font-weight:normal}.gsh_h3,.gsh_csp{margin:16px 0}.gsh_h3+.gsh_csp{margin-top:-8px}.gsh_ovln{text-decoration:overline}.gsh_small .gsh_l .gsh_csp{margin:8px 0}.gsh_small .gsh_csp:first-child,.gsh_small .gsh_h3:first-child{margin-top:0}.gsh_small .gsh_csp:last-child{margin-bottom:0}.gsh_dspfr{text-align:center}.gsh_dspfr svg{margin:8px 0}.gs_pp_tn,.gs_el_ta .gs_pp_mo_tn,.gs_el_ph .gs_pp_mo_tn{width:32px;height:32px;}.gs_pp_sm,.gs_el_ta .gs_pp_mo_sm,.gs_el_ph .gs_pp_mo_sm{width:56px;height:56px;}.gs_pp_nm,.gs_el_ta .gs_pp_mo_nm,.gs_el_ph .gs_pp_mo_nm{width:128px;height:128px;}.gs_ai_pho{float:left;}.gs_ai_t{margin-left:72px;}.gs_ai_pho_pst+.gs_ai_t{margin-left:48px;}.gs_ai_t.gs_ai_pss{margin-left:64px;}.gs_ai_pho_pst+.gs_ai_t.gs_ai_pss{margin-left:40px;}.gs_ai_name{font-size:17px;font-weight:normal;margin-bottom:4px;}.gs_ai_name a{padding:6px 0 4px 0;}.gs_ai_name.gs_ai_name_nlsb{font-size:15px;}.gs_ai_name.gs_ai_name_nlsb a:link,.gs_ai_name.gs_ai_name_nlsb a:visited{padding:7px 0 5px 0; color:#222;}.gs_ai_name.gs_ai_name_nlsb a:active{color:#d14836;}.gs_ai_int{margin-top:5px;}.gs_ai_eml:empty,.gs_ai_int:empty,.gs_ai_cby:empty{display:none;}.gs_ai_one_int{vertical-align:top;font-size:13px;margin-right:8px;white-space:nowrap;display:inline-block;max-width:200px;text-overflow:ellipsis;overflow:hidden;}.gs_el_tc a.gs_ai_one_int{padding:8px 0 5px 0;}.gs_el_ph .gs_ai_eml,.gs_el_ph .gs_ai_cby{margin-top:8px;}.gs_ai_ilnl .gs_ai_int,.gs_ai_ilnl .gs_ai_cby{margin-top:8px;color:#666;}.gs_ai.gs_ai_chpr{position:relative;}.gs_ai_chpr .gs_ai_t{margin-right:276px;}.gs_el_sm .gs_ai_chpr .gs_ai_t{margin-right:156px;}.gs_el_ph .gs_ai_chpr .gs_ai_t{margin-right:0;}.gs_ai_chpr .gs_ai_cby{position:absolute;top:4px;right:0;text-align:right;}.gs_el_sm .gs_ai_chpr .gs_ai_cby,.gs_el_ta .gs_ai_chpr .gs_ai_cby{width:132px;word-wrap:break-word;}.gs_el_ph .gs_ai_chpr .gs_ai_cby{text-align:left;position:static;width:auto;}#gsc_bdy{position:relative;max-width:1200px;margin:0 auto;}.gs_el_ph #gsc_bdy,.gs_el_ta #gsc_bdy{display:flex;flex-flow:column;}.gsc_lcl{position:relative;margin:0 350px 0 0;order:3;}.gs_el_sm .gsc_lcl{margin-right:334px;}.gs_el_ta .gsc_lcl,.gs_el_ph .gsc_lcl{margin:0;}#gsc_prf_t_wrp{position:relative;order:2;overflow:hidden;}.gs_el_tc #gsc_prf_t_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;right:0;width:12px;height:100%;background-image:linear-gradient(to right,rgba(247,247,247,0),rgba(247,247,247,1) 80%);}#gsc_prf_t{width:100%;background-color:#f5f5f5;display:none;white-space:nowrap;overflow-x:auto;padding:0 4px;}.gs_el_ta #gsc_prf_t,.gs_el_ph #gsc_prf_t{display:block;}#gsc_prf_t:after{content:"\00A0";padding:0 4px;}.gsc_prf_tab,.gsc_prf_tab:link{font-size:13px;text-transform:uppercase;padding:13px 12px;display:inline-block;color:#666;cursor:pointer;}.gsc_prf_tab:hover{color:#000;text-decoration:none}.gsc_prf_tab:active{color:#4d90fe;}.gsc_prf_tab[aria-selected="true"]{border-bottom:2px solid #4d90fe;color:#0461f9;cursor:default;}.gs_el_ta #gsc_art,.gs_el_ph #gsc_art,.gs_el_ta #gsc_rsb_cit,.gs_el_ph #gsc_rsb_cit,.gs_el_ta #gsc_rsb_mnd,.gs_el_ph #gsc_rsb_mnd,.gs_el_ta #gsc_rsb_awd,.gs_el_ph #gsc_rsb_awd,.gs_el_ta #gsc_rsb_co,.gs_el_ph #gsc_rsb_co{display:none;}#gsc_bdy[data-tab="gsc_prf_t-art"] #gsc_art,#gsc_bdy[data-tab="gsc_prf_t-cit"] #gsc_rsb_cit,#gsc_bdy[data-tab="gsc_prf_t-mnd"] #gsc_rsb_mnd,#gsc_bdy[data-tab="gsc_prf_t-awd"] #gsc_rsb_awd,#gsc_bdy[data-tab="gsc_prf_t-ath"] #gsc_rsb_co{display:block;}.gsc_rsb{float:right;width:317px;order:4;border-left:1px solid #eee;margin-top:32px;}.gs_el_sm .gsc_rsb{margin-top:16px;}.gs_el_ph .gsc_rsb,.gs_el_ta .gsc_rsb{float:none;width:auto;border:none;margin:0;}.gsc_rsb_s{margin:0 0 48px 16px;position:relative;}.gs_el_sm .gsc_rsb_s{margin:0 0 32px 16px;}.gs_el_ph .gsc_rsb_s,.gs_el_ta .gsc_rsb_s{margin:0;}.gsc_rsb_s:last-child{margin-bottom:0;}.gsc_rsb_header{padding:8px 8px 12px 8px;border-bottom:1px solid #e5e5e5;font-weight:normal;font-size:15px;}.gs_el_sm .gsc_rsb_header{padding:4px 8px 9px 8px;}.gs_el_ph .gsc_rsb_header,.gs_el_ta .gsc_rsb_header{display:none;}.gsc_rsb_action{position:absolute;top:-3px;right:-2px;}.gs_el_sm .gsc_rsb_action{top:-8px;}.gsc_rsb_tap{display:block;position:absolute;right:2px;top:12px;opacity:.5;z-index:1;}.gs_el_ta .gsc_rsb_tap,.gs_el_ph .gsc_rsb_tap{top:24px;right:10px;}.gsc_rsb_hm{border-bottom:1px solid #e5e5e5;padding:3px 6px;}#gsc_rsb_gpl{display:block;margin-top:3px;padding:6px 16px;line-height:15px;color:#0461f9;border:1px solid #4d90fe;border-radius:2px;text-align:center;text-transform:uppercase;}.gs_el_sm #gsc_rsb_gpl{margin-top:0;}.gs_el_ta #gsc_rsb_gpl,.gs_el_ph #gsc_rsb_gpl{display:none;}#gsc_rsb_st{width:100%;}.gsc_rsb_std{text-align:right;padding-right:8px;}.gs_el_ta .gsc_rsb_std,.gs_el_ph .gsc_rsb_std{padding-right:16px;}.gsc_rsb_sc1{text-align:left;padding:2px 8px;}.gs_el_sm .gsc_rsb_sc1{padding:0 8px;}.gs_el_ta .gsc_rsb_sc1,.gs_el_ph .gsc_rsb_sc1{padding:4px 16px;}.gsc_rsb_sth{font-weight:normal;padding:8px 8px 8px 0;border-bottom:1px solid #e5e5e5;text-align:right;}.gs_el_sm .gsc_rsb_sth{padding:4px 8px 4px 0;}.gs_el_ta .gsc_rsb_sth,.gs_el_ph .gsc_rsb_sth{padding:16px 16px 16px 0;}#gsc_rsb_st tbody:before,#gsc_rsb_st tbody:after{content:'';display:block;height:8px;}.gs_el_sm #gsc_rsb_st tbody:before,.gs_el_sm #gsc_rsb_st tbody:after{height:4px;}.gs_el_ph #gsc_hist_opn,.gs_el_ta #gsc_hist_opn{display:none;}.gsc_rsb_f{max-width:118px;word-wrap:break-word;white-space:normal;}.gs_el_ta .gsc_rsb_f{max-width:none;}.gsc_rsb_f:link,.gsc_rsb_f:visited{color:#222;}.gsc_rsb_m_na{color:#dd4b39;}.gsc_rsb_m_a{color:#006621;float:right;position:relative;}.gsc_rsb_m_bar{width:100%;height:4px;margin:8px 0 8px 0;background:#006621;}.gsc_rsb_m_bar_na{background:#dd4b39;width:100%;height:100%;z-index:1;}.gsc_rsb_m{padding:8px;}.gs_el_ta .gsc_rsb_m,.gs_el_ph .gsc_rsb_m{padding:8px 16px;}.gsc_rsb_m_desc{padding-top:16px;color:#777;}.gsc_rsb_m_s{font-size:24px;position:absolute;line-height:0.3;}#gsc_lwp_mndt_lnk{text-transform:uppercase;margin-left:16px;margin-right:-9px;text-align:right;font-size:13px;padding:12px 9px;border-radius:3px;}#gsc_lwp_mndt_lnk:hover,#gsc_lwp_mndt_lnk:active,#gsc_lwp_mndt_lnk:visited{text-decoration:none;color:#1a0dab;}#gsc_lwp_mndt_lnk:hover{background-color:rgba(0,0,0,.05);}#gsc_lwp_mndt_lnk:active{background-color:rgba(0,0,0,.1);}.gsc_rsb_m_title{padding-bottom:12px;}.gsc_rsb_m_header{display:flex;align-items:flex-end;justify-content:space-between;padding:0 8px;}.gs_el_sm .gsc_rsb_m_header{padding:0 8px;}.gsc_rsb_hmv{text-align:center;padding-top:16px;}.gsc_rsb_a{list-style:none;}.gsc_rsb_a>li{position:relative;}.gs_el_ta .gsc_rsb_a>li,.gs_el_ph .gsc_rsb_a>li{border-bottom:1px solid #e5e5e5;}.gsc_rsb_a>li:first-child{margin-top:8px;}.gsc_rsb_a_pht{float:left;width:32px;height:32px;}.gsc_rsb_a_desc{margin:0 33px 0 48px;min-height:32px;display:block;}.gs_el_ph .gsc_rsb_a_desc,.gs_el_ta .gsc_rsb_a_desc{margin:0 33px 0 64px;min-height:56px;}.gsc_rsb_a_desc a{color:#222;}.gsc_rsb_a_ext{display:block;color:#777;font-size:13px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gsc_rsb_a_ext,.gs_el_ta .gsc_rsb_a_ext{white-space:normal;}.gsc_rsb_a_ext2{display:none;}.gs_el_ph .gsc_rsb_a_ext2,.gs_el_ta .gsc_rsb_a_ext2{display:block;}.gsc_rsb_aa{display:block;padding:8px;line-height:normal;cursor:pointer;}.gs_el_ph .gsc_rsb_aa,.gs_el_ta .gsc_rsb_aa{font-size:17px;padding:12px 16px;}.gsc_rsb_aa:hover,.gsc_rsb_aa:active{text-decoration:none;background:#f1f1f1;}.gsc_rsb_aa a:hover{text-decoration:none;}#gsc_prf_w{order:1;padding:32px 0;overflow:hidden;}.gs_el_sm #gsc_prf_w{padding:16px 0;}#gsc_prf_pu{float:left;width:128px;height:128px;text-align:center;}.gs_el_ph #gsc_prf_pu{float:none;width:100%;margin:0 0 8px 0;}#gsc_prf_pua{line-height:0;width:128px;height:128px;}.gs_el_ph #gsc_prf_pua{margin:0 auto;}#gsc_prf_pufi{width:0;height:0;overflow:hidden;}.gsc_prf_pufo #gsc_prf_pufi{width:auto;height:auto;overflow:visible;position:relative;z-index:10;}.gsc_prf_pufo #gsc_prf_pufi2{display:inline-block;background:#fcfcfc;padding:8px 8px 8px 0;}.gsc_prf_puic{position:absolute;bottom:0;width:100%;padding:8px 0;background-color:#000;opacity:.6;}.gsc_prf_pel{cursor:pointer;}#gsc_prf_i{margin:0 16px 0 160px;}.gs_el_sm #gsc_prf_i{margin:0 16px 0 144px;}.gs_el_ph #gsc_prf_i{margin:0 16px;text-align:center;}#gsc_prf_btne{vertical-align:top;margin:-9px 4px;}.gs_el_ph #gsc_prf_btne{position:absolute;top:60px;right:8px;margin:0;}#gsc_prf_btnf{float:right;margin:3px 0 16px 16px;}.gs_el_sm #gsc_prf_btnf{margin-top:0;}.gs_el_ph #gsc_prf_btnf{float:none;margin:0;position:absolute;top:8px;right:8px;border-radius:50%;}#gsc_prf_btnf .gs_lbl{padding:0 4px;}#gsc_prf_in{font-size:24px;line-height:24px;padding:3px 0 12px 0;word-wrap:break-word;}.gs_el_sm #gsc_prf_in{font-size:22px;padding:3px 0 8px 0;}.gs_el_ph #gsc_prf_in{font-size:20px;padding:0 0 2px 0;}.gsc_prf_il{font-size:15px;line-height:18px;padding:1px 0;}.gs_el_ph .gsc_prf_il{font-size:13px;line-height:16px;}.gsc_prf_ila:link,.gsc_prf_ila:visited{text-decoration:underline;color:#222;}#gsc_prf_int{margin-top:5px;}#gsc_prf_int:empty{display:none;}.gsc_prf_inta{margin-right:16px;white-space:nowrap;max-width:200px;text-overflow:ellipsis;overflow:hidden;vertical-align:top;}.gsc_prf_inta:last-child{margin:0}.gs_el_tc .gsc_prf_ila,.gs_el_tc .gsc_prf_inta{padding:8px 0 5px 0;}.gsc_md_pro_tt,.gsc_md_pro_ch #gsc_md_pro_lgtm,#gsc_md_pro_save{display:none;}.gsc_md_pro_ed #gsc_md_pro_ted,.gsc_md_pro_aa #gsc_md_pro_taa,.gsc_md_pro_ra #gsc_md_pro_tra,.gsc_md_pro_an #gsc_md_pro_tan,.gsc_md_pro_ai #gsc_md_pro_tai,.gsc_md_pro_ch #gsc_md_pro_save{display:inline-block;}.gsc_md_pro_el{color:#777;}.gsc_md_pro_ev{padding:4px 0 16px 0;}#gsc_dd_add-d,#gsc_dd_exp-d,#gsc_dd_sort-d,#gsc_dd_mor-d{top:42px;}#gsc_dd_add-d,#gsc_dd_mor-d,#gsc_dd_sort-d{white-space:normal;word-wrap:break-word;width:208px;width:-webkit-max-content;width:max-content;min-width:100px;max-width:208px;}.gs_el_ph #gsc_dd_add-d{left:-9px;}.gs_el_ph #gsc_dd_exp-d{left:auto;right:12px;}.gs_el_ph #gsc_dd_mor-d{left:-58px;}.gs_el_ph #gsc_dd_sort-d{left:10px;}.gs_el_ph #gsc_dd_sort-r{margin-left:-10px;}.gsc_dd_sec,#gsc_dd_exp-d{padding:8px 0;}.gs_el_tc .gsc_dd_sec,.gs_el_tc #gsc_dd_exp-d{padding:4px 0 8px 0;}.gsc_dd_sep{border-top:1px solid #ebebeb;}#gsc_dd_mor-s .gsc_dd_mor-sel,#gsc_dd_sort-s .gsc_dd_sort-sel{color:#dd4b39;}#gsc_dd_mor-p{padding:14px 44px 14px 16px;color:#777;}.gs_el_tc #gsc_dd_mor-p{padding:18px 44px 18px 16px;}.gsc_art_sel #gsc_dd_add-r,.gsc_art_sel #gsc_dd_mor-r,#gsc_btn_mer,#gsc_btn_del,#gsc_dd_exp-r{display:none;}#gsc_dd_mor-r,.gsc_art_sel #gsc_btn_mer,.gsc_art_sel #gsc_btn_del,.gsc_art_sel #gsc_dd_exp-r{display:inline-block;}html:not(.gs_el_ph) #gsc_dd_sort-r{display:none;}#gsc_lwp{margin:24px 0;text-align:center;}.gs_el_sm #gsc_lwp{margin:16px 0;}#gsc_bpf{display:inline-block;verticle-align:middle;}#gsc_a_nn{display:inline-block;vertical-align:middle;padding-right:16px;font-size:13px;}.gs_el_ph #gsc_a_nn{display:none;}@media print{#gs_top #gs_md_s,#gs_top #gs_md_w,#gs_top #gs_hdr,#gs_top #gs_hdr_drs,#gs_top #gs_hdr_drw,#gs_top #gs_ftr,#gs_top #gsc_nag,#gs_top #gsc_prf_nbar_btns,#gs_top #gsc_prf_btne,#gs_top #gsc_prf_btnf,#gs_top #gsc_prf_ivh,#gs_top #gsc_prf_puf,#gs_top #gsc_rsb_co,#gs_top #gsc_bdy #gsc_rsb_co,#gs_top .gsc_g_hist_wrp,#gs_top #gsc_prf_t_wrp,#gs_top .gsc_rsb_header,#gs_top .gsc_a_tb,#gs_top .gsc_a_x,#gs_top #gsc_lwp,#gs_top .gsc_prf_puic,#gs_top #gsc_dd_add-r,#gs_top #gsc_dd_mor-r,#gs_top #gsc_dd_sort-r{display:none;}#gs_top,#gs_top #gsc_bdy,#gs_top #gsc_prf_w,#gs_top #gsc_prf,#gs_top #gsc_prf_pu,#gs_top #gsc_prf_pua,#gs_top #gsc_prf_i,#gs_top .gsc_rsb_s,#gs_top .gsc_lcl,#gs_top .gsc_rsb,#gs_top #gsc_a_tw,#gs_top #gsc_a_t,#gs_top .gsc_prf_il,#gs_top .gsc_prf_ila,#gs_top .gsc_prf_inta,#gs_top #gsc_rsb_st{background:none;border:none;padding:0;margin:0;height:auto;width:auto;min-width:0;max-width:none;float:none;display:block;position:static;color:black;font-weight:normal;font-size:12pt;text-decoration:none;}#gs_top .gsc_a_ac,#gs_top .gsc_a_a,#gs_top #gsc_a_ca,#gs_top .gsc_a_at,#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std,#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh,#gs_top .gsc_a_m,#gs_top .gsc_a_am{color:black;font-weight:normal;font-size:12pt;padding:0;margin:0;background:none;border:none;}#gs_top #gsc_a_trh,#gs_top #gsc_a_trh th{height:0;}#gs_top #gsc_a_ta,#gs_top #gsc_a_ca,#gs_top #gsc_a_ha,#gs_top .gsc_a_a{font-size:11pt;}#gs_top .gsc_a_ac{font-size:10pt}#gs_top #gsc_prf_pu{width:80pt;height:auto;float:left;margin:0 7pt 7pt 0;}#gs_top #gsc_prf_pua{left:auto;transform:none;border-radius:0;}#gs_top #gsc_prf_pua>img{position:static;}#gs_top #gsc_prf_i{margin:0 7pt 7pt 87pt;text-align:left;}#gs_top #gsc_prf_in{font-size:18pt;line-height:18pt;padding:0 0 4pt 0;}#gs_top .gsc_prf_il{padding:2pt 0;}#gs_top #gsc_prf_w{float:left;width:64%;}#gs_top .gsc_rsb{float:right;width:35%;}#gs_top #gsc_art{clear:both;}#gs_top #gsc_rsb_st{display:table;width:100%;max-width:none;margin-top:3pt;}#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std{font-size:10pt;}#gs_top th.gsc_rsb_sc1,#gs_top .gsc_rsb_sth{border-bottom:1pt solid #ccc;}#gs_top .gsc_rsb_f{max-width:60pt;}#gs_top .gsc_rsb_sth{padding-left:14pt;}#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh{padding:6pt 0;}#gs_top #gsc_a_trh{border-bottom:1pt solid #ccc;}#gs_top #gsc_a_ca{display:block;width:auto;}#gs_top #gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:12pt;}#gs_top .gsc_a_h{display:inline;font-size:10pt;}#gs_top .gsc_a_at{color:#008;}#gs_top .gsc_a_m,#gs_top .gsc_a_am{display:inline;position:absolute;}#gs_top .gsc_a_am{padding: 11pt 0 0 8pt;}#gs_top .gsc_a_t .gs_gray{color:black;font-size:10pt;}}.gsc_lwpds_frm{position:relative;height:29px;}.gsc_lwpds_tsiw{position:absolute;top:0;left:0;right:38px;}.gsc_lwpds_tsiw input{border-radius:3px 0 0 3px;}.gsc_lwpds_tsbw{position:absolute;top:0;right:0;}.gsc_lwpds_tsbw button{border-radius:0 3px 3px 0;}.gsc_pgn{text-align:right;font-weight:bold;line-height:29px;}.gsc_pgn_ppn{margin:0 8px;}.gsc_ccb_ck{padding:11px 10px 9px 10px;}.gsc_ccb_svg{stroke:#666;stroke-width:2px;fill:#fff;width:21px;height:21px;vertical-align:top;}.gsc_ccb_lim .gsc_ccb_svg,.gsc_ccb_dis .gsc_ccb_svg{fill:#e2e2e2;stroke:#fff;}.gsc_ccb_lim .gsc_ccb_svg>circle,.gsc_ccb_dis .gsc_ccb_svg>circle{stroke:#e2e2e2;}.gsc_ccb_on .gsc_ccb_svg{fill:#4d90fe;stroke:#fff;}.gsc_ccb_on .gsc_ccb_svg>circle{stroke:#4d90fe;}.gsc_ccb_del:active .gsc_ccb_svg>circle,.gsc_ccb_add:active .gsc_ccb_svg>circle{fill:#2f6de1;}#gsc_md_cod{width:800px;max-width:94%;}.gs_el_ph #gsc_md_cod{width:100%;max-width:100%;}#gsc_md_cod .gs_md_prg{min-height:400px;}.gsc_codb_instr{font-size:16px;margin:1em 0;}#gsc_cods_res{position:relative;margin-bottom:24px;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_cods_res{margin-bottom:16px;}.gsc_cods_hide,.gsc_cod_sugg #gsc_cod_tedit,.gsc_cod_sugg #gsc_cods_frm,.gsc_cod_sugg #gsc_cods_pp,.gsc_cod_lc #gsc_cod_tadd,.gsc_cod_changed #gsc_cod_tedit,.gsc_cod_changed #gsc_cod_tadd,.gsc_cod_lim #gsc_cod_tedit,.gsc_cod_lim #gsc_cod_tadd{display:none;}#gsc_cods_frm{margin:0 0 24px 0;}.gs_el_ph #gsc_cods_frm{margin:0 0 16px 0;}.gsc_ucoar{padding:24px 0;border-bottom:1px solid #eee;}.gs_el_ph .gsc_ucoar{padding:16px 0px;}.gsc_ucoar:first-child{padding-top:0;}.gsc_ucoar:last-child{border-bottom:none;}.gsc_ucoar_cb{float:right;margin-top:-8px;}#gsc_cod_trev{display:none;color:#666;pointer-events:none;}.gsc_cod_changed #gsc_cod_trev,.gsc_cod_lim #gsc_cod_trev{display:inline-block;}.gsc_cod_changed #gsc_cod_trev{color:#1a0dab;pointer-events:auto;}.gsc_fol_cr{margin:0 0 8px 0;}.gs_el_tc .gsc_fol_cr{margin:0;}.gs_el_tc .gsc_fol_cr:first-child{margin-top:-8px;}#gsc_fol_ml{display:block;color:#777;padding:12px 0 4px 0;}</style><script>!function(GSP){/*

 Copyright The Closure Library Authors.
 SPDX-License-Identifier: Apache-2.0
*/
var aa="function"==typeof Object.create?Object.create:function(a){var b=function(){};b.prototype=a;return new b},ba;if("function"==typeof Object.setPrototypeOf)ba=Object.setPrototypeOf;else{var da;a:{var ea={a:!0},fa={};try{fa.__proto__=ea;da=fa.a;break a}catch(a){}da=!1}ba=da?function(a,b){a.__proto__=b;if(a.__proto__!==b)throw new TypeError(a+" is not extensible");return a}:null}
var ha=ba,ia=function(a,b){a.prototype=aa(b.prototype);a.prototype.constructor=a;if(ha)ha(a,b);else for(var c in b)if("prototype"!=c)if(Object.defineProperties){var d=Object.getOwnPropertyDescriptor(b,c);d&&Object.defineProperty(a,c,d)}else a[c]=b[c];a.na=b.prototype},ja=function(){},ka=function(a,b){var c=Array.prototype.slice.call(arguments,1);return function(){var d=c.slice();d.push.apply(d,arguments);return a.apply(this,d)}};var g=function(){this.o=this.o;this.F=this.F};g.prototype.o=!1;g.prototype.isDisposed=function(){return this.o};g.prototype.T=function(){this.o||(this.o=!0,this.H())};g.prototype.H=function(){if(this.F)for(;this.F.length;)this.F.shift()()};function la(a){var b=[],c=0,d;for(d in a)b[c++]=d;return b};function l(a,b){a.classList.add(b)}function n(a,b){a.classList.remove(b)}function p(a,b){return a.classList?a.classList.contains(b):!1}function q(a,b,c){c=void 0!==c?c:!p(a,b);(c?l:n)(a,b)};function r(a){return 0<=(navigator.userAgent||"").indexOf(a)}var ma=r("iPhone")||r("iPad")||r("iPod"),na=r("iPhone")||r("Android")&&r("Mobile");function oa(){if(void 0===b){var a=window.screen;a={width:window.innerWidth,height:window.innerHeight,ma:a.width,la:a.height}}else a=b;var b=a;a=b.width;var c=b.height,d=b.ma;b=b.la;var e=4;if(600>a||48E4>d*b||na)e=1;else if(982>a)e=2;else if(1136>a||590>c)e=3;return e}var pa,qa=/[?&]tc=([01])/.exec(location.search||"");
pa=qa?0<+qa[1]:r("Android")?!0:window.matchMedia&&window.matchMedia("(pointer)").matches?window.matchMedia("(pointer:coarse)").matches:!r("Firefox")||r("Mobile")||r("Tablet")?ma||"ontouchstart"in window||0<(navigator.msMaxTouchPoints||0):!1;function ra(){if(void 0==sa){sa=!1;try{var a=Object.defineProperty({},"passive",{get:function(){sa=!0}});window.addEventListener("testPassive",ja,a);window.removeEventListener("testPassive",ja,a)}catch(b){}}return sa}var sa;var ta=function(a){this.Y=a},ua=new ta("INPUT"),va=new ta("TABLE");function t(a){return document.getElementById(a)}function x(a){return a.id||(a.id="gs_id"+wa++)}function xa(a){a=(void 0===a?null:a)||document.body;return"rtl"==(a?window.getComputedStyle(a,null):null).direction}
function ya(a){var b=[];a=a.elements;for(var c=a.length,d=0;d<c;d++){var e=a[d],f=encodeURIComponent(e.name||""),h=e.type;!f||e.disabled||!("checkbox"!=h&&"radio"!=h||e.checked)||b.push(f+"="+encodeURIComponent(e.value||""))}return b.join("&")}function za(a,b){var c=a.elements[b];c||(c=document.createElement(ua.Y),c.type="hidden",c.name=b,a.appendChild(c));return c}function Aa(a){t("gsc_md_cbyd_c").href=a&&a.match(Ba)?a:"javascript:void(0)"}function Ca(a){a.match(Ba)&&(window.location.href=a)}
var wa=100,Da=/\S+/g,Ba=/^(?:https?:|[^:/?#]*(?:[/?#]|$))/i,Ea=/^(?:#|\/[a-z0-9_-]*(?:[?].*)?$)/i;function y(a){return a.hasOwnProperty("gs_uid")?a.gs_uid:a.gs_uid=++Fa}var Fa=0;var z=function(){this.i=[];this.A={};this.O=this.v=0};z.prototype.add=function(a){var b=y(a);this.A[b]||(this.i.push(a),this.A[b]=this.i.length,++this.v)};z.prototype.remove=function(a){a=y(a);var b=this.A[a];b&&(this.i[b-1]=null,delete this.A[a],2*--this.v<this.i.length&&!this.O&&Ga(this))};z.prototype.notify=function(a){var b=this.i;try{++this.O;for(var c=0;c<b.length;c++){var d=b[c];d&&d.apply(null,arguments)}}finally{!--this.O&&2*this.v<b.length&&Ga(this)}};
var Ga=function(a){var b=a.i,c=b.length;a=a.A;for(var d=0,e=0;e<c;e++){var f=b[e];f&&(b[d]=f,a[y(f)]=++d)}b.length=d};function B(a,b,c,d,e){Ha(a,b,c,void 0===d?!1:d,void 0===e?!1:e,Ia)}function C(a,b,c,d){Ha(a,b,c,void 0===d?!1:d,!1,Ja)}function Ka(a,b,c,d){function e(h){C(f,a,e,c);b(h)}var f=document;c=void 0===c?!1:c;B(f,a,e,c,void 0===d?!1:d)}function D(a){La?La.add(a):a()}var Ma=window.requestAnimationFrame?function(a){window.requestAnimationFrame(a)}:function(a){setTimeout(a,33)};function Na(a){a.stopPropagation();a.preventDefault()}
function Oa(a){return(a.ctrlKey?1:0)|(a.altKey?2:0)|(a.metaKey?4:0)|(a.shiftKey?8:0)}function Ia(a,b,c,d,e){var f=a.addEventListener;e=e&&ra();f.call(a,b,c,e?{passive:e,capture:d}:d)}function Ja(a,b,c,d){a.removeEventListener(b,c,d)}function Ha(a,b,c,d,e,f){if("string"===typeof b)f(a,b,c,d,e);else for(var h=b.length,k=0;k<h;k++)f(a,b[k],c,d,e)}function Pa(){La.notify();La=null}function Qa(){"complete"==document.readyState&&(C(document,"readystatechange",Qa),Pa())}
var La,Ra=!!document.attachEvent,Sa=document.readyState;if(Ra?"complete"!=Sa:"loading"==Sa)La=new z,Ra?B(document,"readystatechange",Qa):Ka("DOMContentLoaded",Pa);function Ta(){Ka(["mousedown","touchstart"],function(){q(document.documentElement,"gs_pfcs",!0);B(document,"keydown",Ua,!0)},!0,!0)}function Ua(a){9==a.keyCode&&(q(document.documentElement,"gs_pfcs",!1),C(document,"keydown",Ua,!0),Ta())}Ta();function Va(a,b,c,d,e){var f=t(a);Wa(f,function(){l(f,"gs_vis");b&&b()},function(){n(f,"gs_vis");c&&c()},d,e)}function Wa(a,b,c,d,e){var f=x(a);if(!E[f]){var h=document.activeElement;Xa(Ya(a),!0);b&&b();G.push(function(k){delete E[f];try{k||(e||h).focus()}catch(m){}c&&c()});E[f]=G.length;h&&a.contains(h)||setTimeout(function(){var k=d,m=k&&"text"==k.type;if(!k||m&&pa)k=a;try{k.focus(),m&&(k.value=k.value)}catch(w){}},0)}}function H(a){Xa((E[a]||1E6)-1,!1)}
function Za(a){a=void 0===a?!1:a;G.pop()(a)}function Xa(a,b){for(b=void 0===b?!1:b;G.length>a;)Za(b||G.length>a+1)}function Ya(a){for(var b=0;a&&!(b=E[a.id]||0);)a=a.parentNode;return b}var G=[],E={};B(document,"click",function(a){var b=G.length;b&&!Oa(a)&&b>Ya(a.target)&&Za(!0)});B(document,"keydown",function(a){27==a.keyCode&&!Oa(a)&&G.length&&Za()});
B(document,"focus",function(a){var b=G.length;if(b)for(var c=Ya(a.target);c<b;){var d="",e;for(e in E)if(E[e]==b){d=e;break}a:{d=(t(d).getAttribute("data-wfc")||"").match(Da)||[];for(var f=0;f<d.length;f++){var h=t(d[f]);if(h&&h.offsetWidth){d=h;break a}}d=void 0}if(d){Na(a);d.focus();break}else Za(!0),--b}},!0);var $a={},ab={},bb;try{bb=window.sessionStorage}catch(a){};function J(a){return"object"==typeof a?a:null}function cb(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.pushState(b,"",a):window.location.assign(a)}function ib(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.replaceState(b,"",a):window.location.replace(a)}function fb(a){var b=[],c;for(c in a)b.push(encodeURIComponent(c)+"="+encodeURIComponent(a[c]));return(a=b.sort().join("&"))?"#"+a:""}
function jb(a){var b={};a=a.split("&");for(var c=0;c<a.length;c++){var d=a[c],e=d.indexOf("=");if(e+1){var f=d.substr(0,e);d=d.substr(e+1)}else f=d,d="";f&&(b[decodeURIComponent(f)]=decodeURIComponent(d))}return b}function kb(a){var b=a.indexOf("#")+1;return jb(b?a.substr(b):"")}function lb(a){var b=a.indexOf("?")+1;a=b?a.substr(b):"";b=a.indexOf("#");return jb(b+1?a.substr(0,b):a)}function mb(a,b){for(var c in b){var d=b[c];void 0!==d?a[c]=d:delete a[c]}}
function eb(a){var b=kb(window.location.hash);mb(b,a);return b}function db(a){var b=gb||J(window.history.state),c={},d;for(d in b)c[d]=b[d];mb(c,a);return c}function nb(){setTimeout(function(){if(!ob){var a=window.history.state;ob=!0;gb=J(a);rb.notify()}sb=!1},0)}var rb=new z,gb,ob=!1,sb=!0,hb="pushState"in window.history,tb;
if("undefined"==typeof GSP)tb=!1;else{var ub=.001*Date.now(),vb=GSP.eventId,wb=!1,K,xb=bb;if(!("nh"in $a)){var yb=xb&&xb.getItem("nh"),zb;if(yb)try{zb=JSON.parse(yb)}catch(a){}ab.nh=zb}K=ab.nh;K instanceof Array||(K=[]);for(var Ab=K.length,Bb=0,Cb=0;Cb<Ab;Cb++){var Db=K[Cb];if(Db instanceof Array&&2==Db.length){var Eb=Db[1]==vb;wb=wb||Eb;10>=Ab-Cb&&+Db[0]>ub-86400&&!Eb&&(K[Bb++]=Db)}}K.length=Bb;K.push([ub,vb]);var Fb=K,Gb=bb;ab.nh=Fb;try{Gb&&Gb.setItem("nh",JSON.stringify(Fb))}catch(a){}tb=wb}
var Hb=tb;"onpageshow"in window?B(window,"pageshow",nb):D(nb);B(window,hb?"popstate":"hashchange",function(a){"loading"!=document.readyState&&(a=a.state,ob=!0,gb=J(a),rb.notify())});function Ib(){Jb&&(C(t("gs_alrt_l"),"click",Jb),Jb=void 0)}function Kb(){var a=Lb();l(a,"gs_anm");l(a,"gs_vis");B(document,"click",Mb);clearTimeout(Nb);Nb=setTimeout(Mb,4E3);++Ob;setTimeout(Pb,0)}function Mb(){Ob||(C(document,"click",Mb),clearTimeout(Nb),Nb=void 0,Ib(),n(Lb(),"gs_vis"))}function Lb(){return t("gs_alrt")}function Pb(){Ob=0}var Nb,Ob=0,Jb;D(function(){var a=t("gs_alrt_m");a&&(a.innerHTML&&!Hb&&Kb(),B(window,"pagehide",function(){Ob=0;Mb();n(Lb(),"gs_anm")}))});function Qb(a,b,c){var d=new XMLHttpRequest;d.onreadystatechange=function(){if(4==d.readyState){var e=d.status,f=d.responseText,h=d.responseURL,k=window.location,m=k.protocol;k="//"+k.host+"/";h&&h.indexOf(m+k)&&h.indexOf("https:"+k)&&(e=0,f="");c(e,f)}};d.open(b?"POST":"GET",a,!0);d.setRequestHeader("X-Requested-With","XHR");b&&d.setRequestHeader("Content-Type","application/x-www-form-urlencoded");b?d.send(b):d.send();return d}function Rb(a){a&&(a.onreadystatechange=ja,a.abort())};var Sb=function(a,b,c){this.type=a;this.currentTarget=this.target=b;this.g=void 0===c?null:c;this.P=!1};Sb.prototype.stopPropagation=function(){this.g&&this.g.stopPropagation();this.P=!0};var L=function(a){a.g&&Na(a.g);a.P=!0};var M=function(a,b){this.R=a;this.ka=b},Tb=function(a,b,c){this.R=a;this.types=b;this.listener=c};function Ub(a,b){var c=b.length;if(c){var d=y(a),e=Vb[d];if(!e){e=Vb[d]=[];d=Wb(b[0].R);for(var f in d){var h=Xb[f];h||(h=Xb[f]=Object.create(null));for(var k in d[f]){var m=h[k];m||(m=h[k]=[]);m.push(a)}}Yb(a,e,b[0],Zb);for(f=1;f<c;f++)Yb(a,e,b[f],$b)}}}function O(a,b,c){ac(new Sb(a,b,void 0===c?null:c))}
function P(a,b,c){var d=bc;"string"===typeof b&&(cc[0]=b,b=cc);var e=b.length;a=Wb(a);for(var f in a)for(var h in a[f])for(var k=0;k<e;k++)d(f,h,b[k],c)}function Wb(a){"string"===typeof a&&(dc[0]=a,a=dc);for(var b=a.length,c=Object.create(null),d=0;d<b;d++){var e=a[d],f=e.charAt(0),h=e.substr(1);if("#"!=f&&"."!=f||!h)throw Error("bad selector: "+e);(e=c[f])||(e=c[f]=Object.create(null));e[h]=!0}return c}
function bc(a,b,c,d){var e=ec[c];e||("touchstart"!=c&&"mouseover"!=c&&"mouseout"!=c&&B(document,c,fc,"focus"==c||"blur"==c),e=ec[c]=Object.create(null));(c=e[a])||(c=e[a]=Object.create(null));(a=c[b])||(a=c[b]=new z);a.add(d)}function fc(a){var b=a.target;b&&3==b.nodeType&&(b=b.parentNode);ac(new Sb(a.type,b,a))}
function ac(a){for(var b=a.target;b&&b!=document&&!b.disabled&&!p(b,"gs_dis");){a.currentTarget=b;var c=b.id;if(c&&!gc("#",c,a))break;c=b.classList||[];for(var d=c.length,e=0;e<d;e++)if(!gc(".",c[e],a))return;b=b.parentNode}}function gc(a,b,c){var d=ec[c.type];(b=(a=d&&d[a])&&a[b])&&b.notify(c);return!c.P}function Yb(a,b,c,d){var e=c.R;c=c.ka;for(var f in c){var h=ka(d,a,c[f]);P(e,f,h);b.push(new Tb(e,f,h))}}function Zb(a,b,c){var d=c.currentTarget;a=hc(a,d)||a;a=ic(a,d);b.call(a,c)}
function $b(a,b,c){a:{for(var d=c.currentTarget;d&&d!=document;){var e=hc(a,d);if(e){a=ic(e,d);break a}d=d.parentNode}a=void 0}a&&b.call(a,c)}function ic(a,b){var c=jc(b),d=kc[c];d||(d=kc[c]=[]);for(var e=d.length,f=0;f<e;f++){var h=d[f];if(h instanceof a)return h}b=new a(b);d.push(b);a=y(a);(d=lc[a])||(d=lc[a]=[]);d.push(c);return b}function hc(a,b){var c,d=b.id;d&&(c=mc(a,c,"#",d));b=b.classList||[];d=b.length;for(var e=0;e<d;e++)c=mc(a,c,".",b[e]);return c}
function mc(a,b,c,d){c=(d=(c=Xb[c])&&c[d])?d.length:0;for(var e=0;e<c;e++){var f=d[e];!(f===a||f.prototype instanceof a)||b&&!(f===b||f.prototype instanceof b)||(b=f)}return b}function jc(a){var b=a.getAttribute("data-duid");b||a.setAttribute("data-duid",b=""+nc++);return b}var ec=Object.create(null),dc=[""],cc=[""],Xb=Object.create(null),Vb=Object.create(null),lc=Object.create(null),kc=Object.create(null),nc=100;window.gs_evt_dsp=fc;function oc(){var a=".gs_md_li";if("string"===typeof a){var b=a.charAt(0),c=a.slice(1);if("#"==b)a=function(d){return d.id==c&&0<d.offsetWidth};else if("."==b)a=function(d){return p(d,c)&&0<d.offsetWidth};else throw Error("bad selector: "+a);}return a}function pc(a,b){return a&&((void 0===b?0:b)?a.lastElementChild:a.firstElementChild)}function qc(a,b){return a&&((void 0===b?0:b)?a.previousElementSibling:a.nextElementSibling)}function rc(a,b,c){c=void 0===c?!1:c;return sc(a,b,oc(),c,!1)}
function sc(a,b,c,d,e){for(var f;b&&a;){if(c(b)){if(e)return b}else for(f=pc(b,d);f;f=qc(f,d))if(e=sc(f,f,c,d,!0))return e;for(e=!0;;){if(b==a)return null;f=b.parentNode;if(b=qc(b,d))break;b=f}}return null};function tc(a){return!!p(a,"gs_sel")+2*!!p(a,"gs_par")}function uc(a){return+a.getAttribute("data-s")}function vc(a,b,c){c=void 0===c?!1:c;q(a,"gs_sel",1==b);q(a,"gs_par",2==b);a.setAttribute("aria-checked",wc[b]);c||a.setAttribute("data-s",""+b)}var wc=["false","true","mixed"];var Q=function(){this.j=Object.create(null);this.l=0};Q.prototype.clear=function(){this.j=Object.create(null);this.l=0};Q.prototype.has=function(a){return a in this.j};Q.prototype.get=function(a){return this.j[a]};Q.prototype.set=function(a,b){this.has(a)||this.l++;this.j[a]=b};Q.prototype.delete=function(a){this.has(a)&&(delete this.j[a],this.l--)};var xc=function(a){var b=window,c=this;this.i=new z;this.V=0;this.S=[b,a,function(){c.V++||Ma(d)},!1];var d=function(){c.V=0;c.i.notify()}};xc.prototype.addListener=function(a){this.i.v||B.apply(null,this.S);this.i.add(a)};xc.prototype.removeListener=function(a){this.i.remove(a);this.i.v||C.apply(null,this.S)};var yc=new xc("scroll"),zc=new xc("resize");var Ac=new z;function Bc(){var a=document.documentElement,b=oa();b={gs_el_ph:1==b,gs_el_ta:2==b,gs_el_sm:4!=b,gs_el_tc:pa||1==b};var c;for(c in b){var d=b[c];if(p(a,c)!=d){var e=!0;q(a,c,d)}}e&&Ac.notify()}q(document.documentElement,"gs_el_ios",ma);Bc();zc.addListener(Bc);B(window,["pageshow","load"],Bc);function R(a,b,c,d){function e(){var u=ca&&p(h,"gs_el_ph");q(F,"gs_vis",!u);h.style.overflowY=Yd&&!u?"scroll":""}function f(){var u=h.clientHeight,I=+A.getAttribute("data-h");I||(w.style.maxHeight="none",I=m.offsetHeight);I=Math.max((u-I)/2,10);u=Math.max(u-48-2*I,10);var Jc=ca&&p(h,"gs_el_ph");m.style.top=Jc?"auto":I+"px";w.style.maxHeight=Jc?"none":u+"px";Cc(w)}b=void 0===b?"":b;c=void 0===c?"":c;d=void 0===d?"":d;var h=document.documentElement,k=t("gs_top"),m=t(a),w=t(a+"-bdy"),v=t(m.getAttribute("data-cid")||
m.id+"-bdy")||m,F=t(m.getAttribute("data-shd")||"gs_md_s"),A=Dc(m),ca=!!A&&p(A,"gs_md_wmw"),N=window.pageYOffset,Yd=k.scrollHeight>h.clientHeight,pb=!!E[a],qb=pb?"":S,Lc=b&&"#"!=b[0]&&!d,$d=a==S&&b==Ec&&c==T;Fc=b;Lc?(pb?q(v,"gs_md_ldg",!0):Gc(m,v,'<div class="gs_md_prg">'+t("gs_md_ldg").innerHTML+"</div>"),O("gs-md-ldin",v)):(d&&Gc(m,v,d),O("gs-md-lded",v));qb&&(++Hc,H(qb),--Hc);S=a;Ec=b;T=c;Ic=d;$d||Hc||(Kc+=1,(qb?ib:cb)(Mc(),Nc()));pb||Wa(m,function(){A&&l(A,"gs_vis");l(m,"gs_vis");q(m,"gs_abt",
sb);Oc(a);Ac.add(e);e();A&&w&&(f(),zc.addListener(f));l(k,"gs_nscl");k.style.top=-N+"px"},function(){Ac.remove(e);zc.removeListener(f);A&&n(A,"gs_vis");n(m,"gs_vis");n(m,"gs_abt");n(F,"gs_vis");h.style.overflowY="";n(k,"gs_nscl");k.style.top="auto";Rb(U);U=null;window.scrollTo(0,N);S=Ec=T=Ic="";var u=Kc;Kc=0;Hc||(0<u?window.history.go(-u):ib(Mc(),Nc()))},Pc(m),Qc(m));Lc&&(Rb(U),U=null,U=Qb(b,c,function(u,I){U=null;u=200==u;Gc(m,v,u?I:Rc());u&&a==S&&b==Ec&&c==T&&(Ic=I,ib(Mc(),Nc()));O("gs-md-lded",
v)}))}function Dc(a){a=a.parentNode;return p(a,"gs_md_wnw")?a:null}function Pc(a){return(a=a.getAttribute("data-ifc"))?t(a):null}function Qc(a){return(a=a.getAttribute("data-cfc"))?t(a):null}
function Gc(a,b,c){q(b,"gs_md_ldg",!1);for(var d=b.querySelectorAll("[data-duid]"),e=d.length,f={},h=0;h<e;h++){for(var k=jc(d[h]),m=kc[k],w=m?m.length:0,v=0;v<w;v++){var F=m[v],A=y(F.constructor),ca=f[A];ca||(ca=f[A]={});ca[k]=!0;F&&"function"==typeof F.T&&F.T()}delete kc[k]}for(var N in f){N=+N;d=f[N];h=(e=lc[N])?e.length:0;for(m=k=0;m<h;m++)w=e[m],w in d||(e[k++]=w);k?e.length=k:delete lc[N]}b.innerHTML=c;Oc(a.id);Rb(U);U=null}
function Oc(a){if(a=document.querySelector("#"+a+">.gs_md_bdy"))a.scrollTop=a.scrollLeft=0,Cc(a)}function Cc(a){var b=a.style,c="padding"+(xa(a)?"Left":"Right");b[c]="";var d=a.offsetWidth-a.clientWidth;2<d&&(a=parseInt(window.getComputedStyle(a,null)[c],10)||0,b[c]=Math.max(a-d,0)+"px")}function Rc(){return'<div class="gs_md_prg"><div class="gs_alrt">'+t("gs_md_err").innerHTML+"</div></div>"}function Mc(){return{d:S||void 0,u:Ec||void 0,p:T?"1":void 0}}function Nc(){return{n:Kc,p:T,h:Ic}}
var U=null,Fc="",S="",Ec="",T="",Ic="",Kc=0,Hc=0;rb.add(function(){var a=kb(window.location.hash),b=a.d||"",c=b?t(b):null;++Hc;if(c){c=a.u||"";a=0<+a.p;var d=gb||J(window.history.state)||{},e=+d.n||0,f=""+(d.p||"");d=""+(d.h||"");c.match(Ea)||(c="");a!=!!f?R(b,"","",Rc()):b==S&&c==Ec&&f==T&&d==Ic||R(b,c,f,d);Kc=e}else S&&H(S);--Hc});var Sc=function(a){g.call(this);this.D=a;this.K=Object.create(null);this.C=null;a=a.querySelectorAll(".gs_in_txtw>input[type=text]");for(var b=a.length;b--;){var c=a[b],d=c.parentNode.querySelector(".gs_in_txts");c=c.name;d&&c&&(this.K[c]=d.innerHTML)}};ia(Sc,g);Sc.prototype.H=function(){Rb(this.C);this.D=this.C=null;g.prototype.H.call(this)};
Sc.prototype.ga=function(a){var b=this;L(a);if((a=this.D)&&!this.C){var c="json=&"+ya(a);Tc(this,!0);this.C=Qb(a.action,c,function(d,e){b.C=null;Tc(b,!1);var f=b.D,h=f.getAttribute("data-alrt");if(h=h?t(h):null)h.innerHTML="";try{var k=200==d&&JSON.parse(e)}catch(A){}k&&"object"==typeof k||(Uc(h,t("gs_md_err").innerHTML),k={});if(d=k.L)Ca(""+d);else{(d=k.M)&&Uc(h,d);d=1E6;if(h&&h.innerHTML){var m=h;d=h.getBoundingClientRect().top}f=f.elements;k=k.E;"object"==typeof k||(k=Object.create(null));for(var w in b.K){h=
f[w];e=void 0;var v=""+(k[w]||""),F=h.parentNode.querySelector(".gs_in_txts");q(h.parentNode,"gs_in_txte",!!v);F&&(F.innerHTML=v||b.K[w]||"");v&&(e=h.getBoundingClientRect().top)<d&&(m=h,d=e)}m&&m.scrollIntoView&&(0>d||d+20>window.innerHeight)&&m.scrollIntoView()}})}};
var Tc=function(a,b){a=a.D;var c=a.getAttribute("data-bsel");a=c?document.querySelectorAll(c):a.querySelectorAll("button");for(c=a.length;c--;){var d=a[c];d.disabled=b;q(d,"gs_bsp",b)}},Uc=function(a,b){if(a)a.innerHTML=b;else{var c=void 0===c?"":c;var d=void 0===d?"":d;var e=void 0===e?[]:e;t("gs_alrt_m").innerHTML=b;Lb().action=d.match(Ba)?d:"";a=t("gs_alrt_l");a.textContent=c;c=t("gs_alrt_h");c.innerHTML="";for(var f in e)b=document.createElement("input"),b.type="hidden",b.name=f,b.value=e[f],
c.appendChild(b);Ib();q(a,"gs_fm_s",!0);Kb()}};Ub(Sc,[new M(".gs_ajax_frm",{submit:Sc.prototype.ga})]);var Vc=[[1,0,1],[2,0,1]];P(".gs_cb_gen","click",function(a){var b=a.currentTarget,c=tc(b),d=2==+b.getAttribute("data-s");vc(b,Vc[+d][c],!0);O("gs-change",b,a.g)});P(".gs_cb_gen",["keydown","keyup"],function(a){var b=a.currentTarget,c=a.g.keyCode;"BUTTON"!=b.tagName||13!=c&&32!=c||(L(a),"keydown"==a.type&&b.click())});P([".gs_cb_gen",".gs_md_li"],"keydown",function(a){var b=a.currentTarget,c=b.tagName,d=a.g.keyCode;"BUTTON"!=c&&(32==d||13==d&&"A"!=c)&&(L(a),b.click())});var Wc=["click","contextmenu","mouseup"].concat(navigator.sendBeacon?[]:["mousedown","touchstart"]),Xc="",Yc=null;function Zc(){Yc=null}function $c(a){navigator.sendBeacon?navigator.sendBeacon(a):Yc&&a==Yc.src||((Yc=new Image).src=a,setTimeout(Zc,1E3))}function ad(){var a=lb(document.location.href).hl||"";a="/scholar_bfnav?url="+encodeURIComponent(document.location.href)+"&hl="+encodeURIComponent(a)+"&ei="+GSP.eventId;$c(a)}D(function(){Xc=Hb?"&bn=1":"";Hb&&ad()});
B(window,"pageshow",function(a){a.persisted&&(Xc="&bn=1",ad())});
B(document,Wc,function(a){if(!("click"==a.type&&a.button||"mouseup"==a.type&&1!=a.button)){var b,c;a:{for(a=a.target;a;){var d=a.nodeName;if("A"==d)break a;if("SPAN"==d||"B"==d||"I"==d||"EM"==d||"IMG"==d)a=a.parentNode;else break}a=null}a&&(b=a.getAttribute("href"))&&(c=a.getAttribute("data-clk"))&&(b="/scholar_url?url="+encodeURIComponent(b)+"&"+c+"&ws="+window.innerWidth+"x"+window.innerHeight+"&at=",c=encodeURIComponent,a=(a=a.getAttribute("data-clk-atid"))&&t(a),b=b+c(a&&a.innerText||"")+Xc,$c(b))}},
!1,!0);P(".gs_fm_s","click",function(a){a=a.currentTarget.getAttribute("data-fm")||"";(a=t(a))&&a.submit()});var V=function(a){this.m=x(a.querySelector(".gs_md_d"));this.G=x(a.querySelector(".gs_md_tb"))};V.prototype.I=function(a){var b=t(this.m);return void 0!==a?rc(b,b,a):null};V.prototype.open=function(a){a=this.I(a);if(p(t(this.G),"gs_sel"))try{a&&a.focus()}catch(c){}else{var b=t(this.G);Va(this.m,function(){l(b,"gs_sel")},function(){n(b,"gs_sel")},a,b)}};V.prototype.close=function(){H(this.m)};V.prototype.Z=function(a){L(a);p(t(this.G),"gs_sel")?this.close():this.open("keydown"==a.g.type?!1:void 0)};
V.prototype.U=function(a){var b=a.g.keyCode;if(38==b||40==b)L(a),this.open(38==b)};V.prototype.aa=function(a){a.target.id==this.m&&this.U(a)};Ub(V,[new M(".gs_md_rmb",{}),new M(".gs_md_tb",{"gs-press":V.prototype.Z,keydown:V.prototype.U}),new M(".gs_md_d",{keydown:V.prototype.aa})]);var W=function(a){V.call(this,a);this.ia=x(a.querySelector(".gs_md_in"));this.ja=x(a.querySelector(".gs_md_tb .gs_lbl"))};ia(W,V);W.prototype.I=function(){return t(this.m).querySelector(".gs_md_li[aria-selected]")};W.prototype.ba=function(a){bd(this,a)};W.prototype.J=function(a){var b=a.g.keyCode;13!=b&&32!=b||bd(this,a)};
var bd=function(a,b){var c=b.currentTarget,d=t(a.ia),e=a.I();c!=e&&(d.value=c.getAttribute("data-v"),t(a.ja).innerHTML=c.innerHTML,e&&cd(e,!1),cd(c,!0));L(b);a.close();O("gs-change",d,b.g)},cd=function(a,b){q(a,"gs_sel",b);b?a.setAttribute("aria-selected","true"):a.removeAttribute("aria-selected")};Ub(W,[new M(".gs_md_ris",{}),new M(".gs_md_li",{click:W.prototype.ba,keydown:W.prototype.J})]);P("#gs_lp","click",function(a){L(a);R("gs_lp_d")});P("#gs_lp_cur","click",function(a){L(a);H("gs_lp_d")});var dd=function(a){this.W=x(a)};dd.prototype.J=function(a){var b=a.currentTarget,c=a.g.keyCode;if(38==c||40==c){var d=t(this.W);d=rc(d,b,38==c)||rc(d,d,38==c)}else if(37==c||39==c)a:{c=!!(37==c^xa(b.parentNode));d=b.parentNode;var e=d.children,f=e.length;if(d.id!=this.W){for(;e[--f]!=b;);d=qc(d,c)||pc(d.parentNode,c);e=d.children;if(f=Math.min(f+1,e.length))if(d=e[f-1],p(d,"gs_md_li")&&d.offsetLeft!=b.offsetLeft)break a}d=void 0}d&&(L(a),d.focus())};
Ub(dd,[new M(".gs_md_ulr",{}),new M(".gs_md_li",{keydown:dd.prototype.J})]);P("#gs_hdr_mnu","click",function(a){L(a);R("gs_hdr_drw")});P("#gs_hdr_drw_mnu","click",function(a){L(a);H("gs_hdr_drw")});P("#gs_hdr_act_i","click",function(a){L(a);1==oa()?Ca(document.querySelector("#gs_hdr_drw_bot>a").href):Va("gs_hdr_act_d")});P("#gs_hdr_drw","keydown",function(a){var b=a.g.keyCode;if(38==b||40==b){var c=a.currentTarget;if(b=rc(c,c,38==b))L(a),b.focus()}});
P("#gs_hdr_tsi",["focus","blur"],function(a){function b(){var h=d.getBoundingClientRect().top-10;10<Math.abs(h)&&window.scrollBy(0,h);clearTimeout(e);c()}function c(){C(window,f,b)}var d=a.target;a="focus"==a.type;q(t("gs_hdr"),"gs_hdr_ifc",a);if(a&&pa&&!(749<window.innerHeight)){var e=setTimeout(c,1E3),f=["scroll","resize"];B(window,f,b)}});P("#gs_hdr_tsi",["input","gs-change"],function(a){q(t("gs_hdr_frm"),"gs_hdr_tsc",!!a.currentTarget.value)});
P("#gs_hdr_tsc","mousedown",function(a){L(a);var b=t("gs_hdr_tsi");b.value="";b.focus();O("input",b,a.g)});P("#gs_hdr_sre","click",function(a){L(a);var b=t("gs_hdr");Va("gs_hdr_frm",function(){n(b,"gs_hdr_src");l(b,"gs_hdr_srx")},function(){l(b,"gs_hdr_src");n(b,"gs_hdr_srx")},t("gs_hdr_tsi"))});P(".gs_md_x","click",function(a){(a=a.currentTarget.getAttribute("data-mdx"))&&H(a)});var X=function(){},ed,fd;X.prototype.$=function(a){a.g.button||(L(a),gd(a))};X.prototype.ca=function(a){hd(a)&&(L(a),gd(a))};X.prototype.da=function(a){hd(a)&&L(a)};X.prototype.ea=function(a){if(!a.g.button){L(a);var b=a.g;b&&(id=b.clientX||0,jd=b.clientY||0,B(document,kd,ld,!0),clearTimeout(ed),ed=setTimeout(md,2E3));gd(a)}};X.prototype.ha=function(a){L(a);if(nd){var b=a.g;if(b=(b=b&&b.touches)&&1==b.length&&b[0])od=b.clientX,pd=b.clientY,B(document,qd,rd,!0),clearTimeout(fd),fd=setTimeout(sd,2E3)}gd(a)};
var hd=function(a){a=a.g.keyCode;return 32==a||13==a},gd=function(a){O("gs-press",a.currentTarget,a.g)},md=function(){C(document,kd,ld,!0);clearTimeout(ed);ed=void 0},ld=function(a){"mousedown"!=a.type&&10>Math.abs(a.clientX-id)&&10>Math.abs(a.clientY-jd)?(Na(a),"click"==a.type&&md()):md()},sd=function(){C(document,qd,rd,!0);clearTimeout(fd);fd=void 0},rd=function(a){"touchstart"!=a.type&&10>Math.abs(a.clientX-od)&&10>Math.abs(a.clientY-pd)?(Na(a),"click"==a.type&&sd()):sd()},id=0,jd=0,kd=["mousedown",
"mouseup","click"],nd=r("Android")&&!r("Chrome"),od=0,pd=0,qd=["touchstart","mousedown","mouseup","click"];Ub(X,[new M(".gs_press",{click:X.prototype.$,keydown:X.prototype.ca,keyup:X.prototype.da,mousedown:X.prototype.ea,touchstart:X.prototype.ha})]);function td(){var a=0>ud.getBoundingClientRect().top;vd!=a&&(vd=a,q(wd,"gs_sth_vis",a),a?xd():(yd.style.left="",yd.style.width="",zd()))}function xd(){if(vd){var a=ud.getBoundingClientRect();yd.style.left=a.left+"px";yd.style.width=a.width+"px";zd()}}function zd(){O("gs-sth-change",t("gs_sth"))}var wd,ud,yd,vd=!1;D(function(){if(wd=t("gs_sth"))ud=wd.querySelector(".gs_sth_g"),yd=wd.querySelector(".gs_sth_b"),yc.addListener(td),zc.addListener(xd),td()});function Ad(){var a=t("gsc_rsb_co");if(a){a=a.querySelectorAll("img.gs_pp_df");for(var b=0;b<a.length;b++){var c=a[b];c.getAttribute("data-srcset")&&(c.setAttribute("srcset",c.getAttribute("data-srcset")),c.removeAttribute("data-srcset"));c.getAttribute("data-src")&&(c.setAttribute("src",c.getAttribute("data-src")),c.removeAttribute("data-src"))}}};var Bd=/\S+@\S+\.\S+/;function Cd(a){return p(a,"gsc_ccb_dis")||p(a,"gsc_ccb_lim")}function Dd(){for(var a=0>=Ed(),b=t("gsc_cods_res").querySelectorAll(".gsc_ccb_add"),c=b.length;c--;){var d=b[c];p(d,"gsc_ccb_on")||q(d,"gsc_ccb_lim",a)}};var Fd=function(a){this.X=a};Fd.prototype.fa=function(a){L(a);a=a.currentTarget.getAttribute("data-a");this.X.setAttribute("data-a",a||"");O("gsc-navigate",this.X)};var Gd=[new M(".gsc_pgn",{}),new M([".gsc_pgn_ppr",".gsc_pgn_pnx"],{click:Fd.prototype.fa})];function Hd(a,b){b=void 0===b?"":b;var c=t("gsc_md_cod");a+=fb({t:Id});R(c.id,a,"",b)}function Jd(a){if(Id!=a){var b=t("gsc_md_cod");n(b,Id);l(b,a);Id=a}}function Kd(){var a=kb(Fc).t;"gsc_cod_sugg"!=a&&"gsc_cod_lc"!=a||Jd(a)}function Ld(){var a=Md();a=a?a.value:"";var b=(t("gsc_cods_urls").getAttribute("data-sa")||"").replace(Nd,"$1"+encodeURIComponent(a));a=a?b:t("gsc_cods_urls").getAttribute("data-lc")||"";Hd(a)}
function Od(a){var b=t("gsc_cods_frm");if(b){b=b.elements;var c=b[1];b[0].disabled=c.disabled=a;q(c,"gs_bsp",a)}a=a?null:t("gsc_codb_data");if(c=t("gsc_cods_pp")){var d=a&&a.getAttribute("data-prev");b=a&&a.getAttribute("data-next");var e=a&&a.getAttribute("data-start"),f=a&&a.getAttribute("data-end");c.querySelector(".gsc_pgn_ppn").textContent=e&&f?e+" - "+f:"";e=c.querySelector(".gsc_pgn_ppr");e.disabled=!d;e.setAttribute("data-a",d||"");c=c.querySelector(".gsc_pgn_pnx");c.disabled=!b;c.setAttribute("data-a",
b||"")}a&&(Pd=+a.getAttribute("data-max")||0,za(t("gsc_cods_save"),"xsrf").value=a.getAttribute("data-xsrf")||"")}function Qd(){var a=0<Y.l||0<Z.l,b=Ed(),c=0>=b;t("gsc_cod_done").disabled=!a||0>b;q(t("gsc_cod_t"),"gsc_cod_changed",a);a=t("gsc_cod_trev");a.textContent=a.getAttribute(c?"data-lim":"data-txt")||"";q(t("gsc_cod_t"),"gsc_cod_lim",c)}function Ed(){return Pd-Y.l+("gsc_cod_sugg"==Id?0:Z.l)}function Md(){return t("gsc_cods_tsi")}
function Rd(a){for(var b="",c=la(a.j),d=c.length;d--;)b+=a.get(c[d]);return b}var Id="gsc_cod_lc",Pd=0,Nd=/([?&]mauthors=)([^&]*)/,Y=new Q,Z=new Q;function Sd(a){q(t("gsc_a_sp"),"gs_vis",0==a);q(t("gsc_a_err"),"gs_vis",2==a)}function Td(){return document.querySelectorAll("#gsc_a_t input[type=checkbox]")}function Ud(){O("gsc-works-change",t("gsc_a_t"))}function Vd(){var a=t("gsc_x_all");if(a){var b=document.querySelectorAll("#gsc_a_t input[type=checkbox]:checked");var c=b.length;var d=Td().length;c=c?c==d?1:2:0;vc(a,c);2==c&&(Wd=b)}Ud()}var Wd=[];var Xd="",Zd=0,ae=0;function be(a){for(var b=[!1,!1,!1],c=0;c<b.length;c++){var d=t(ce[c]);d&&(b[c]=!!a(d))}return b}function de(){var a=t("gsc_fol_m");if(a){var b=t("gsc_fol_b");if(!(a=!Bd.test(a.value))){a:{a=be(tc);for(var c=be(uc),d=0;d<a.length;d++)if(a[d]!=c[d]){a=!0;break a}a=!1}a=!a}b.disabled=a}}var ce=["gsc_fol_a","gsc_fol_c","gsc_fol_r"],ee=["follow_articles_btn","follow_citations_btn","follow_related_btn"];function fe(){p(document.documentElement,"gs_el_ph")||p(document.documentElement,"gs_el_ta")||Ad()};function ge(a){if(a){a.id&&a.removeAttribute("id");for(var b=0;b<a.children.length;b++)ge(a.children[b])}};function he(){var a=t("gsc_prf_pufii");if(r("MSIE ")){var b=t("gsc_prf_puf");Va("gsc_prf_pufi",function(){l(b,"gsc_prf_pufo")},function(){n(b,"gsc_prf_pufo")},a)}else a.click()};function ie(){var a=document.querySelectorAll(".gsc_prf_pnl"),b=document.documentElement;b=p(b,"gs_el_ph")||p(b,"gs_el_ta");for(var c=0;c<a.length;c++)a[c].setAttribute("role",b?"tabpanel":"region")};var je=kb(window.location.hash),ke=je.u||"";"gs_md_cita-d"==je.d&&ke.match(Ea)&&0<=ke.indexOf("view_citation")&&Ca(ke);P("#gsc_md_cod","gs-md-ldin",function(){Kd();Od(!0)});P("#gsc_md_cod","gs-md-lded",function(){Kd();Od(!1);for(var a=t("gsc_cods_res").querySelectorAll(".gsc_ccb_ck"),b=a.length;b--;){var c=a[b];if(!Cd(c)){var d=c.getAttribute("data-authorid")||"";d=(p(c,"gsc_ccb_add")?Y:Z).has(d);q(c,"gsc_ccb_on",d)}}Dd();Qd();a=lb(Fc);(b=Md())&&(b.value=a.mauthors||"")});
P("#gsc_cods_frm","gsc-lwpds-submit",Ld);P("#gsc_cods_pp","gsc-navigate",function(a){(a=a.currentTarget.getAttribute("data-a"))&&Hd(a)});
P([".gsc_ccb_add",".gsc_ccb_del"],"click",function(a){a=a.currentTarget;if(!Cd(a)){var b=!p(a,"gsc_ccb_on");q(a,"gsc_ccb_on",b);var c=p(a,"gsc_ccb_add")?".gsc_ccb_del":".gsc_ccb_add",d=a.parentNode;(c=d&&d.querySelector(c))&&n(c,"gsc_ccb_on");c=a.getAttribute("data-authorid")||"";Y.delete(c);Z.delete(c);b&&(p(a,"gsc_ccb_add")?Y:Z).set(c,t("gsc_ucoar-"+c).outerHTML);Dd();Qd()}});
P("#gsc_cod_trev","click",function(){var a=t("gsc_cods_res").cloneNode(!0),b=a.querySelector("#gsc_codb_content");b||(b=document.createElement("div"),b.id="gsc_codb_content",a.appendChild(b));var c=Rd(Y)+Rd(Z);b.innerHTML=c;(b=Md())&&(b.value="");Hd("",a.innerHTML)});P("#gsc_cod_done","click",function(){var a=t("gsc_cods_save");za(a,"colleague_add").value=la(Y.j).join(",");za(a,"colleague_del").value=la(Z.j).join(",");a.submit()});
P(["#gsc_coauth_opn",".gsc_rsb_btne",".gsc_rsb_btnv"],"click",function(){Jd("gsc_cod_lc");Pd=0;Y.clear();Z.clear();var a=Md();a&&(a.value="");Ld()});P(".gsc_rsb_aa",["click","keydown"],function(a){if("keydown"!=a.type||a.g&&!Oa(a.g)&&13==a.g.keyCode)a.g&&Na(a.g),(a=(a=a.currentTarget.querySelector("a"))?a.getAttribute("href"):"")&&Ca(a)});P("#gsc_prf_t-ath","click",function(){Ad()});D(function(){Ac.add(fe);fe()});P(".gsc_lwpds_frm","submit",function(a){L(a);O("gsc-lwpds-submit",a.target)});
var le=window.location.href.split("#")[0];Xd=le.replace(/([?&])(cstart|pagesize)=[^&]*/g,"$1");Zd=Math.max(+le.replace(/.*[?&]cstart=([^&]*).*/,"$1")||0,0);ae=+le.replace(/.*[?&]pagesize=([^&]*).*/,"$1")||0;ae=Math.max(Math.min(ae,100),20);
P("#gsc_bpf_more","click",function(a){var b=a.currentTarget,c=ae,d=100>c?100-c:100;a=(Xd+"&cstart="+(Zd+c)+"&pagesize="+d).replace(/([?&])&+/g,"$1");Sd(0);b.disabled=!0;Qb(a,"json=1",function(e,f){b.disabled=!1;try{var h=200==e&&JSON.parse(f)}catch(m){}if(h&&"object"==typeof h){ae=c+=d;Sd(1);e=t("gsc_a_b");f=document.createElement(va.Y);f.innerHTML=""+h.B;f=Array.prototype.slice.call(f.rows);for(var k=0;k<f.length;k++)e.appendChild(f[k]);Vd();if(e=t("gsc_a_nn"))f=e.innerHTML.replace(/[0-9]+$/,""+
t("gsc_a_b").rows.length),e.innerHTML=f;b.disabled=!h.N}else Sd(2)})});P(["#gsc_fol_a","#gsc_fol_c","#gsc_fol_r"],"gs-change",de);P("#gsc_fol_m","input",de);P("#gsc_fol_f","submit",function(a){a.g&&a.g.preventDefault();a=t("gsc_fol_f");var b=t("gsc_fol_inp");b.innerHTML="";for(var c=be(tc),d=be(uc),e=0;e<c.length;e++)if(c[e]!=d[e]){var f=ee[e],h=document.createElement("input");h.type="hidden";h.name=c[e]?f:"un"+f;b.appendChild(h)}O("gsc-fol-submit",a)});P("#gsc_fol_f","gsc-fol-submit",function(a){a.currentTarget.submit()});
P("#gsc_md_hist","gs-md-lded",function(){var a=t("gsc_md_hist_c");if(!a.innerHTML){var b=document.getElementsByClassName("gsc_g_hist_wrp");1==b.length&&(a.appendChild(b[0].cloneNode(!0)),ge(a.lastChild))}});P(["#gsc_hist_opn",".gsc_md_hist_b"],"click",function(){var a=document.documentElement;!t("gsc_hist_opn")||p(a,"gs_el_ph")||p(a,"gs_el_ta")||R("gsc_md_hist")});
P("#gsc_lwp_mndt_lnk","click",function(a){var b=a.currentTarget.getAttribute("href")+"&tzom="+(new Date).getTimezoneOffset();window.location.assign(b);a.g.preventDefault()});P("#gsc_prf_btne","click",function(){var a=t("gsc_md_pro-d");a.setAttribute("data-ifc","");R(a.id,fb({t:"gsc_md_pro_ed"}))});P("#gsc_prf_btnf","click",function(){R("gsc_md_fol")});P("#gsc_md_fol_pub","click",function(){t("gsc_fol_mpf").submit()});P("#gsc_prf_iv_tg","click",function(){q(t("gsc_prf_w"),"gsc_prf_why")});
P(".gsc_prf_pel",["click","keydown"],function(a){("keydown"!=a.type||13==a.g.keyCode&&a.g&&!Oa(a.g))&&he()});P("#gsc_prf_pufii","change",function(){t("gsc_prf_puf").submit()});P(".gsc_prf_tab","click",function(a){var b=t("gsc_bdy");b.setAttribute("data-tab",a.currentTarget.id);b=b.querySelectorAll(".gsc_prf_tab");for(var c=0;c<b.length;c++){var d=b[c];d.setAttribute("aria-selected",""+(d==a.currentTarget))}});D(function(){Ac.add(ie);ie()});
P("#gsc_md_cbyd","gs-md-ldin",function(){var a=t("gsc_md_cbyd_merge");a&&(a.disabled=!0);Aa("")});P("#gsc_md_cbyd","gs-md-lded",function(){var a=t("gsc_md_cbyd_f"),b=t("gsc_md_cbyd_merge"),c=Fc,d=lb(c).s||"";c=kb(c).c||"";a.elements.s.value=d;Aa(c);b&&a.elements.choose&&(b.disabled=!1,b.getBoundingClientRect().bottom<window.innerHeight&&b.focus())});
P("#gsc_md_cbym",["gs-md-ldin","gs-md-lded"],function(){var a=lb(Fc).s||"",b=t("gsc_md_cbym_e");b&&a&&0>a.indexOf("&")&&b.setAttribute("data-href",(b.getAttribute("data-href")||"").replace(/(&citation_for_view=)[^&]*/,"$1"+a))});P("#gsc_md_cbym_e","click",function(a){a=a.currentTarget.getAttribute("data-href")||"";R("gs_md_cita-d",a)});Ub(Fd,Gd);D(function(){return setTimeout(Vd,0)});P(".gsc_a_x","change",Vd);
P("#gsc_x_all","gs-change",function(a){a=tc(a.currentTarget);for(var b=2==a?Wd:Td(),c=b.length;c--;)b[c].checked=0!=a;Ud()});P(".gsc_a_acm","click",function(a){L(a);var b=a.currentTarget;a=b.href;var c=b.getAttribute("data-eid")||"";b=b.getAttribute("data-eud")||"";a=t("gsc_md_cbyd_f").action+"&update_op=merge_options&s="+(b+","+c)+fb({c:a});R("gsc_md_cbyd",a)});
P(".gsc_a_am","click",function(a){a=a.currentTarget.getAttribute("data-eid")||"";a=(t("gsc_md_cbym_l").getAttribute("data-act")||"")+"&update_op=merge_options&s="+a;R("gsc_md_cbym",a)});P("#gs_sth","gs-sth-change",function(a){var b=t("gsc_a_tr0"),c=t("gsc_a_trh"),d=b.querySelector(".gsc_a_t"),e=c.querySelector(".gsc_a_t");p(a.currentTarget,"gs_sth_vis")?(e.style.width=d.offsetWidth+"px",b.style.height=c.offsetHeight+"px"):e.style.width=b.style.height="auto"});
P("#gs_md_cita-b-save","click",function(){var a=t("gsc_ecd_form");za(a,"continue").value=window.location.pathname+window.location.search;O("submit",a)});P(".gsc_ecd_form_tsel","click",function(a){var b=t("gsc_ecd_table"),c=za(t("gsc_ecd_form"),"articletype");a=a.currentTarget;c.value=a.getAttribute("data-type")||"";b.className=a.getAttribute("data-class")||"";b=document.querySelectorAll("#gsc_ecd_citation_type button");for(c=b.length;c--;)q(b[c],"gs_sel",b[c]==a)});
}({"customAC":2,"eventId":"o1JAYcKcCMX_mQGs3bn4Dw"});</script></head><body><div id="gs_top" onclick=""><style>#gs_md_s,.gs_md_wnw{z-index:1200;position:fixed;top:0;left:0;width:100%;height:100%;visibility:hidden;}#gs_md_s{background-color:#fff;opacity:.5;}.gs_el_ta #gs_md_s,.gs_el_ph #gs_md_s{background-color:#666;}.gs_md_wnw{transition:all 0s .218s;}#gs_md_s.gs_vis,.gs_md_wnw.gs_vis{visibility:visible;transition:all 0s;}.gs_md_wnw>.gs_md_d{position:relative;margin:0 auto;width:464px;box-shadow:2px 2px 8px rgba(0,0,0,.2);white-space:normal;}.gs_el_ta .gs_md_wnw>.gs_md_d,.gs_el_ph .gs_md_wnw>.gs_md_d{box-shadow:2px 2px 8px rgba(0,0,0,.65);}.gs_el_ph .gs_md_wnw>.gs_md_d{width:80%;max-width:440px;}.gs_el_ph .gs_md_wmw>.gs_md_d{width:100%;height:100%;max-width:none;border:none;box-shadow:none;transform:translate(0,100%);transform:translate(0,100vh);transition:transform .27s cubic-bezier(.4,0,.6,1),opacity 0s .27s,visibility 0s .27s,max-height 0s .27s;}.gs_el_ph .gs_md_wmw>.gs_md_d.gs_vis{transform:translate(0,0);transition:transform .3s cubic-bezier(0,0,.2,1);}.gs_md_wmw>.gs_md_d.gs_abt,.gs_el_ph .gs_md_wmw>.gs_md_d.gs_abt{transition:none;}.gs_md_hdr{display:flex;align-items:center;height:47px;border-bottom:1px solid #e0e0e0;border-bottom-color:rgba(0,0,0,.12);background-color:#f5f5f5;}.gs_md_hdr>a,.gs_md_hdr>a.gs_btn_lrge{flex:0 0 auto;width:41px;height:47px;}.gs_el_ph .gs_md_hdr>a{margin:0 2px 0 0;}.gs_el_ph a.gs_md_hdr_c{margin:0 0 0 2px;}.gs_md_hdr_b{margin:0 41px 0 16px;}.gs_el_ph .gs_md_hdr_b{margin:0 16px;}.gs_md_hdr_t:empty~.gs_md_hdr_b{margin-left:0;}.gs_md_hdr_b:empty{width:41px;margin:0;}.gs_el_ph .gs_md_hdr_b:empty{margin-right:2px;}.gs_md_hdr_b:empty:not(:last-child){display:none;}.gs_md_hdr_b>button{min-width:51px;height:33px;}.gs_md_hdr_t{flex:1 1 auto;font-size:18px;font-weight:normal;color:#666;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;text-align:center;}.gs_md_bdy{overflow-y:auto;box-sizing:border-box;padding:24px 41px 0 41px;}.gs_md_bdy:after{display:block;content:"";clear:both;padding-bottom:24px;}.gs_el_ph .gs_md_bdy{padding:16px 16px 0 16px;}.gs_el_ph .gs_md_bdy:after{padding-bottom:16px;}.gs_el_ph .gs_md_wmw .gs_md_bdy{position:absolute;width:100%;top:48px;bottom:0;}.gs_md_lbl{display:block;font-size:16px;margin:0 0 16px 0;word-wrap:break-word;}.gs_md_btns{margin:24px 0 0 0;white-space:nowrap;}.gs_el_ph .gs_md_btns{margin:16px 0 0 0;}.gs_md_btns button{margin-right:16px;}.gs_md_btns button:last-child{margin-right:0;}.gs_md_prg{margin:24px 0;text-align:center;}.gs_md_prg .gs_alrt{padding:4px 16px;}.gs_md_ldg:before{content:"";position:absolute;top:0;left:0;bottom:0;right:0;background-color:#fff;opacity:.5;z-index:100;}</style><div id="gs_md_ldg" style="display:none">Loading...</div><div id="gs_md_err" style="display:none">The system can't perform the operation now. Try again later.</div><div id="gs_md_s"></div><div data-h="0" class="gs_md_wnw"><div id="gsc_md_hist" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_hist-t" data-wfc="gsc_md_hist-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_hist-x" role="button" aria-label="Cancel" data-mdx="gsc_md_hist" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_hist-t" class="gs_md_hdr_t">Citations per year</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_hist-bdy" class="gs_md_bdy"><style>#gsc_md_hist{width:80%;max-width:386px;}#gsc_md_hist_c{position:relative;width:100%;}</style><div id="gsc_md_hist_c"></div></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbyd" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbyd-t" data-cid="gsc_md_cbyd_l" data-wfc="gsc_md_cbyd-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbyd-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbyd" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbyd-t" class="gs_md_hdr_t">Duplicate citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbyd-bdy" class="gs_md_bdy"><form id="gsc_md_cbyd_f" action="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works" method="post"><input type="hidden" name="s" value=""><div class="gs_md_lbl">The following articles are merged in Scholar. Their <a id="gsc_md_cbyd_c" href="javascript:void(0)">combined citations</a> are counted only for the first article.</div><div id="gsc_md_cbyd_l"></div></form></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbym" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbym-t" data-cid="gsc_md_cbym_l" data-wfc="gsc_md_cbym-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbym-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbym" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbym-t" class="gs_md_hdr_t">Merged citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbym-bdy" class="gs_md_bdy"><div class="gs_md_lbl">This "Cited by" count includes citations to the following articles in Scholar. The ones marked <span id="gsc_md_cbym_s">*</span> may be different from the article in the profile.</div><div id="gsc_md_cbym_l" data-act="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works"></div></div></div></div><div data-h="900" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cod" class="gs_md_d gs_ttzi gsc_cod_lc" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cod-t" data-cid="gsc_cods_res" data-wfc="gsc_md_cod-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cod-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cod" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cod-t" class="gs_md_hdr_t"><span id="gsc_cod_t"><span id="gsc_cod_tadd">Add co-authors</span><span id="gsc_cod_tedit">Co-authors</span><a id="gsc_cod_trev" href="javascript:void(0)" data-txt="Review" data-lim="Limit reached"></a></span></h2><div class="gs_md_hdr_b"><button type="button" id="gsc_cod_done" aria-label="Add co-authors" disabled="" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gsc_md_cod-bdy" class="gs_md_bdy"><div id="gsc_cods_urls" class="gsc_cods_hide" data-ls="" data-lc="/citations?view_op=list_colleagues&amp;hl=en&amp;json=&amp;user=OB_eiO0AAAAJ" data-sa=""></div><form id="gsc_cods_save" action="" method="POST"><input type="hidden" name="colleague_add"><input type="hidden" name="colleague_del"></form><div id="gsc_cods_res"></div></div></div></div><div data-h="800" class="gs_md_wnw gs_md_wmw"><div id="gs_md_cita-d" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gs_md_cita-d-t" data-cid="gs_md_cita-l" data-wfc="gs_md_cita-d-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gs_md_cita-d-x" role="button" aria-label="Cancel" data-mdx="gs_md_cita-d" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gs_md_cita-d-t" class="gs_md_hdr_t"></h2><div class="gs_md_hdr_b"><button type="button" id="gs_md_cita-b-save" aria-label="Save" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gs_md_cita-d-bdy" class="gs_md_bdy"><style>#gs_md_cita-d{width:90%;max-width:1000px;}.gs_el_ph #gs_md_cita-d{width:100%;max-width:none;}#gs_md_cita-d .gs_md_prg{min-height:600px;}</style><div id="gs_md_cita-l" aria-live="assertive"></div></div></div></div><div data-h="0" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_fol" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_fol-t" data-wfc="gsc_md_fol-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_fol-x" role="button" aria-label="Cancel" data-mdx="gsc_md_fol" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_fol-t" class="gs_md_hdr_t">Follow this author</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_fol-bdy" class="gs_md_bdy"><form method="post" id="gsc_fol_f" action="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYUGkI_cnEA8z2ZdXU6ubh5c4IjglGtG9"><input type="hidden" name="user" value="OB_eiO0AAAAJ"><div id="gsc_fol_inp"></div><div id="gsc_fol_cb"><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_a" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles by this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_c" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New citations to this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_r" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles related to this author's research</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div></div><div id="gsc_fol_email"><label id="gsc_fol_ml" for="gsc_fol_m">Email address for updates</label><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="email_for_op" value="" id="gsc_fol_m" maxlength="100" autocapitalize="off" autocorrect="off"></div></div><div class="gs_md_btns"><button type="submit" id="gsc_fol_b" disabled="" class=" gs_btn_act gs_btn_lrge gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">Done</span></span></button></div></form></div></div></div><!--[if lte IE 9]><div class="gs_alrt" style="padding:16px"><div>Sorry, some features may not work in this version of Internet Explorer.</div><div>Please use <a href="//www.google.com/chrome/">Google Chrome</a> or <a href="//www.mozilla.com/firefox/">Mozilla Firefox</a> for the best experience.</div></div><![endif]--><div id="gs_hdr_drs"></div><div id="gs_hdr_drw" class="gs_md_ulr" role="dialog" tabindex="-1" data-shd="gs_hdr_drs" data-wfc="gs_hdr_drw_mnu" data-cfc="gs_hdr_mnu"><div id="gs_hdr_drw_in"><div id="gs_hdr_drw_top"><a href="javascript:void(0)" id="gs_hdr_drw_mnu" role="button" aria-controls="gs_hdr_drw" aria-label="Options" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_drw_lgo" href="/schhp?hl=en" aria-label="Homepage"></a></div><div><div class="gs_hdr_drw_sec"><a href="/citations?hl=en" role="menuitem" class="gs_btnPRO gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My profile</span></a><a href="/scholar?scilib=1&amp;hl=en" role="menuitem" class="gs_btnL gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My library</span></a><a href="/citations?view_op=metrics_intro&amp;hl=en" role="menuitem" class="gs_btnJ gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Metrics</span></a><a href="/scholar_alerts?view_op=list_alerts&amp;hl=en" role="menuitem" class="gs_btnM gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Alerts</span></a></div><div class="gs_hdr_drw_sec"><a href="/scholar_settings?hl=en" role="menuitem" class="gs_btnP gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Settings</span></a></div></div><div id="gs_hdr_drw_bot" class="gs_hdr_drw_sec"><a href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den" class=" gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Sign in</span></a></div></div></div><div id="gs_hdr" role="banner" class="gs_hdr_src"><a href="javascript:void(0)" id="gs_hdr_mnu" role="button" aria-controls="gs_hdr_drw" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_lgo" class="" href="/schhp?hl=en" aria-label="Homepage"></a><div id="gs_hdr_md"><div id="gs_hdr_srch"><form id="gs_hdr_frm" action="/citations"><input type="hidden" name="view_op" value="search_authors"><input type="hidden" name="hl" value="en"><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="mauthors" value="" id="gs_hdr_tsi" placeholder="Search profiles" size="50" maxlength="2048" autocapitalize="off" aria-label="Search"></div><span id="gs_hdr_tsc"><span class="gs_ico gs_ico_X"></span></span><button type="submit" id="gs_hdr_tsb" name="btnG" aria-label="Search" class="gs_btnG gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></form></div></div><a href="javascript:void(0)" id="gs_hdr_sre" role="button" aria-controls="gs_hdr_frm" aria-label="Search" class="gs_btnTSB gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><div id="gs_hdr_act"><a id="gs_hdr_act_s" href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den">Sign in</a></div></div><style>#gs_alrt{position:fixed;bottom:48px;left:16px;max-width:384px;z-index:1250;display:flex;justify-content:space-between;align-items:center;font-size:13px;line-height:16px;color:#e2e2e2;background:#333;text-align:left;border-radius:3px;box-shadow:0 3px 5px -1px rgba(0,0,0,.2),0 6px 10px 0 rgba(0,0,0,.14),0 1px 18px 0 rgba(0,0,0,.12);visibility:hidden;transform-origin:center;transform:scale(0.8,0.8) translate(0,100%);}.gs_el_ph #gs_alrt{bottom:0;left:0;width:100%;max-width:none;border-radius:0;box-shadow:none;transform:scale(1,1) translate(0,100%);}#gs_alrt.gs_vis{visibility:visible;transform:scale(1,1) translate(0,0);}#gs_alrt.gs_anm{transition:transform .067s cubic-bezier(.4,0,1,1),visibility 0s .067s;}#gs_alrt.gs_vis.gs_anm{transition:transform .067s cubic-bezier(0,0,.2,1);}.gs_el_ph #gs_alrt.gs_anm{transition:transform .084s cubic-bezier(.4,0,1,1),visibility 0s .084s;}.gs_el_ph #gs_alrt.gs_vis.gs_anm{transition:transform .1s cubic-bezier(0,0,.2,1);}#gs_alrt_m{display:block;padding:16px;}#gs_alrt_l{display:block;padding:8px;margin:0 8px 0 -8px;border-radius:3px;color:#fcc934;text-transform:uppercase;text-decoration:none;}#gs_alrt_l:hover{background-color:rgba(255,255,255,.05)}#gs_alrt_l:active{background-color:rgba(255,255,255,.1)}#gs_alrt_l:empty{display:none}#gs_alrt_m a{padding:8px 0;color:#e2e2e2;text-decoration:underline;}#gs_alrt_m a:active{color:#f6aea9}</style><form action="" method="post" id="gs_alrt"><span id="gs_alrt_m"></span><span id="gs_alrt_h"></span><a id="gs_alrt_l" href="javascript:void(0)" class="gs_fm_s" data-fm="gs_alrt"></a></form><div id="gs_bdy"><div id="gs_bdy_sb" role="navigation"><div id="gs_bdy_sb_in"></div></div><div id="gs_bdy_ccl" role="main"><div id="gsc_bdy" class="gs_scl" data-tab="gsc_prf_t-art"><div class="gsc_rsb" role="navigation"><a id="gsc_rsb_gpl" class="gsc_rsb_s" href="/citations?hl=en">Get my own profile</a><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_cit" role="region" aria-labelledby="gsc_prf_t-cit"><h3 class="gsc_rsb_header"><span class="gsc_rsb_title">Cited by</span><button type="button" id="gsc_hist_opn" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu gsc_rsb_action"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></h3><table id="gsc_rsb_st"><thead><tr><th class="gsc_rsb_sth"></th><th class="gsc_rsb_sth">All</th><th class="gsc_rsb_sth">Since 2016</th></tr></thead><tbody><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="This is the number of citations to all publications. The second column has the &quot;recent&quot; version of this metric which is the number of new citations in the last 5 years to all publications.">Citations</a></td><td class="gsc_rsb_std">10744</td><td class="gsc_rsb_std">7120</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="h-index is the largest number h such that h publications have at least h citations. The second column has the &quot;recent&quot; version of this metric which is the largest number h such that h publications have at least h new citations in the last 5 years.">h-index</a></td><td class="gsc_rsb_std">53</td><td class="gsc_rsb_std">44</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="i10-index is the number of publications with at least 10 citations. The second column has the &quot;recent&quot; version of this metric which is the number of publications that have received at least 10 new citations in the last 5 years.">i10-index</a></td><td class="gsc_rsb_std">140</td><td class="gsc_rsb_std">118</td></tr></tbody></table><style>.gsc_g_t{position:absolute;bottom:0;color:#777;font-size:11px;}.gsc_g_a{position:absolute;bottom:13px;width:15px;background:#777;}.gsc_g_a:hover,.gsc_g_a:focus,.gsc_g_a:active{text-decoration:none;cursor:default;}.gsc_g_al{position:absolute;bottom:15px;left:7px;color:#222;background:white;font-size:11px;padding:1px;border:1px solid #777;border-radius:1px;visibility:hidden;opacity:0;transition:opacity .218s,visibility 0s .218s;}.gsc_g_a:hover .gsc_g_al,.gsc_g_a:focus .gsc_g_al,.gsc_g_a:active .gsc_g_al{visibility:visible;opacity:1;transition:all 0s;}#gsc_md_hist{max-width:518px;}.gsc_md_hist_w{position:relative;overflow:hidden;margin-right:43px;}.gs_md_bdy .gsc_md_hist_w,.gs_el_ph .gsc_md_hist_w,.gs_el_ta .gsc_md_hist_w{overflow-x:auto;padding-bottom:16px;}.gsc_md_hist_b{position:relative;height:174px;width:100%;}.gsc_md_hist_b .gsc_g_a{bottom:auto;}.gsc_md_hist_b .gsc_g_t{bottom:auto;top:161px;}.gsc_md_hist_b:after{position:absolute;right:472px;content:"\00A0";}.gsc_g_hist_x{position:relative;margin-right:45px;}.gsc_g_hist_xl{position:absolute;right:8px;width:35px;}.gs_el_ta .gsc_g_hist_xl,.gs_el_ph .gsc_g_hist_xl{right:16px;}.gsc_g_hist_wrp{padding-top:32px;position:relative;}.gs_el_ta .gsc_g_hist_wrp,.gs_el_ph .gsc_g_hist_wrp{padding-right:8px;}.gs_md_bdy .gsc_g_hist_wrp{border-top:0;}.gs_el_tc .gs_md_bdy .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ph .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ta .gsc_g_hist_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;left:0;width:20px;height:100%;background-image:linear-gradient(to left,rgba(255,255,255,0),rgba(255,255,255,1) 80%);}.gsc_g_x,.gsc_g_xt{position:absolute;left:0;border-bottom:1px solid #eee;width:100%;text-align:right;}.gsc_g_x{border-bottom:1px solid #eee;}.gsc_g_xtl{position:absolute;color:#777;}.gsc_g_gtr{position:absolute;}.gsc_g_a:last-child .gsc_g_al{right:0;left:auto;}</style><div class="gsc_g_hist_wrp" dir="rtl"><div class="gsc_g_hist_x"><div class="gsc_g_x" style="top:160px;"></div><div class="gsc_g_xt" style="top:0px;"></div><div class="gsc_g_xt" style="top:80px;"></div><div class="gsc_g_xt" style="top:120px;"></div><div class="gsc_g_xt" style="top:40px;"></div></div><div class="gsc_g_hist_xl"><div class="gsc_g_xtl" style="top:153px;">0</div><div class="gsc_g_xtl" style="top:-7px;">1400</div><div class="gsc_g_xtl" style="top:73px;">700</div><div class="gsc_g_xtl" style="top:113px;">350</div><div class="gsc_g_xtl" style="top:33px;">1050</div></div><div class="gsc_md_hist_w"><div class="gsc_md_hist_b"><span class="gsc_g_t" style="right:419px">2008</span><span class="gsc_g_t" style="right:387px">2009</span><span class="gsc_g_t" style="right:355px">2010</span><span class="gsc_g_t" style="right:323px">2011</span><span class="gsc_g_t" style="right:291px">2012</span><span class="gsc_g_t" style="right:259px">2013</span><span class="gsc_g_t" style="right:227px">2014</span><span class="gsc_g_t" style="right:195px">2015</span><span class="gsc_g_t" style="right:163px">2016</span><span class="gsc_g_t" style="right:131px">2017</span><span class="gsc_g_t" style="right:99px">2018</span><span class="gsc_g_t" style="right:67px">2019</span><span class="gsc_g_t" style="right:35px">2020</span><span class="gsc_g_t" style="right:3px">2021</span><a href="javascript:void(0)" class="gsc_g_a" style="right:424px;top:157px;height:3px;z-index:14"><span class="gsc_g_al">32</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:392px;top:150px;height:10px;z-index:13"><span class="gsc_g_al">94</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:360px;top:137px;height:23px;z-index:12"><span class="gsc_g_al">204</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:328px;top:127px;height:33px;z-index:11"><span class="gsc_g_al">293</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:296px;top:107px;height:53px;z-index:10"><span class="gsc_g_al">472</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:264px;top:91px;height:69px;z-index:9"><span class="gsc_g_al">607</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:232px;top:74px;height:86px;z-index:8"><span class="gsc_g_al">756</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:200px;top:60px;height:100px;z-index:7"><span class="gsc_g_al">880</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:168px;top:31px;height:129px;z-index:6"><span class="gsc_g_al">1136</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:136px;top:43px;height:117px;z-index:5"><span class="gsc_g_al">1024</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:104px;top:30px;height:130px;z-index:4"><span class="gsc_g_al">1144</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:72px;top:22px;height:138px;z-index:3"><span class="gsc_g_al">1216</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:40px;top:4px;height:156px;z-index:2"><span class="gsc_g_al">1366</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:8px;top:35px;height:125px;z-index:1"><span class="gsc_g_al">1096</span></a></div></div></div></div><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_mnd" role="region" aria-labelledby="gsc_prf_t-mnd"><div class="gsc_rsb_header gsc_rsb_m_header"><div class="gsc_rsb_m_title">Public access</div><a href="/citations?view_op=list_mandates&amp;hl=en&amp;user=OB_eiO0AAAAJ" id="gsc_lwp_mndt_lnk">View all</a></div><div class="gsc_rsb_hm gs_ota gs_oph"><button type="button" onclick="window.location='/citations?view_op\x3dlist_mandates\x26hl\x3den\x26user\x3dOB_eiO0AAAAJ'" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></div><div class="gsc_rsb_m"><div class="gsc_rsb_m_a"><span>43 articles</span></div><div class="gsc_rsb_m_na"><div>5 articles</div></div><div class="gsc_rsb_m_bar"><div class="gsc_rsb_m_bar_na" style="width:10%"></div></div><div class="gsc_rsb_m_a"><span>available</span></div><div class="gsc_rsb_m_na"><span>not available</span></div><div class="gsc_rsb_m_desc">Based on funding mandates</div></div></div></div><div class="gsc_lcl" role="main" id="gsc_prf_w"><div id="gsc_prf"><button type="button" id="gsc_prf_btnf" class="gs_btnMW gs_in_ib gs_btn_act gs_btn_lsu gs_btn_mph"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Follow</span></span></button><div id="gsc_prf_pu"><div id="gsc_prf_pua" class="gs_rimg"><style>#gsc_prf_pup-img{width:128px;height:128px;}@media print{#gs_top #gsc_prf_pup-img{width:80pt;height:80pt;}}</style><img alt="Chloe Orkin" sizes="print 80px,128px" src="/citations/images/avatar_scholar_128.png" id="gsc_prf_pup-img" srcset="/citations/images/avatar_scholar_128.png 128w,/citations/images/avatar_scholar_256.png 256w"></div></div><div id="gsc_prf_i"><div id="gsc_prf_in">Chloe Orkin</div><div class="gsc_prf_il">Professor of HIV Medicine , <a href="/citations?view_op=view_org&amp;hl=en&amp;org=11628095156398365105" class="gsc_prf_ila">Queen Mary University of London</a></div><div class="gsc_prf_il" id="gsc_prf_ivh">Verified email at qmul.ac.uk</div><div class="gsc_prf_il" id="gsc_prf_int"><a href="/citations?view_op=search_authors&amp;hl=en&amp;mauthors=label:hiv" class="gsc_prf_inta gs_ibl">HIV</a></div></div></div></div><div id="gsc_prf_t_wrp" role="navigation"><div id="gsc_prf_t" role="tablist"><a id="gsc_prf_t-art" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_art" aria-selected="true">Articles</a><a id="gsc_prf_t-cit" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_cit">Cited by</a><a id="gsc_prf_t-mnd" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_mnd">Public access</a></div></div><div class="gsc_lcl gsc_prf_pnl" id="gsc_art" role="region" aria-labelledby="gsc_prf_t-art"><form method="post" action="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYUGkI_cnEA8z2ZdXU6ubh5c4IjglGtG9"><div id="gsc_a_tw"><table id="gsc_a_t"><thead><tr id="gsc_a_tr0" aria-hidden="true"><th class="gsc_a_t"></th><th class="gsc_a_c"></th><th class="gsc_a_y"></th></tr><tr id="gsc_a_trh"><th class="gsc_a_t" scope="col"><span id="gsc_a_ta"><a href="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works&amp;sortby=title" class="gsc_a_a">Title</a></span><div id="gsc_dd_sort-r" class="gs_md_r gs_md_rmb gs_md_rmbl"><button type="button" id="gsc_dd_sort-b" aria-controls="gsc_dd_sort-d" aria-haspopup="true" ontouchstart="gs_evt_dsp(event)" class=" gs_in_se gs_btn_mnu gs_btn_flat gs_btn_lrge gs_btn_half gs_btn_lsu gs_press gs_md_tb"><span class="gs_wr"><span class="gs_lbl">Sort</span><span class="gs_icm"></span></span></button><div id="gsc_dd_sort-d" class="gs_md_d gs_md_ulr" role="menu" tabindex="-1"><div id="gsc_dd_sort-s" class="gs_oph gsc_dd_sec gsc_dd_sep"><a role="menuitem" href="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works" tabindex="-1" class="gs_md_li gsc_dd_sort-sel">Sort by citations</a><a role="menuitem" href="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works&amp;sortby=pubdate" tabindex="-1" class="gs_md_li">Sort by year</a><a role="menuitem" href="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works&amp;sortby=title" tabindex="-1" class="gs_md_li">Sort by title</a></div></div></div></th><th class="gsc_a_c" scope="col" dir="rtl"><span id="gsc_a_ca"><div class="gs_nph">Cited by</div><div class="gs_oph">Cited by</div></span></th><th class="gsc_a_y" scope="col"><span class="gsc_a_h" id="gsc_a_ha"><a href="/citations?hl=en&amp;user=OB_eiO0AAAAJ&amp;view_op=list_works&amp;sortby=pubdate" class="gsc_a_a">Year</a></span></th></tr></thead><tbody id="gsc_a_b"><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:J_g5lzvAfSwC" class="gsc_a_at">Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study</a><div class="gs_gray">F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ...</div><div class="gs_gray">The Lancet 381 (9868), 735-743<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5037546950312337300" class="gsc_a_ac gs_ibl">529</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:p__nRnzSRKYC" class="gsc_a_at">Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy</a><div class="gs_gray">MT May, M Gompels, V Delpech, K Porter, C Orkin, S Kegg, P Hay, ...</div><div class="gs_gray">AIDS (London, England) 28 (8), 1193<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13512011772897333751" class="gsc_a_ac gs_ibl">501</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:XvxMoLDsR5gC" class="gsc_a_at">Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals</a><div class="gs_gray">D Corti, JPM Langedijk, A Hinz, MS Seaman, F Vanzetta, ...</div><div class="gs_gray">PloS one 5 (1), e8805<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16746151112030571073" class="gsc_a_ac gs_ibl">484</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:BUYA1_V_uYcC" class="gsc_a_at">Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study</a><div class="gs_gray">HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ...</div><div class="gs_gray">Clinical Infectious Diseases 51 (8), 963-972<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13327546836521266632" class="gsc_a_ac gs_ibl">420</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:bFI3QPDXJZMC" class="gsc_a_at">Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study</a><div class="gs_gray">M May, M Gompels, V Delpech, K Porter, F Post, M Johnson, D Dunn, ...</div><div class="gs_gray">Bmj 343<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6942797246183684445" class="gsc_a_ac gs_ibl">397</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:_FxGoFyzp5QC" class="gsc_a_at">British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012</a><div class="gs_gray">I Williams, D Churchill, J Anderson, M Boffito, M Bower, G Cairns, ...</div><div class="gs_gray">HIV medicine 13 (S2), 1-6<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10055963537817576786,946937288016608385,358247385294501347,7850032169334277738" class="gsc_a_ac gs_ibl">390</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:xtoqd-5pKcoC" class="gsc_a_at">Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label&nbsp;…</a><div class="gs_gray">JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ...</div><div class="gs_gray">The lancet HIV 2 (8), e319-e327<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15105278691534112608" class="gsc_a_ac gs_ibl">345</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:2P1L_qKh6hAC" class="gsc_a_at">Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active&nbsp;…</a><div class="gs_gray">A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ...</div><div class="gs_gray">The Lancet Infectious Diseases 16 (1), 43-52<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5324225540120609170" class="gsc_a_ac gs_ibl">285</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:kNdYIx-mwKoC" class="gsc_a_at">British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011</a><div class="gs_gray">D Asboe, C Aitken, M Boffito, C Booth, P Cane, A Fakoya, AM Geretti, ...</div><div class="gs_gray">HIV med 13 (1), 1-44<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8491647607298485144" class="gsc_a_ac gs_ibl">218</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:FPJr55Dyh1AC" class="gsc_a_at">Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2&nbsp;…</a><div class="gs_gray">P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...</div><div class="gs_gray">The Lancet 393 (10167), 143-155<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15556387734449868118" class="gsc_a_ac gs_ibl">211</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:u-x6o8ySG0sC" class="gsc_a_at">Brief communication: rituximab in HIV-associated multicentric Castleman disease</a><div class="gs_gray">M Bower, T Powles, S Williams, TN Davis, M Atkins, S Montoto, C Orkin, ...</div><div class="gs_gray">Annals of internal medicine 147 (12), 836-839<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=79769441504458447" class="gsc_a_ac gs_ibl">211</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:vDijr-p_gm4C" class="gsc_a_at">Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naive patients in the ARTEMIS trial</a><div class="gs_gray">C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, ...</div><div class="gs_gray">HIV medicine 14 (1), 49-59<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13055281860326798459" class="gsc_a_ac gs_ibl">210</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:ruyezt5ZtCIC" class="gsc_a_at">Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study</a><div class="gs_gray">JM Molina, C Orkin, DM Iser, FX Zamora, M Nelson, C Stephan, ...</div><div class="gs_gray">The Lancet 385 (9973), 1098-1106<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15190839808626331403" class="gsc_a_ac gs_ibl">209</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:PELIpwtuRlgC" class="gsc_a_at">Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind&nbsp;…</a><div class="gs_gray">J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, ...</div><div class="gs_gray">The Lancet 390 (10107), 2063-2072<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10034844556363086398" class="gsc_a_ac gs_ibl">204</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:yqoGN6RLRZoC" class="gsc_a_at">Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials</a><div class="gs_gray">PE Sax, KM Erlandson, JE Lake, GA Mccomsey, C Orkin, S Esser, ...</div><div class="gs_gray">Clinical Infectious Diseases 71 (6), 1379-1389<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=307688571037310537" class="gsc_a_ac gs_ibl">187</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:e5wmG9Sq2KIC" class="gsc_a_at">Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study</a><div class="gs_gray">EM Berkowitz, G Moyle, HJ Stellbrink, D Schürmann, S Kegg, M Stoll, ...</div><div class="gs_gray">The Journal of infectious diseases 211 (8), 1279-1287<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11795272880472651439" class="gsc_a_ac gs_ibl">167</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:M7yex6snE4oC" class="gsc_a_at">Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial</a><div class="gs_gray">NI Paton, RL Goodall, DT Dunn, S Franzen, Y Collaco-Moraes, ...</div><div class="gs_gray">Jama 308 (4), 353-361<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14513220074523919589" class="gsc_a_ac gs_ibl">157</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:vbGhcppDl1QC" class="gsc_a_at">Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.</a><div class="gs_gray">WM El-Sadr, B Grund, J Neuhaus, A Babiker, CJ Cohen, J Darbyshire, ...</div><div class="gs_gray">Annals of internal medicine 149 (5), 289-299<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13658656611538058827" class="gsc_a_ac gs_ibl">150</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:lSLTfruPkqcC" class="gsc_a_at">Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication</a><div class="gs_gray">W Stöhr, D Back, D Dunn, C Sabin, A Winston, R Gilson, D Pillay, T Hill, ...</div><div class="gs_gray">Antiviral therapy 13 (5), 675-685<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5054530551696900631" class="gsc_a_ac gs_ibl">149</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;citation_for_view=OB_eiO0AAAAJ:YsMSGLbcyi4C" class="gsc_a_at">Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials</a><div class="gs_gray">CJ Cohen, JM Molina, I Cassetti, P Chetchotisakd, A Lazzarin, C Orkin, ...</div><div class="gs_gray">Aids 27 (6), 939-950<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=568056887999346358" class="gsc_a_ac gs_ibl">145</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:5Ul4iDaHHb8C" class="gsc_a_at">HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the&nbsp;…</a><div class="gs_gray">S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson, M Shanyinde, ...</div><div class="gs_gray">Journal of clinical oncology 30 (33), 4111<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8543273606783410719" class="gsc_a_ac gs_ibl">131</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:eflP2zaiRacC" class="gsc_a_at">B ritish HIV Association guidelines for HIV‐associated malignancies 2014</a><div class="gs_gray">Writing Group, M Bower, A Palfreeman, M Alfa‐Wali, C Bunker, F Burns, ...</div><div class="gs_gray">HIV medicine 15, 1-92<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8767386926501604811" class="gsc_a_ac gs_ibl">115</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:9Nmd_mFXekcC" class="gsc_a_at">Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study</a><div class="gs_gray">JK Rockstroh, K Lacombe, RM Viani, C Orkin, D Wyles, AF Luetkemeyer, ...</div><div class="gs_gray">Clinical Infectious Diseases 67 (7), 1010-1017<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12544403949335629977" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:Tyk-4Ss8FVUC" class="gsc_a_at">Persistence of HIV-1 transmitted drug resistance mutations</a><div class="gs_gray">H Castro, D Pillay, P Cane, D Asboe, V Cambiano, A Phillips, DT Dunn, ...</div><div class="gs_gray">The Journal of infectious diseases 208 (9), 1459-1463<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=397463881230942477" class="gsc_a_ac gs_ibl">105</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:wbdj-CoPYUoC" class="gsc_a_at">Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human&nbsp;…</a><div class="gs_gray">C Orkin, KE Squires, JM Molina, PE Sax, WW Wong, O Sussmann, ...</div><div class="gs_gray">Clinical Infectious Diseases 68 (4), 535-544<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8666150545327667697" class="gsc_a_ac gs_ibl">101</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:LgRImbQfgY4C" class="gsc_a_at">Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection</a><div class="gs_gray">C Orkin, K Arasteh, M Górgolas Hernández-Mora, V Pokrovsky, ...</div><div class="gs_gray">New England Journal of Medicine 382 (12), 1124-1135<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13847686996166400115" class="gsc_a_ac gs_ibl">99</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:DJbcl8HfkQkC" class="gsc_a_at">Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat&nbsp;…</a><div class="gs_gray">C Orkin, JM Molina, E Negredo, JR Arribas, J Gathe, JJ Eron, ...</div><div class="gs_gray">The Lancet HIV 5 (1), e23-e34<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17923654751540157774" class="gsc_a_ac gs_ibl">95</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:VOx2b1Wkg3QC" class="gsc_a_at">Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study</a><div class="gs_gray">D Dieterich, JK Rockstroh, C Orkin, F Gutiérrez, MB Klein, J Reynes, ...</div><div class="gs_gray">Clinical Infectious Diseases 59 (11), 1579-1587<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8709138115273312818" class="gsc_a_ac gs_ibl">95</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:M3NEmzRMIkIC" class="gsc_a_at">Late diagnosis in the HAART era: proposed common definitions and associations with mortality.</a><div class="gs_gray">CA Sabin, A Schwenk, MA Johnson, B Gazzard, M Fisher, J Walsh, ...</div><div class="gs_gray">AIDS (London, England) 24 (5), 723-727<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4314090658310798276" class="gsc_a_ac gs_ibl">90</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:XoXfffV-tXoC" class="gsc_a_at">A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals</a><div class="gs_gray">M Fisher, GJ Moyle, M Shahmanesh, C Orkin, M Kingston, E Wilkins, ...</div><div class="gs_gray">JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (5), 562-568<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15212867671692169777" class="gsc_a_ac gs_ibl">89</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:86PQX7AUzd4C" class="gsc_a_at">Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial</a><div class="gs_gray">NI Paton, W Stöhr, A Arenas-Pinto, M Fisher, I Williams, M Johnson, ...</div><div class="gs_gray">The lancet HIV 2 (10), e417-e426<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15824051414216721741" class="gsc_a_ac gs_ibl">86</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:3s1wT3WcHBgC" class="gsc_a_at">Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated&nbsp;…</a><div class="gs_gray">C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ...</div><div class="gs_gray">The Lancet HIV 4 (12), e536-e546<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6409235752962813331" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:ML0RJ9NH7IQC" class="gsc_a_at">96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study</a><div class="gs_gray">GJ Moyle, HJ Stellbrink, J Compston, C Orkin, JR Arribas, P Domingo, ...</div><div class="gs_gray">Antiviral therapy 18 (7), 905-913<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13381946157309062977" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:kuK5TVdYjLIC" class="gsc_a_at">Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study</a><div class="gs_gray">R Gilson, SL Man, A Copas, A Rider, S Forsyth, T Hill, L Bansi, K Porter, ...</div><div class="gs_gray">HIV medicine 11 (2), 152-160<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14102915143124228914" class="gsc_a_ac gs_ibl">78</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:8d8msizDQcsC" class="gsc_a_at">British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015</a><div class="gs_gray">D Churchill, L Waters, N Ahmed, B Angus, M Boffito, M Bower, D Dunn, ...</div><div class="gs_gray">HIV medicine 17 (S4), S2-S104<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16350599371286382504" class="gsc_a_ac gs_ibl">77</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:dshw04ExmUIC" class="gsc_a_at">CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK</a><div class="gs_gray">M Bower, M Fisher, T Hill, I Reeves, J Walsh, C Orkin, AN Phillips, L Bansi, ...</div><div class="gs_gray">haematologica 94 (6), 875<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7496954916005280359" class="gsc_a_ac gs_ibl">77</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:D_sINldO8mEC" class="gsc_a_at">A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients</a><div class="gs_gray">JJ Eron, C Orkin, J Gallant, JM Molina, E Negredo, A Antinori, A Mills, ...</div><div class="gs_gray">AIDS (London, England) 32 (11), 1431<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8755202993107443779" class="gsc_a_ac gs_ibl">76</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:SP6oXDckpogC" class="gsc_a_at">Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a&nbsp;…</a><div class="gs_gray">C Orkin, E DeJesus, M Ramgopal, G Crofoot, P Ruane, A LaMarca, ...</div><div class="gs_gray">The lancet HIV 4 (5), e195-e204<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7544236130376069355" class="gsc_a_ac gs_ibl">75</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:UeHWp8X0CEIC" class="gsc_a_at">Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an&nbsp;…</a><div class="gs_gray">AN Phillips, C Leen, A Wilson, J Anderson, D Dunn, A Schwenk, C Orkin, ...</div><div class="gs_gray">The Lancet 370 (9603), 1923-1928<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=246128488170152772" class="gsc_a_ac gs_ibl">75</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:HE397vMXCloC" class="gsc_a_at">British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013</a><div class="gs_gray">E Wilkins, M Nelson, K Agarwal, D Awoyemi, E Barnes, S Bhagani, ...</div><div class="gs_gray">HIV medicine 14, 1-71<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9665358740896345993" class="gsc_a_ac gs_ibl">72</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:DUooU5lO8OsC" class="gsc_a_at">Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults</a><div class="gs_gray">F Raffi, C Orkin, A Clarke, L Slama, J Gallant, E Daar, K Henry, ...</div><div class="gs_gray">Journal of acquired immune deficiency syndromes (1999) 75 (2), 226<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17005337915181432041,7579047260968994624" class="gsc_a_ac gs_ibl">71</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:j3f4tGmQtD8C" class="gsc_a_at">BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update)</a><div class="gs_gray">L Waters, N Ahmed, B Angus, M Boffito, M Bower, D Churchill, D Dunn, ...</div><div class="gs_gray">BHIVA) BHA, ed. London, UK: BHIVA<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3999804066843327863" class="gsc_a_ac gs_ibl">70</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:b0M2c_1WBrUC" class="gsc_a_at">Neurocognitive function in HIV infected patients on antiretroviral therapy</a><div class="gs_gray">A Winston, A Arenas-Pinto, W Stöhr, M Fisher, CM Orkin, K Aderogba, ...</div><div class="gs_gray">PloS one 8 (4), e61949<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7099714521108842996" class="gsc_a_ac gs_ibl">70</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:mB3voiENLucC" class="gsc_a_at">Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials</a><div class="gs_gray">SK Gupta, FA Post, JR Arribas, JJ Eron Jr, DA Wohl, AE Clarke, PE Sax, ...</div><div class="gs_gray">AIDS (London, England) 33 (9), 1455<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3323933214085345595" class="gsc_a_ac gs_ibl">68</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:Tiz5es2fbqcC" class="gsc_a_at">Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma</a><div class="gs_gray">S Montoto, J Wilson, K Shaw, M Heath, A Wilson, C McNamara, C Orkin, ...</div><div class="gs_gray">Aids 24 (6), 851-856<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7843716275068860151" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:tKAzc9rXhukC" class="gsc_a_at">Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom</a><div class="gs_gray">A Tostevin, E White, D Dunn, S Croxford, V Delpech, I Williams, D Asboe, ...</div><div class="gs_gray">HIV medicine 18 (3), 204-213<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11705630162755253373" class="gsc_a_ac gs_ibl">62</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:tOudhMTPpwUC" class="gsc_a_at">Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease</a><div class="gs_gray">L Garvey, A Winston, J Walsh, F Post, K Porter, B Gazzard, M Fisher, ...</div><div class="gs_gray">Neurology 76 (8), 693-700<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8135519782989271487" class="gsc_a_ac gs_ibl">59</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:0izLItjtcgwC" class="gsc_a_at">Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort</a><div class="gs_gray">ÁH Borges, J Hoy, E Florence, D Sedlacek, HJ Stellbrink, V Uzdaviniene, ...</div><div class="gs_gray">Clinical Infectious Diseases 64 (10), 1413-1421<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16539502484697203477" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:ClCfbGk0d_YC" class="gsc_a_at">Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations<sup>*</sup></a><div class="gs_gray">L Bansi, C Sabin, V Delpech, T Hill, M Fisher, J Walsh, T Chadborn, ...</div><div class="gs_gray">HIV medicine 11 (7), 432-438<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15705966061787626947" class="gsc_a_ac gs_ibl">56</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:dTyEYWd-f8wC" class="gsc_a_at">HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era</a><div class="gs_gray">R Coutinho, AD Pria, S Gandhi, K Bailey, P Fields, K Cwynarski, A Wilson, ...</div><div class="gs_gray">Aids 28 (5), 689-697<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10203340307919853797" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:FAceZFleit8C" class="gsc_a_at">Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes</a><div class="gs_gray">ZM Younossi, M Stepanova, M Sulkowski, S Naggie, M Puoti, C Orkin, ...</div><div class="gs_gray">The Journal of infectious diseases 212 (3), 367-377<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16347075600711231045" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:0N-VGjzr574C" class="gsc_a_at">Potential health risks of complementary alternative medicines in HIV patients</a><div class="gs_gray">D Ladenheim, O Horn, U Werneke, M Phillpot, A Murungi, N Theobald, ...</div><div class="gs_gray">HIV medicine 9 (8), 653-659<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15496904390151304236" class="gsc_a_ac gs_ibl">54</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:CdxZDUztZiMC" class="gsc_a_at">UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy</a><div class="gs_gray">MT May, M Gompels, V Delpech, K Porter, C Orkin, S Kegg, P Hay, ...</div><div class="gs_gray">AIDS 28 (8), 1193-1202<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5048142102345118303" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:_axFR9aDTf0C" class="gsc_a_at">The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK–trends in HCV testing and the impact of HCV on HIV treatment outcomes</a><div class="gs_gray">J Turner, L Bansi, R Gilson, B Gazzard, J Walsh, D Pillay, C Orkin, ...</div><div class="gs_gray">Journal of viral hepatitis 17 (8), 569-577<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15843662503609520740" class="gsc_a_ac gs_ibl">52</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:QYdC8u9Cj1oC" class="gsc_a_at">NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials</a><div class="gs_gray">S Brown, DM Simpson, G Moyle, BJ Brew, G Schifitto, N Larbalestier, ...</div><div class="gs_gray">AIDS research and therapy 10 (1), 1-12<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17593534814761588208" class="gsc_a_ac gs_ibl">49</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:35N4QoGY0k4C" class="gsc_a_at">Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1&nbsp;…</a><div class="gs_gray">M Aboud, C Orkin, D Podzamczer, JR Bogner, D Baker, ...</div><div class="gs_gray">The Lancet HIV 6 (9), e576-e587<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5104202707043715067" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:RYcK_YlVTxYC" class="gsc_a_at">Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study</a><div class="gs_gray">J O'Connor, C Smith, FC Lampe, MA Johnson, DR Chadwick, M Nelson, ...</div><div class="gs_gray">The Lancet HIV 4 (7), e295-e302<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5042960537703821481" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:9c2xU6iGI7YC" class="gsc_a_at">Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)‐B<sup>*</sup>5701 in HIV‐1‐infected UK subjects</a><div class="gs_gray">C Orkin, ST Sadiq, L Rice, F Jackson, UK EPI team</div><div class="gs_gray">HIV medicine 11 (3), 187-192<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17452912154428898609" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:WZBGuue-350C" class="gsc_a_at">Infection‐related and‐unrelated malignancies, HIV and the aging population</a><div class="gs_gray">L Shepherd, ÁH Borges, B Ledergerber, P Domingo, A Castagna, ...</div><div class="gs_gray">HIV medicine 17 (8), 590-600<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14550646898186876488" class="gsc_a_ac gs_ibl">45</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:4xDN1ZYqzskC" class="gsc_a_at">Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study</a><div class="gs_gray">VJ Apea, YI Wan, R Dhairyawan, ZA Puthucheary, RM Pearse, CM Orkin, ...</div><div class="gs_gray">BMJ open 11 (1), e042140<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14996129782827682197" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:4TOpqqG69KYC" class="gsc_a_at">Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III&nbsp;…</a><div class="gs_gray">DA Wohl, C Orkin, M Doroana, JH Pilotto, S Sungkanuparph, P Yeni, ...</div><div class="gs_gray">International Medical Press<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2033173473410156351" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:9ZlFYXVOiuMC" class="gsc_a_at">THLBB04: Once‐daily dolutegravir (DTG; S/GSK1349572) is non‐inferior to raltegravir (RAL) in antiretroviral‐naive adults 48 week results from SPRING‐2 (ING113086)</a><div class="gs_gray">F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ...</div><div class="gs_gray">Journal Of The International Aids Society 15<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=768014796303640734" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:UxriW0iASnsC" class="gsc_a_at">An epidemiologic study to determine the prevalence of the HLA-B* 5701 allele among HIV-positive patients in Europe</a><div class="gs_gray">C Orkin, J Wang, C Bergin, JM Molina, A Lazzarin, M Cavassini, S Esser, ...</div><div class="gs_gray">Pharmacogenetics and genomics 20 (5), 307-314<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7517274245872219856" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:W7OEmFMy1HYC" class="gsc_a_at">Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease</a><div class="gs_gray">T Powles, J Stebbing, S Montoto, M Nelson, B Gazzard, C Orkin, A Webb, ...</div><div class="gs_gray">Blood, The Journal of the American Society of Hematology 110 (12), 4132-4133<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=557643012266562348" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:EUQCXRtRnyEC" class="gsc_a_at">Long‐term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study</a><div class="gs_gray">RA Hughes, JAC Sterne, J Walsh, L Bansi, R Gilson, C Orkin, T Hill, ...</div><div class="gs_gray">HIV medicine 12 (10), 583-593<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7063319334341520786" class="gsc_a_ac gs_ibl">43</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:xtRiw3GOFMkC" class="gsc_a_at">Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study</a><div class="gs_gray">UK CHIC Study Steering Committee, TJ Barber, AM Geretti, J Anderson, ...</div><div class="gs_gray">Antiviral therapy 16 (6), 805-814<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7277714031786366105" class="gsc_a_ac gs_ibl">43</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:bnK-pcrLprsC" class="gsc_a_at">Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study</a><div class="gs_gray">J Rockstroh, K Lacombe, RM Viani, C Orkin, D Wyles, A Luetkemeyer, ...</div><div class="gs_gray">Journal of Hepatology 1 (66), S102-S103<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9576082652874929028" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:cWzG1nlazyYC" class="gsc_a_at">The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of&nbsp;…</a><div class="gs_gray">CA Sabin, CJ Smith, V Delpech, J Anderson, L Bansi, R Gilson, ...</div><div class="gs_gray">HIV medicine 10 (1), 35-43<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17922392155320487723" class="gsc_a_ac gs_ibl">42</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:Ug5p-4gJ2f0C" class="gsc_a_at">Long-active cabotegravir+ rilpivirine for HIV maintenance: flair week 48 results</a><div class="gs_gray">C Orkin, K Arasteh, MG Hernández-Mora, V Pokrovsky, ET Overton, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15224880216402858061" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:kzcrU_BdoSEC" class="gsc_a_at">Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures</a><div class="gs_gray">AA Benzie, LK Bansi, CA Sabin, S Portsmouth, T Hill, M Johnson, ...</div><div class="gs_gray">Aids 21 (11), 1423-1430<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11477581976286026436" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:kRWSkSYxWN8C" class="gsc_a_at">Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign</a><div class="gs_gray">C Orkin, S Flanagan, E Wallis, G Ireland, R Dhairyawan, J Fox, ...</div><div class="gs_gray">HIV medicine 17 (3), 222-230<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9067479004424689392" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:HDshCWvjkbEC" class="gsc_a_at">Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1–infected patients with HIV-1 RNA≤ 100,000 copies/mL: week 96 pooled ECHO&nbsp;…</a><div class="gs_gray">G Behrens, B Rijnders, M Nelson, C Orkin, C Cohen, A Mills, RA Elion, ...</div><div class="gs_gray">AIDS patient care and STDs 28 (4), 168-175<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3384206538570178002" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:t6usbXjVLHcC" class="gsc_a_at">Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring</a><div class="gs_gray">A Winston, S Jose, S Gibbons, D Back, W Stohr, F Post, M Fisher, ...</div><div class="gs_gray">Journal of Antimicrobial Chemotherapy 68 (6), 1354-1359<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9651520256865606870" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:4DMP91E08xMC" class="gsc_a_at">Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK</a><div class="gs_gray">PJ Easterbrook, AN Phillips, T Hill, R Matthias, M Fisher, B Gazzard, ...</div><div class="gs_gray">HIV medicine 9 (1), 47-56<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2368499842016876285" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:-_dYPAW6P2MC" class="gsc_a_at">Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection</a><div class="gs_gray">JF Morlese, CM Orkin, R Abbas, C Burton, NA Qazi, MR Nelson, N Imami, ...</div><div class="gs_gray">Aids 17 (9), 1411-1413<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11957862482325544497" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:OcBU2YAGkTUC" class="gsc_a_at">A randomized study comparing a three-and four-drug HAART regimen in first-line therapy (QUAD study)</a><div class="gs_gray">C Orkin, J Stebbing, M Nelson, M Bower, M Johnson, S Mandalia, ...</div><div class="gs_gray">Journal of Antimicrobial Chemotherapy 55 (2), 246-251<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18224958525636259991" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:2osOgNQ5qMEC" class="gsc_a_at">Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom</a><div class="gs_gray">JL Mbisa, E Fearnhill, DT Dunn, D Pillay, D Asboe, PA Cane, ...</div><div class="gs_gray">Clinical Infectious Diseases 61 (5), 829-836<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=165540547964991260" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:9pM33mqn1YgC" class="gsc_a_at">Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study</a><div class="gs_gray">MCF Prosperi, N Mackie, S Di Giambenedetto, M Zazzi, R Camacho, ...</div><div class="gs_gray">Journal of antimicrobial chemotherapy 66 (8), 1886-1896<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16321251880365230415" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:hC7cP41nSMkC" class="gsc_a_at">N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients</a><div class="gs_gray">DA Duprez, J Neuhaus, R Tracy, LH Kuller, SG Deeks, C Orkin, A Stoehr, ...</div><div class="gs_gray">AIDS (London, England) 25 (5), 651<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3033592240943534167" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:NMxIlDl6LWMC" class="gsc_a_at">Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence</a><div class="gs_gray">C Orkin, JM Llibre, S Gallien, A Antinori, GMN Behrens, A Carr</div><div class="gs_gray">HIV medicine 19 (1), 18-32<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4472886190762359286" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:SeFeTyx0c_EC" class="gsc_a_at">Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.</a><div class="gs_gray">H Khachi, R O'Connell, D Ladenheim, C Orkin</div><div class="gs_gray">Journal of antimicrobial chemotherapy 64 (4), 871-873<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6332289175944086233" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:5awf1xo2G04C" class="gsc_a_at">Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and&nbsp;…</a><div class="gs_gray">D Hagins, C Orkin, ES Daar, A Mills, C Brinson, E DeJesus, FA Post, ...</div><div class="gs_gray">HIV medicine 19 (10), 724-733<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10467155129915417468" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:sSrBHYA8nusC" class="gsc_a_at">Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load≤ 100 000 copies/m L in the pooled ECHO and THRIVE phase 3, randomized, double&nbsp;…</a><div class="gs_gray">JM Molina, N Clumeck, C Orkin, LT Rimsky, S Vanveggel, M Stevens, ...</div><div class="gs_gray">HIV medicine 15 (1), 57-62<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8373346312153638698" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:uc_IGeMz5qoC" class="gsc_a_at">Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial</a><div class="gs_gray">G Fätkenheuer, C Duvivier, A Rieger, J Durant, D Rey, W Schmidt, A Hill, ...</div><div class="gs_gray">Journal of antimicrobial chemotherapy 67 (3), 685-690<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6761105032097027962" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:gsN89kCJA0AC" class="gsc_a_at">Data linkage reduces loss to follow-up in an observational HIV cohort study</a><div class="gs_gray">T Hill, L Bansi, C Sabin, A Phillips, D Dunn, J Anderson, P Easterbrook, ...</div><div class="gs_gray">Journal of clinical epidemiology 63 (10), 1101-1109<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14081209407969027164" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:HtS1dXgVpQUC" class="gsc_a_at">Disease progression in HIV-1–infected viremic controllers</a><div class="gs_gray">KC Groves, DF Bibby, DA Clark, A Isaksen, JR Deayton, J Anderson, ...</div><div class="gs_gray">Journal of acquired immune deficiency syndromes (1999) 61 (4), 407<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17971587136701053792" class="gsc_a_ac gs_ibl">33</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:8k81kl-MbHgC" class="gsc_a_at">Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters <i>vs</i>. late starters</a><div class="gs_gray">L Waters, M Fisher, J Anderson, C Wood, V Delpech, T Hill, J Walsh, ...</div><div class="gs_gray">HIV medicine 12 (5), 289-298<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1260531992497682000" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:70eg2SAEIzsC" class="gsc_a_at">Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV&nbsp;…</a><div class="gs_gray">D Wohl, M Doroana, C Orkin, JH Pilotto, S Sungkanuparph, P Yeni, ...</div><div class="gs_gray">18th Conference on Retroviruses and Opportunistic Infections 27<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5252837123771302212" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:uJ-U7cs_P_0C" class="gsc_a_at">A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected&nbsp;…</a><div class="gs_gray">GJ Moyle, C Orkin, M Fisher, J Dhar, J Anderson, E Wilkins, J Ewan, ...</div><div class="gs_gray">PLoS One 10 (2), e0116297<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12154958714514567293" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:abG-DnoFyZgC" class="gsc_a_at">Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?</a><div class="gs_gray">LK Bansi, AA Benzie, AN Phillips, S Portsmouth, T Hill, C Leen, ...</div><div class="gs_gray">AIDS (London, England) 22 (3), 349-356<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7120126094514721375" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:z_wVstp3MssC" class="gsc_a_at">Factors influencing lopinavir and atazanavir plasma concentration</a><div class="gs_gray">W Stöhr, D Back, D Dunn, C Sabin, A Winston, R Gilson, D Pillay, T Hill, ...</div><div class="gs_gray">Journal of antimicrobial chemotherapy 65 (1), 129-137<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14308583250418028609" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:L7CI7m0gUJcC" class="gsc_a_at">Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and&nbsp;…</a><div class="gs_gray">H Dreja, E O'Sullivan, C Pade, KM Greene, H Gao, K Aubin, J Hand, ...</div><div class="gs_gray">Journal of general virology 91 (11), 2794-2803<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13736281217942641313" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:edDO8Oi4QzsC" class="gsc_a_at">A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study</a><div class="gs_gray">S Jose, V Delpech, A Howarth, F Burns, T Hill, K Porter, CA Sabin, ...</div><div class="gs_gray">The Lancet HIV 5 (6), e301-e308<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15462783071081199971" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:q3CdL3IzO_QC" class="gsc_a_at">A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)</a><div class="gs_gray">J Stebbing, M Nelson, C Orkin, S Mandalia, M Bower, A Pozniak, ...</div><div class="gs_gray">Journal of Antimicrobial Chemotherapy 53 (3), 501-505<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15182185157082018687" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:rO6llkc54NcC" class="gsc_a_at">Molecular epidemiology of HIV-1 subtype B reveals heterogeneous transmission risk: implications for intervention and control</a><div class="gs_gray">EM Volz, S Le Vu, O Ratmann, A Tostevin, D Dunn, C Orkin, S O’Shea, ...</div><div class="gs_gray">The Journal of infectious diseases 217 (10), 1522-1529<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6431699942498665057" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:AXPGKjj_ei8C" class="gsc_a_at">Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy</a><div class="gs_gray">W Stöhr, DT Dunn, A Arenas-Pinto, C Orkin, A Clarke, I Williams, ...</div><div class="gs_gray">Aids 30 (17), 2617-2624<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9772594865039745976" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:4hFrxpcac9AC" class="gsc_a_at">High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?</a><div class="gs_gray">C Orkin, E Leach, S Flanagan, E Wallis, M Ruf, GR Foster, CYW Tong</div><div class="gs_gray">Epidemiology &amp; Infection 143 (13), 2837-2840<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16732713672828658169" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:tS2w5q8j5-wC" class="gsc_a_at">Vitamin D deficiency in HIV: a shadow on long-term management?</a><div class="gs_gray">C Orkin, DA Wohl, A Williams, H Deckx</div><div class="gs_gray">AIDS reviews 16 (2), 59-74<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8310653727749428951" class="gsc_a_ac gs_ibl">23</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:kz9GbA2Ns4gC" class="gsc_a_at">Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil&nbsp;…</a><div class="gs_gray">JJ Eron, C Orkin, D Cunningham, F Pulido, FA Post, S De Wit, ...</div><div class="gs_gray">Antiviral research 170, 104543<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12751641114875670339" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=OB_eiO0AAAAJ:hqOjcs7Dif8C" class="gsc_a_at">Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended&nbsp;…</a><div class="gs_gray">K Arasteh, D Ward, A Plettenberg, JM Livrozet, C Orkin, C Cordes, J Guo, ...</div><div class="gs_gray">HIV medicine 13 (4), 236-244<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1059797001704458072" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:PVjk1bu6vJQC" class="gsc_a_at">Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naïve adults with HIV-1 infection: week 48 results of the phase&nbsp;…</a><div class="gs_gray">KE Squires, JM Molina, PE Sax, WW Wong, C Orkin, O Sussmann, D Tutu, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 20, 110-+<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15809479562985870121" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:j8SEvjWlNXcC" class="gsc_a_at">Development and application of a new measure of engagement in out‐patient HIV care</a><div class="gs_gray">AR Howarth, FM Burns, V Apea, S Jose, T Hill, VC Delpech, A Evans, ...</div><div class="gs_gray">HIV medicine 18 (4), 267-274<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12079338935316900206" class="gsc_a_ac gs_ibl">21</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:J-pR_7NvFogC" class="gsc_a_at">Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection</a><div class="gs_gray">M Martinello, S Bhagani, E Gane, C Orkin, G Cooke, GJ Dore, ...</div><div class="gs_gray">Journal of viral hepatitis 25 (10), 1180-1188<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9290314300438248419" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:HoB7MX3m0LUC" class="gsc_a_at">Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once&nbsp;…</a><div class="gs_gray">J Gallant, C Orkin, JM Molina, E Negredo, A Antinori, A Mills, J Eron, ...</div><div class="gs_gray">HIV MEDICINE 19, S32-S32<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6260633715703220484" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:QIV2ME_5wuYC" class="gsc_a_at">Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration</a><div class="gs_gray">J Dorward, N Garrett, D Scott, M Buckland, C Orkin, G Baily</div><div class="gs_gray">Journal of clinical virology 52 (4), 367-369<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2670203155700495686" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:dhFuZR0502QC" class="gsc_a_at">Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.</a><div class="gs_gray">KJ Lee, D Dunn, R Gilson, K Porter, L Bansi, T Hill, AN Phillips, CA Sabin, ...</div><div class="gs_gray">AIDS (London, England) 22 (15), 1943-1950<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2688910625578987865" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:KxtntwgDAa4C" class="gsc_a_at">Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3</a><div class="gs_gray">K Porter, S Walker, T Hill, J Anderson, C Leen, M Johnson, B Gazzard, ...</div><div class="gs_gray">JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (2), 202-205<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7387293576511989438" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:p2g8aNsByqUC" class="gsc_a_at">BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015</a><div class="gs_gray">D Churchill, L Waters, N Ahmed, B Angus, M Boffito, M Bower, D Dunn, ...</div><div class="gs_gray">London: British HIV Association (BHIVA)<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7765312189116973211" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:nrtMV_XWKgEC" class="gsc_a_at">Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with&nbsp;…</a><div class="gs_gray">AM Geretti, T Conibear, A Hill, JA Johnson, L Tambuyzer, K Thys, ...</div><div class="gs_gray">Journal of Antimicrobial Chemotherapy 69 (4), 1090-1097<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14086351057421024105" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:OR75R8vi5nAC" class="gsc_a_at">Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone</a><div class="gs_gray">L Waters, L Bansi, D Asboe, A Pozniak, E Smit, C Orkin, E Fearnhill, ...</div><div class="gs_gray">Antiviral therapy 18 (2), 213-219<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18236836551397125318" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:NyGDZy8z5eUC" class="gsc_a_at">Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results&nbsp;…</a><div class="gs_gray">C Orkin, E DeJesus, PE Sax, JR Arribas, SK Gupta, C Martorell, ...</div><div class="gs_gray">The Lancet HIV 7 (6), e389-e400<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7749998506612556120" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:eQOLeE2rZwMC" class="gsc_a_at">Neurocognitive function and neuroimaging markers in virologically suppressed HIV-positive patients randomized to ritonavir-boosted protease inhibitor monotherapy or standard&nbsp;…</a><div class="gs_gray">A Arenas-Pinto, W Stöhr, HR Jäger, L Haddow, A Clarke, M Johnson, ...</div><div class="gs_gray">Clinical Infectious Diseases 63 (2), 257-264<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=701568686996765719" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LO7wyVUgiFcC" class="gsc_a_at">CEDGE co-infection: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV</a><div class="gs_gray">J Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ...</div><div class="gs_gray">Vienna, April, 22-26<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16380940660899154148" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:KlAtU1dfN6UC" class="gsc_a_at">Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials</a><div class="gs_gray">JK Rockstroh, M Puoti, M Rodriguez-Torres, D Dieterich, A Gaggar, L Ni, ...</div><div class="gs_gray">Hepatology 60, 295A-296A<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=185620755842041814" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:AHdEip9mkN0C" class="gsc_a_at">Decline in hepatitis C virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: progress to HCV microelimination in the United Kingdom?</a><div class="gs_gray">LJ Garvey, GS Cooke, C Smith, C Stingone, I Ghosh, S Dakshina, L Jain, ...</div><div class="gs_gray">Clinical Infectious Diseases 72 (2), 233-238<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13339308524187475550" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:fbc8zXXH2BUC" class="gsc_a_at">Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients</a><div class="gs_gray">C Orkin, JJ Eron, J Rockstroh, D Podzamczer, S Esser, L Vandekerckhove, ...</div><div class="gs_gray">Aids 34 (5), 707-718<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4104022925140357673" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:IRz6iEL74y4C" class="gsc_a_at">Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naïve, HIV-1-infected adults&nbsp;…</a><div class="gs_gray">C Orkin, J Eron, J Rockstroh, D Podzamczer, S Esser, L Vandekerckhove, ...</div><div class="gs_gray">Journal of the International AIDS Society 21<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17177566653105522149" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LjlpjdlvIbIC" class="gsc_a_at">TestMeEast: a campaign to increase HIV testing in hospitals and to reduce late diagnosis</a><div class="gs_gray">R Bath, R O'Connell, M Lascar, R Ferrand, S Strachan, N Matin, I Bassnet, ...</div><div class="gs_gray">AIDS care 28 (5), 608-611<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10648213389057918021" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_B80troHkn4C" class="gsc_a_at">Routine HIV testing within the emergency department of a major trauma centre: a pilot study</a><div class="gs_gray">R Bath, K Ahmad, C Orkin</div><div class="gs_gray">HIV medicine 16 (5), 326-328<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10024519445776380989" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:bKqednn6t2AC" class="gsc_a_at">Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial</a><div class="gs_gray">M Boffito, J Fox, C Bowman, M Fisher, C Orkin, E Wilkins, A Jackson, ...</div><div class="gs_gray">Vaccine 31 (48), 5680-5686<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18066256842098661369" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:P7Ujq4OLJYoC" class="gsc_a_at">Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection</a><div class="gs_gray">M Martinello, C Orkin, G Cooke, S Bhagani, E Gane, R Kulasegaram, ...</div><div class="gs_gray">Hepatology 72 (1), 7-18<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1249065878850461233" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:MLfJN-KU85MC" class="gsc_a_at">Safety and efficacy of ombitasvir, paritaprevir with ritonavir±dasabuvir with or without ribavirin in patients with human immunodeficiency virus-1 and hepatitis C virus&nbsp;…</a><div class="gs_gray">JK Rockstroh, C Orkin, RM Viani, D Wyles, AF Luetkemeyer, A Lazzarin, ...</div><div class="gs_gray">Open forum infectious diseases 4 (3)<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14292098946136595878" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:mvPsJ3kp5DgC" class="gsc_a_at">Pneumococcal vaccination in people living with HIV</a><div class="gs_gray">J Thornhill, A Sivaramakrishnan, C Orkin</div><div class="gs_gray">Vaccine 33 (28), 3159-3160<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9054303613236789003" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:u9iWguZQMMsC" class="gsc_a_at">Virological response to initial antiretroviral regimens containing abacavir or tenofovir</a><div class="gs_gray">L Bansi, C Sabin, R Gilson, B Gazzard, C Leen, J Anderson, D Dunn, ...</div><div class="gs_gray">The Journal of infectious diseases 200 (5), 710-714<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7798018501016455293" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:XiVPGOgt02cC" class="gsc_a_at">Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat&nbsp;…</a><div class="gs_gray">JM Molina, J Gallant, C Orkin, E Negredo, L Bhatti, J Gathe, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 20, 28-28<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9579677415713993041" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:B3FOqHPlNUQC" class="gsc_a_at">Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression</a><div class="gs_gray">JL O’Connor, CJ Smith, FC Lampe, T Hill, M Gompels, P Hay, D Chadwick, ...</div><div class="gs_gray">Aids 28 (6), 919-924<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8349456221966675874" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:1lhNe0rCu4AC" class="gsc_a_at">Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials</a><div class="gs_gray">G Rizzardini, ET Overton, C Orkin, S Swindells, K Arasteh, ...</div><div class="gs_gray">Journal of acquired immune deficiency syndromes (1999) 85 (4), 498<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16854214817200297166" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ZHo1McVdvXMC" class="gsc_a_at">A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England</a><div class="gs_gray">A Gourlay, J Fox, M Gafos, S Fidler, N Nwokolo, A Clarke, R Gilson, ...</div><div class="gs_gray">BMJ open 7 (8), e016494<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6397286932047626813" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:g3aElNc5_aQC" class="gsc_a_at">Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?</a><div class="gs_gray">C Orkin, A Jeffery-Smith, GR Foster, CYW Tong</div><div class="gs_gray">BMJ open 6 (5), e010661<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13948725191104468573" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:mlAyqtXpCwEC" class="gsc_a_at">Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study</a><div class="gs_gray">DI Dolling, DT Dunn, KA Sutherland, D Pillay, JL Mbisa, CM Parry, ...</div><div class="gs_gray">Journal of Antimicrobial Chemotherapy 68 (10), 2339-2343<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17311169328355976850" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:8AbLer7MMksC" class="gsc_a_at">ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults</a><div class="gs_gray">C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, ...</div><div class="gs_gray">Journal of the International AIDS Society 13 (4), 1-2<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8474903807467837817" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:UebtZRa9Y70C" class="gsc_a_at">A systematic review of risk of HIV transmission through biting or spitting: implications for policy</a><div class="gs_gray">FV Cresswell, J Ellis, J Hartley, CA Sabin, C Orkin, DR Churchill</div><div class="gs_gray">HIV medicine 19 (8), 532-540<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1005203708796119879" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:EkHepimYqZsC" class="gsc_a_at">No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom</a><div class="gs_gray">E White, E Smit, D Churchill, S Collins, C Booth, A Tostevin, C Sabin, ...</div><div class="gs_gray">The Journal of infectious diseases 214 (9), 1302-1308<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12876243149092321740" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:jgBuDB5drN8C" class="gsc_a_at">Long-acting cabotegravir+ rilpivirine for HIV treatment: FLAIR week 96 results</a><div class="gs_gray">C Orkin, S Oka, P Philibert, C Brinson, A Bassa, D Gusev, O Degen, ...</div><div class="gs_gray">Conference on Retroviruses and Opportunistic Infections, 8-11<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10635720923315028093" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:a3BOlSfXSfwC" class="gsc_a_at">LB1. Doravirine/lamivudine/tenofovir DF continues to be noninferior to efavirenz/emtricitabine/tenofovir DF in treatment-naïve adults with HIV-1 infection: week 96 results of&nbsp;…</a><div class="gs_gray">C Orkin, K Squires, JM Molina, P Sax, W Wong, O Sussmann, G Lin, ...</div><div class="gs_gray">Open Forum Infectious Diseases 5 (suppl_1), S759-S759<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17070390435453939484" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ufrVoPGSRksC" class="gsc_a_at">The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people</a><div class="gs_gray">L Shepherd, ÁH Borges, R Harvey, M Bower, A Grulich, M Silverberg, ...</div><div class="gs_gray">HIV medicine 19 (2), 90-101<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=869109911746451850" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WF5omc3nYNoC" class="gsc_a_at">Antiretrovirals, fractures, and osteonecrosis in a large European HIV cohort</a><div class="gs_gray">AH Borges, J Hoy, E Florence, D Sedlacek, HJ Stellbrink, V Uzdaviniene, ...</div><div class="gs_gray">23rd Conference on Retroviruses and Opportunistic Infections<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=767755500377464370" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:9vf0nzSNQJEC" class="gsc_a_at">Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection</a><div class="gs_gray">S Flanagan, A Crawford-Jones, C Orkin</div><div class="gs_gray">Expert review of clinical pharmacology 7 (6), 691-704<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10259012578570294126" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:PR6Y55bgFSsC" class="gsc_a_at">Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment</a><div class="gs_gray">A Arenas-Pinto, A Winston, W Stöhr, J Day, R Wiggins, SP Quah, ...</div><div class="gs_gray">PLoS One 9 (7), e103498<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5622592594860862457" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:nb7KW1ujOQ8C" class="gsc_a_at">Non‐uptake of highly active antiretroviral therapy among patients with a CD 4 count&lt; 350 cells/μ L in the UK</a><div class="gs_gray">C Kober, M Johnson, M Fisher, T Hill, J Anderson, L Bansi, M Gompels, ...</div><div class="gs_gray">HIV medicine 13 (1), 73-78<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7386911769240383387" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Bg7qf7VwUHIC" class="gsc_a_at">Durable suppression and low rate of virologic failures 3 years after switch to DTG+ RPV 2DRug Regimen: SWORD 1 and 2 Studies</a><div class="gs_gray">J van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ...</div><div class="gs_gray">25th Annual Conference of the British HIV Association, 2-5<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18017452413899671311" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_FM0Bhl9EiAC" class="gsc_a_at">Virological failure and development of new resistance mutations according to CD 4 count at combination antiretroviral therapy initiation</a><div class="gs_gray">S Jose, K Quinn, D Dunn, A Cox, C Sabin, S Fidler, ...</div><div class="gs_gray">HIV medicine 17 (5), 368-372<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16339040837045696924" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ipzZ9siozwsC" class="gsc_a_at">Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy</a><div class="gs_gray">CL Alesandro, D Dunn, D Pillay, CA Sabin, E Fearnhill, AM Gerettsabini, ...</div><div class="gs_gray">Clinical Infectious Diseases 50 (9), 1275-1285<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7762251123966590105" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:RGFaLdJalmkC" class="gsc_a_at">Rituximab in HIV-associated multicentric Castleman disease</a><div class="gs_gray">M Bower, T Powles, S Williams, TN Davis, M Atkins, S Montoto, C Orkin, ...</div><div class="gs_gray">Ann Intern Med 147 (12), 836-839<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4851063171075603561" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:u-coK7KVo8oC" class="gsc_a_at">Effect of doravirine on body weight and body mass index in treatment naïve adults with HIV-1</a><div class="gs_gray">C Orkin, R Elion, M Thompson, J Rockstroh, ZJ Xu, EA Martin, C Hwang, ...</div><div class="gs_gray">HIV MEDICINE 20, 7-8<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16199658194567114002" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:OU6Ihb5iCvQC" class="gsc_a_at">Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department–uncovering the iceberg?</a><div class="gs_gray">S Parry, N Bundle, S Ullah, GR Foster, K Ahmad, CYW Tong, ...</div><div class="gs_gray">Epidemiology &amp; Infection 146 (8), 1026-1035<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7665046877474313819" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:l7t_Zn2s7bgC" class="gsc_a_at">Opt-out HIV testing in adult critical care units</a><div class="gs_gray">J Thornhill, G Mandersloot, R Bath, C Orkin</div><div class="gs_gray">Lancet 383 (9927), 1460<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8131660433057290699" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:9yKSN-GCB0IC" class="gsc_a_at">Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice</a><div class="gs_gray">RK Gupta, C Loveday, U Kalidindi, M Lechelt, C Skinner, C Orkin</div><div class="gs_gray">International journal of STD &amp; AIDS 18 (9), 630-632<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=133683812643393324" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:CB2v5VPnA5kC" class="gsc_a_at">Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study</a><div class="gs_gray">C Orkin, S Oka, P Philibert, C Brinson, A Bassa, D Gusev, O Degen, ...</div><div class="gs_gray">The Lancet HIV 8 (4), e185-e196<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14442404667055245220" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:buQ7SEKw-1sC" class="gsc_a_at">Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir+ rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and&nbsp;…</a><div class="gs_gray">J van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ...</div><div class="gs_gray">Journal of Acquired Immune Deficiency Syndromes (1999) 85 (3), 325<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15946422427341305543" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4MWp96NkSFoC" class="gsc_a_at">Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in Euro SIDA</a><div class="gs_gray">S Amele, L Peters, M Sluzhynska, A Yakovlev, A Scherrer, P Domingo, ...</div><div class="gs_gray">HIV medicine 20 (4), 264-273<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13392392241271889539" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4OULZ7Gr8RgC" class="gsc_a_at">Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug&nbsp;…</a><div class="gs_gray">AM Geretti, E White, C Orkin, A Tostevin, P Tilston, D Chadwick, C Leen, ...</div><div class="gs_gray">Journal of Antimicrobial Chemotherapy 74 (3), 746-753<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1379492660773189184" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:738O_yMBCRsC" class="gsc_a_at">Once-daily doravirine in HIV-1-infected, antiretroviral-naive adults: an integrated efficacy analysis</a><div class="gs_gray">C Orkin, JM Molina, J Lombaard, E DeJesus, A Rodgers, S Kumar, ...</div><div class="gs_gray">Clin Infect Dis<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7944056549172770031,17490804749027193782" class="gsc_a_ac gs_ibl">6</a><span class="gsc_a_m"><a href="javascript:void(0)" class="gsc_a_am" data-eid="OB_eiO0AAAAJ:738O_yMBCRsC">*</a></span></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:d1gkVwhDpl0C" class="gsc_a_at">Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D: A: D Study</a><div class="gs_gray">CI Hatleberg, L Ryom, W El‐Sadr, A Mocroft, P Reiss, S De Wit, F Dabis, ...</div><div class="gs_gray">Journal of the International AIDS Society 21 (3), e25083<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=92443056815167081" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:e_rmSamDkqQC" class="gsc_a_at">Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy&nbsp;…</a><div class="gs_gray">C Orkin, E DeJesus, M Ramgopal, G Crofoot, P Ruane, A LaMarca, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 19<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14576828449402098543" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:PoWvk5oyLR8C" class="gsc_a_at">Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?</a><div class="gs_gray">M Gompels, DT Dunn, A Phillips, D Dooley, A De Burgh Thomas, ...</div><div class="gs_gray">Journal of Infectious Diseases 205 (4), 540-547<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14851195979741362555" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Z5m8FVwuT1cC" class="gsc_a_at">Is 1 alanine transaminase&gt; 200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study</a><div class="gs_gray">L Bansi, J Turner, R Gilson, F Post, B Gazzard, C Leen, J Anderson, ...</div><div class="gs_gray">JAIDS Journal of Acquired Immune Deficiency Syndromes 52 (3), 391-396<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13360823741695161546" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:NJ774b8OgUMC" class="gsc_a_at">Durability of efavirenz compared to nevirapine with long-term follow-up of an antiretroviral-naive patient cohort: 07</a><div class="gs_gray">G Matthews, Y Gileece, C Orkin, S Mandalia, M Nelson, B Fisher, ...</div><div class="gs_gray">Hiv Medicine 4 (3), 197-198<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5485927988471823801" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:hsZV8lGYWTMC" class="gsc_a_at">Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials</a><div class="gs_gray">KM Erlandson, CC Carter, K Melbourne, TT Brown, C Cohen, M Das, ...</div><div class="gs_gray">Clinical Infectious Diseases<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13379214762643269735" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:PVgj2kMGcgYC" class="gsc_a_at">Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases</a><div class="gs_gray">M Cevik, C Orkin, PE Sax</div><div class="gs_gray">Open Forum Infectious Diseases 7 (6), ofaa202<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11767006202564859242" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4fGpz3EwCPoC" class="gsc_a_at">Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis</a><div class="gs_gray">M Thompson, C Orkin, JM Molina, P Sax, P Cahn, K Squires, X Xu, ...</div><div class="gs_gray">Clinical Infectious Diseases 70 (7), 1336-1343<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14555356431792519470" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Ak0FvsSvgGUC" class="gsc_a_at">Implementing U= U in clinical practice: results of a British HIV association members survey</a><div class="gs_gray">N Gupta, Y Gilleece, C Orkin</div><div class="gs_gray">Sexually transmitted infections<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10422362358095031759" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:3htObqc8RwsC" class="gsc_a_at">Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study</a><div class="gs_gray">GD Huhn, JJ Eron, PM Girard, C Orkin, JM Molina, E DeJesus, R Petrovic, ...</div><div class="gs_gray">AIDS research and therapy 16 (1), 1-11<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3239343576202254441" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:V3AGJWp-ZtQC" class="gsc_a_at">Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens</a><div class="gs_gray">A Cozzi‐Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, ...</div><div class="gs_gray">HIV medicine 19 (2), 102-117<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9172808636885592963" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:olpn-zPbct0C" class="gsc_a_at">Renal, inflammatory and bone biomarkers following switch to the DTG+ RPV 2-drug regimen: the SWORD-1 &amp; SWORD-2 studies</a><div class="gs_gray">C Orkin, JM Llibre, L Kahl, E Blair, B Wynne, L Curtis, K Angelis, R Shah, ...</div><div class="gs_gray">16th European AIDS Conference, 25-27<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9635667033801406249" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:wMgC3FpKEyYC" class="gsc_a_at">A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet&nbsp;…</a><div class="gs_gray">CC Iwuji, D Churchill, S Bremner, N Perry, Y To, D Lambert, C Bruce, ...</div><div class="gs_gray">BMC infectious diseases 20 (1), 1-12<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14716558360443823315" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:fPk4N6BV_jEC" class="gsc_a_at">B/f/taf versus abc/dtg/3tc or dtg+ f/taf in treatment-naïve adults with high baseline viral load or low baseline cd4 count in two phase iii randomized, controlled clinical&nbsp;…</a><div class="gs_gray">D Podzamczer, H Stellbrink, C Orkin, A Pozniak, J Arribas, E Koenig, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6633678014761687544" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ns9cj8rnVeAC" class="gsc_a_at">Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study</a><div class="gs_gray">L Peters, A Mocroft, D Grint, S Moreno, A Calmy, D Jevtovic, ...</div><div class="gs_gray">Antiviral therapy<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4764030570687973966" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:YOwf2qJgpHMC" class="gsc_a_at">Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: the&nbsp;…</a><div class="gs_gray">M Martinello, S Bhagani, EJ Gane, C Orkin, G Cooke, R Kulasegaram, ...</div><div class="gs_gray">Hepatology 66, 574A-575A<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1721517377652423865" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:i2xiXl-TujoC" class="gsc_a_at">Predicting virological decay in patients starting combination antiretroviral therapy</a><div class="gs_gray">RA Hughes, JAC Sterne, J Walsh, F Post, M Nelson, S Jose, T Hill, ...</div><div class="gs_gray">AIDS 30 (11), 1817-1827<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14761913683127793319" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:VLnqNzywnoUC" class="gsc_a_at">High efficacy of grazoprevir/elbasvir (GZR/EBR) in HCV genotype 1, 4, and 6-infected patients with HIV co-infection: SVR24 data from the phase 3 C-EDGE Co-infection Study</a><div class="gs_gray">JK Rockstroh, M Nelson, C Katlama, JP Lalezari, J Mallolas, M Bloch, ...</div><div class="gs_gray">Hepatology 62 (suppl 1), 317A<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12252314781852717241" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:zYLM7Y9cAGgC" class="gsc_a_at">Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia?</a><div class="gs_gray">E Wallis, J Thornhill, J Saunders, C Orkin</div><div class="gs_gray">Sexually transmitted infections 91 (3), 153-153<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=369103572065164906" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:2KloaMYe4IUC" class="gsc_a_at">Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir&nbsp;…</a><div class="gs_gray">C Orkin, N Clumeck, PM Girard, K Henry, J Gathe, J Rockstroh, ...</div><div class="gs_gray">Hiv Medicine 15<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17038594792840470500" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:j7_hQOaDUrUC" class="gsc_a_at">Doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) versus efavirenz/emtricitabine/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week&nbsp;…</a><div class="gs_gray">C Orkin, KE Squires, JM Molina, PE Sax, O Sussmann, G Lin, S Kumar, ...</div><div class="gs_gray">Clinical Infectious Diseases 73 (1), 33-42<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4282132710032184686" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:FiytvqdAVhgC" class="gsc_a_at">Gender disparities in coronavirus disease 2019 clinical trial leadership</a><div class="gs_gray">M Cevik, SA Haque, J Manne-Goehler, K Kuppalli, PE Sax, MS Majumder, ...</div><div class="gs_gray">Clinical Microbiology and Infection<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17776454323058142055" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:PaBasH6fAo0C" class="gsc_a_at">Changes in weight and BMI with first-line doravirine-based therapy</a><div class="gs_gray">C Orkin, R Elion, M Thompson, JK Rockstroh, FA Bognar, ZJ Xu, C Hwang, ...</div><div class="gs_gray">AIDS (London, England) 35 (1), 91<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2271159794951481030" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:U4n9YNQMCAIC" class="gsc_a_at">Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1</a><div class="gs_gray">C Orkin, J Molina, Y Yazdanpanah, C Chahin Anania, E DeJesus, J Eron, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23, 51-52<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6586559497931317964" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:KbBQZpvPDL4C" class="gsc_a_at">Determining the origins of human immunodeficiency virus type 1 drug-resistant minority variants in people who are recently infected using phylogenetic reconstruction</a><div class="gs_gray">JL Mbisa, P Kirwan, A Tostevin, J Ledesma, DF Bibby, A Brown, R Myers, ...</div><div class="gs_gray">Clinical Infectious Diseases 69 (7), 1136-1143<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11185600717269542071" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:1qzjygNMrQYC" class="gsc_a_at">Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom&nbsp;…</a><div class="gs_gray">N Bundle, S Balasegaram, S Parry, S Ullah, RJ Harris, K Ahmad, ...</div><div class="gs_gray">Eurosurveillance 24 (27), 1800377<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9173880227849565168" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ye4kPcJQO24C" class="gsc_a_at">Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data</a><div class="gs_gray">OT Stirrup, DT Dunn, A Tostevin, CA Sabin, A Pozniak, D Asboe, A Cox, ...</div><div class="gs_gray">AIDS research and therapy 15 (1), 1-14<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10672964650494293649" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:P5F9QuxV20EC" class="gsc_a_at">Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+ 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG+ TDF/FTC) at 48 Weeks in Antiretroviral Treatment&nbsp;…</a><div class="gs_gray">C Orkin, N Porteiro, M Berhe, R Dretler, P Viciana, YT Tseng, C Oprea, ...</div><div class="gs_gray">infection 165, 50<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7353303028940622101" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:N5tVd3kTz84C" class="gsc_a_at">Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate</a><div class="gs_gray">M Cevik, C Orkin</div><div class="gs_gray">Current Opinion in HIV and AIDS 13 (4), 315-319<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10826942087496104861" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:hMod-77fHWUC" class="gsc_a_at">Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe</a><div class="gs_gray">JR Santos, A Cozzi‐Lepri, A Phillips, S De Wit, C Pedersen, P Reiss, ...</div><div class="gs_gray">HIV medicine 19 (5), 324-338<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4454451987282643943" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:qjMakFHDy7sC" class="gsc_a_at">A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada</a><div class="gs_gray">S Patterson, S Jose, H Samji, A Cescon, E Ding, J Zhu, J Anderson, ...</div><div class="gs_gray">HIV medicine 18 (9), 655-666<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=185346164458648275" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ZuybSZzF8UAC" class="gsc_a_at">Week 48 results of EMERALD: a phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) Plus&nbsp;…</a><div class="gs_gray">C Orkin, JM Molina, J Gallant, E Negredo, J Gathe, J Eron, E Van Landuyt, ...</div><div class="gs_gray">Open Forum Infectious Diseases 4 (suppl_1), S737-S738<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11017869551941552713" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:u5HHmVD_uO8C" class="gsc_a_at">Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in&nbsp;…</a><div class="gs_gray">C Orkin, J Rockstroh, E DeJesus, K Henry, J Molina, J Gathe, X Wei, ...</div><div class="gs_gray">Hiv Medicine 14<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18327258998465495351" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WJVC3Jt7v1AC" class="gsc_a_at">An innovative joint approach to HIV and lymphoma care</a><div class="gs_gray">R Dhairyawan, S Longwill, C Orkin, S Montoto</div><div class="gs_gray">Sexually transmitted infections 88 (1), 71-71<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17161330126611927213" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:pyW8ca7W8N0C" class="gsc_a_at">Artemis: 192-Week efficacy and safety of once daily darunavir/ritonavir (DRV/r) versus lopinavir/R (LPV/r) in treatment-naive HIV-1-infected adults</a><div class="gs_gray">A Lazzarin, C Orkin, E De Jesus, H Khanlou, A Stoehr, K Supparatpinyo, ...</div><div class="gs_gray">Infection 39, S26-S27<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6922576102345872287" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:anf4URPfarAC" class="gsc_a_at">Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom</a><div class="gs_gray">S Burns, S Cameron, P Cane, I Chrystie, D Churchill, V Delpech, D Pillay, ...</div><div class="gs_gray">AIDS 21 (8), 1035-1039<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16393378034196254565" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:7BrZ7Jt4UNcC" class="gsc_a_at">Long-acting injectable HIV therapies: the next frontier</a><div class="gs_gray">J Thornhill, C Orkin</div><div class="gs_gray">Current Opinion in Infectious Diseases 34 (1), 8-15<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=418678053018110799" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:otzGkya1bYkC" class="gsc_a_at">Estimated glomerular filtration rate slopes on tenofovir alafenamide</a><div class="gs_gray">F Ibrahim, L Campbell, AC Bailey, S Stockwell, L Waters, C Orkin, ...</div><div class="gs_gray">HIV medicine 21 (9), 607-612<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5954405494243938489" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:nVrZBo8bIpAC" class="gsc_a_at">Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation</a><div class="gs_gray">OT Stirrup, D Asboe, A Pozniak, CA Sabin, R Gilson, NE Mackie, ...</div><div class="gs_gray">HIV medicine 21 (5), 309-321<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2364997074142837758" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:fFSKOagxvKUC" class="gsc_a_at">Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison</a><div class="gs_gray">FC Lampe, AJ Rodger, W Burman, A Grulich, G Friedland, W El Sadr, ...</div><div class="gs_gray">AIDS (London, England) 33 (15), 2337<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7448492503918455290" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Aul-kAQHnToC" class="gsc_a_at">Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials</a><div class="gs_gray">C Orkin, C Kityo, E Koenig, E Natukunda, F Ajana, B Gandhi-Patel, Y Liu, ...</div><div class="gs_gray">HIV MEDICINE 20, 22-22<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8697359617605294897" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:8xutWZnSdmoC" class="gsc_a_at">Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults</a><div class="gs_gray">C Orkin, PE Sax, J Arribas, S Gupta, C Martorell, JL Stephens, ...</div><div class="gs_gray">HIV MEDICINE 20, 94-95<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5798151853442173845" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:r_AWSJRzSzQC" class="gsc_a_at">An integrated safety analysis comparing once-daily doravirine (DOR) to darunavir+ ritonavir (DRV+ r) and efavirenz (EFV) in HIV-1-infected, antiretroviral therapy (ART)-naïve&nbsp;…</a><div class="gs_gray">M Thompson, C Orkin, JM Molina, JM Gatell, PE Sax, GH Chan</div><div class="gs_gray">ID Week<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1035167258674141538" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:RHpTSmoSYBkC" class="gsc_a_at">Safety and efficacy of DTG+ RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location [abstract no. P22]</a><div class="gs_gray">C Orkin, MA Khuong-Josses, T Lutz, D Baker, R Rubio, E Blair, L Kahl, ...</div><div class="gs_gray">HIV Med 19 (Suppl 2), S28-9<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3889399091876055239" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:AvfA0Oy_GE0C" class="gsc_a_at">Impact of transmitted thymidine analogue mutations on responses to first-line ART</a><div class="gs_gray">AM Geretti, E White, A Beloukas, C Orkin, A Tostevin, P Tilston, ...</div><div class="gs_gray">23rd Conference on retroviruses and opportunistic infections (CROI), 22-25<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13216522031282104092" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:tH6gc1N1XXoC" class="gsc_a_at">Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2&nbsp;…</a><div class="gs_gray">F Raffi, A Rachlis, HJ Stellbrink</div><div class="gs_gray">Lancet 384 (9946), 856-856<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15062101546300285195" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WA5NYHcadZ8C" class="gsc_a_at">Changes in patient-reported neuropsychiatric outcomes during the SENSE trial: First-line treatment with two nucleoside analogues plus etravirine or efavirenz</a><div class="gs_gray">C Orkin, M Nelson, C Katlama, P Morlat, H Furrer, Y van Delft, M Janssen, ...</div><div class="gs_gray">Health Outcomes Research in Medicine 3 (3), e113-e119<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9722871295870109333" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_xSYboBqXhAC" class="gsc_a_at">Switching to a simplified single-tablet regimen (STR) of Atripla (ATR) from a two-or three-pill combination of the individual components (efavirenz [EFV], emtricitabine [FTC&nbsp;…</a><div class="gs_gray">G Moyle, C Orkin, M Fisher, S Taylor, J Ross, H Wang, C Simcock</div><div class="gs_gray">HIV MEDICINE 12, 79-79<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6984086147933457293" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:MhiOAD_qIWkC" class="gsc_a_at">ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve, HIV-1-infected adults HIV 10</a><div class="gs_gray">C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, ...</div><div class="gs_gray">Glasgow<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3875017867569646040" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:TFP_iSt0sucC" class="gsc_a_at">Comparison of renal and bone toxicities, and CV serum risk markers, in the ASSERT study: 48-week results from a prospective randomised trial: PS10/1</a><div class="gs_gray">HJ Stellbrink, G Moyle, C Orkin, J Arribas, H Pearce, P Zucchi</div><div class="gs_gray">Hiv Medicine 10<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10945758493265913669" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WqliGbK-hY8C" class="gsc_a_at">Prospective epidemiological study of the prevalence of HLA-B* 5701 in HIV-1-infected UK subjects</a><div class="gs_gray">C Orkin, T Sadiq, F Jackson, L Rice, TS McCaughney</div><div class="gs_gray">11th European AIDS conference<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10605046291061317796" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:eJXPG6dFmWUC" class="gsc_a_at">ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir vs lopinavir/r in treatment-naïve HIV-1-infected adults. 10th International Congess on Drug Therapy in&nbsp;…</a><div class="gs_gray">C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, ...</div><div class="gs_gray">Abstract P3<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10879100099947032272" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:-mN3Mh-tlDkC" class="gsc_a_at">Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK</a><div class="gs_gray">H Asad, IJ Collins, RL Goodall, S Crichton, T Hill, K Doerholt, C Foster, ...</div><div class="gs_gray">HIV medicine<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=345440865679605774" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:owLR8QvbtFgC" class="gsc_a_at">Acute Kidney Injury in COVID-19: multicentre prospective analysis of registry data</a><div class="gs_gray">YI Wan, Z Bien, VJ Apea, CM Orkin, R Dhairyawan, CJ Kirwan, ...</div><div class="gs_gray">Clinical Kidney Journal<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=502540251403679779" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:lgwcVrK6X84C" class="gsc_a_at">Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 infection</a><div class="gs_gray">C Orkin, JM Molina, Y Yazdanpanah, CC Anania, E DeJesus, J Eron, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23, 15-16<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8041942104374918017" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:nZcligLrVowC" class="gsc_a_at">Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents</a><div class="gs_gray">M Cevik, C Orkin</div><div class="gs_gray">Expert opinion on investigational drugs 28 (12), 1021-1024<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16383331496431669857" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:1taIhTC69MYC" class="gsc_a_at">Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz+ tenofovir+ emtricitabine for HIV</a><div class="gs_gray">OT Stirrup, CA Sabin, AN Phillips, I Williams, D Churchill, A Tostevin, ...</div><div class="gs_gray">Journal of virus eradication 5 (4), 204-211<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4466533239849855873" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:HbR8gkJAVGIC" class="gsc_a_at">Durable suppression and low rate of virological failures 3 years after switch to DTG plus RPV two-drug regimen: SWORD 1 and 2 studies</a><div class="gs_gray">J Van Wyk, C Orkin, R Rubio-Garcia, J Bogner, D Baker, ...</div><div class="gs_gray">HIV MEDICINE 20, 18-19<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15133391368978312536" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WbkHhVStYXYC" class="gsc_a_at">‘Just another vial…’: a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK</a><div class="gs_gray">L Cullen, P Grenfell, A Rodger, C Orkin, S Mandal, T Rhodes</div><div class="gs_gray">BMJ open 9 (4), e024085<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7916216141854178460" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:vV6vV6tmYwMC" class="gsc_a_at">THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection</a><div class="gs_gray">M Martinello, C Orkin, G Cooke, S Bhagani, E Gane, R Kulasegaram, ...</div><div class="gs_gray">Journal of Hepatology 70 (1), e231<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11290360370766213060" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:IUKN3-7HHlwC" class="gsc_a_at">Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services</a><div class="gs_gray">F Finnerty, Y Azad, C Orkin</div><div class="gs_gray">The Lancet HIV 6 (2), e76<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17388924932497364287" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:eMMeJKvmdy0C" class="gsc_a_at">Long-active cabotegravir plus rilpivirine for HIV maintenance: FLAIR week-48 results</a><div class="gs_gray">C Orkin, K Arasteh, MG Hernandez-Mora, VV Pokrovsky, ET Overton, ...</div><div class="gs_gray">HIV Medicine 20 (S5), 6-7<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9777717656341113225" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:t7zJ5fGR-2UC" class="gsc_a_at">Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16–18 May 2018, Marseille, France: from HIV and comorbidities to global health</a><div class="gs_gray">C Psomas, S Kinloch, C Sabin, V Soriano, C Solas, C Orkin, J Bernardino, ...</div><div class="gs_gray">Journal of virus eradication 4 (3), 196-207<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12430802882155883917" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Zph67rFs4hoC" class="gsc_a_at">Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort</a><div class="gs_gray">A Roen, K Laut, A Pelchen‐Matthews, E Borodulina, L Caldeira, A Clarke, ...</div><div class="gs_gray">HIV medicine 19 (4), 252-260<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1687340775748614662" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:1yQoGdGgb4wC" class="gsc_a_at">A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs. ABC/DTG/3TC in treatment-naïve adults at week 48</a><div class="gs_gray">J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, ...</div><div class="gs_gray">9th IAS Conference on HIV Science (IAS 2017)<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11086048198577152466" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:zA6iFVUQeVQC" class="gsc_a_at">Linkage to care after routine HIV, hepatitis B &amp; C testing in the emergency department: the ‘Going Viral’campaign</a><div class="gs_gray">R Dhairyawan, R O'Connell, S Flanagan, E Wallis, C Orkin</div><div class="gs_gray">Sexually transmitted infections 92 (7), 557-557<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6450799180043837878" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:hMsQuOkrut0C" class="gsc_a_at">Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT)</a><div class="gs_gray">N Marshall, M McNulty, C Smith, L Swaden, F Burns, C Orkin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13830156579500991457" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Mojj43d5GZwC" class="gsc_a_at">High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE coinfection study</a><div class="gs_gray">E Barr, JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, ...</div><div class="gs_gray">JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31, 66-66<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9726294268883082950" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:NXb4pA-qfm4C" class="gsc_a_at">HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients?</a><div class="gs_gray">AJ Williams, E Wallis, C Orkin</div><div class="gs_gray">International journal of STD &amp; AIDS 27 (7), 537-542<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16560889563662179811" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:TQgYirikUcIC" class="gsc_a_at">Effectiveness of opt-out HIV testing on a medical assessment unit in a high-prevalence area: P118</a><div class="gs_gray">L Raman, J Duschl, E Wallis, C Orkin</div><div class="gs_gray">Hiv Medicine 16<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4016138179972370518" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:M05iB0D1s5AC" class="gsc_a_at">‘Legion’of medical students participates in largest hospital-based HIV testing week initiative-breaking down testing barriers in the doctors of tomorrow: P235</a><div class="gs_gray">S Wikeley, R Bradbury, R Bath, R O'Connell, N Matin, J Saunders, ...</div><div class="gs_gray">Hiv Medicine 15<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=902299184744870045" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ILKRHgRFtOwC" class="gsc_a_at">P2. 042 An Audit of HIV Testing Rates in Patients Admitted with Pneumonia Pre-and Post-Implementation of Opt-Out HIV Testing For Acute Medical Admissions</a><div class="gs_gray">E Wallis, J Saunders, C Orkin</div><div class="gs_gray">Sexually Transmitted Infections 89 (Suppl 1), A100-A101<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13786459279826012559" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:yFnVuubrUp4C" class="gsc_a_at">TRANxITION 144‐week results: switching virologically stable HIV patients from immediate‐release nevirapine (NVP IR) to extended‐release NVP (XR)</a><div class="gs_gray">K Arastéh, M Drulak, J Guo, J Livrozet, C Orkin, A Quinson, D Ward</div><div class="gs_gray">Journal of the International AIDS Society 15, 1-1<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18099551786705276187" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LPZeul_q3PIC" class="gsc_a_at">Rilpivirine efficacy, virology and safety in ARV treatment‐naïve patients with viral load≤ 100,000 HIV‐1 RNA c/mL: ECHO and THRIVE 96‐week results</a><div class="gs_gray">JM Molina, N Clumeck, C Orkin, L Rimsky, S Vanveggel, M Stevens</div><div class="gs_gray">Journal of the International AIDS Society 15, 1-2<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8560547575936381110" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:HtEfBTGE9r8C" class="gsc_a_at">HIV specialists must lead the way to make HIV testing truly routine: P150</a><div class="gs_gray">L Byrne, T Whitburn, S Vearncombe, C Orkin, H Noble</div><div class="gs_gray">Hiv Medicine 12, 64-65<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8573448491137709712" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:IjCSPb-OGe4C" class="gsc_a_at">HIV in the older patient: an overlooked population?: P158</a><div class="gs_gray">A Nori, N Jethwa, E Chung, C Orkin</div><div class="gs_gray">Hiv Medicine 12<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=282183384678188937" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:6bLC7aUMtPcC" class="gsc_a_at">Browse Articles</a><div class="gs_gray">N Lee, YH Yen, CH Hung, SN Lu, JH Wang, JC Wang, CH Chen, KM Kee, ...</div><div class="gs_gray">Antiviral Therapy 16, 237-247<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9245153858925826989" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:K3LRdlH-MEoC" class="gsc_a_at">Non-germinal centre subtype of AIDS-related diffuse large B-cell lymphomas associated with improved survival: O33</a><div class="gs_gray">M Bower, S Montoto, K Cwynarski, S Lumsden, R Rajab, J Okosun, ...</div><div class="gs_gray">Hiv Medicine 11<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7957098234902625653" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ULOm3_A8WrAC" class="gsc_a_at">Switching from Kivexa [KVX] ABC/3TC+ efavirenz [EFV] to Atripla [ATR](EFV/FTC/TDF) reduces cholesterol in hypercholesterolemic subjects: preliminary results of a 24-week&nbsp;…</a><div class="gs_gray">C Orkin, G Moyle, M Fisher, H Wang, J Ewan</div><div class="gs_gray">Hiv Medicine 11<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1712107450325790704" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:D03iK_w7-QYC" class="gsc_a_at">Comparison of bone and renal toxicities in the ASSERT study: final 96 week results from a prospective randomized safety trial</a><div class="gs_gray">GJ Moyle, HI Stellbrink, J Compston, C Orkin, J Arribas, P Domingo, ...</div><div class="gs_gray">ANTIVIRAL THERAPY 15, A19-A19<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6841787756639799909" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_Ybze24A_UAC" class="gsc_a_at">Sarcoid-like immune restoration inflammatory syndrome (IRIS) presenting with hypercalcaemia and renal failure in HIV infection: P81</a><div class="gs_gray">J Okosun, F Martin, M Murphy, C Orkin, J Moore-Gillon</div><div class="gs_gray">Hiv Medicine 9, 31-32<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11870975324174422671" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:AXkvAH5U_nMC" class="gsc_a_at">Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials</a><div class="gs_gray">C Orkin, F Ajana, C Kityo, E Koenig, E Natukunda, B Gandhi-Patel, ...</div><div class="gs_gray">JAIDS Journal of Acquired Immune Deficiency Syndromes<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:rHJHxKgnXwkC" class="gsc_a_at">Ethnicity and acute hospital admissions: Multi-center analysis of routine hospital data</a><div class="gs_gray">YI Wan, AJ Robbins, VJ Apea, CM Orkin, RM Pearse, ZA Puthucheary, ...</div><div class="gs_gray">EClinicalMedicine, 101077<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:SjuI4pbJlxcC" class="gsc_a_at">Correction to Lancet HIV 2021; 8: e185–96</a><div class="gs_gray">C Orkin, S Oka, P Philibert</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:q-HalDI95KYC" class="gsc_a_at">Four year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive adults</a><div class="gs_gray">K Workowski, C Orkin, P Sax, D Hagins, E Koenig, J Stephens, S Gupta, ...</div><div class="gs_gray">HIV MEDICINE 22, 32-33<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:DBa1UEJaJKAC" class="gsc_a_at">Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir+ rilpivirine for treatment in adults with HIV-1 infection (ITT-E&nbsp;…</a><div class="gs_gray">C Orkin, R D'Amico, EB Morell, DHS Tan, H Katner, Y Singh, HJ Stellbrink, ...</div><div class="gs_gray">Journal of the International AIDS Society 24 (S4), 22-23<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:prdVHNxh-e8C" class="gsc_a_at">The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London</a><div class="gs_gray">T Crocker-Buque, S Williams, AR Brentnall, R Gabe, S Duffy, JR Prowle, ...</div><div class="gs_gray">The International Journal of Tuberculosis and Lung Disease 25 (5), 358-366<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:7wO8s98CvbsC" class="gsc_a_at">Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine</a><div class="gs_gray">M Nelson, A Winston, A Hill, R Mngqibisa, A Bassa, C Orkin, M Rassool, ...</div><div class="gs_gray">AIDS 35 (5), 759-767<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:jU7OWUQzBzMC" class="gsc_a_at">Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results</a><div class="gs_gray">R D'Amico, C Orkin, E Bernal Morell, DHS Tan, H Katner, Y Singh, ...</div><div class="gs_gray">INFECTION 49 (SUPPL 1), S7-S7<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WC23djZS0W4C" class="gsc_a_at">Long-acting injectable HIV therapies: the next frontier: Republication</a><div class="gs_gray">J Thornhill, C Orkin</div><div class="gs_gray">Current Opinion in HIV and AIDS 16 (2), 98-105<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:3NQIlFlcGxIC" class="gsc_a_at">Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.</a><div class="gs_gray">M Nelson, A Winston, A Hill, R Mngqibisa, A Bassa, C Orkin, M Rassool, ...</div><div class="gs_gray">AIDS (London, England)<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:WHdLCjDvYFkC" class="gsc_a_at">Clinical Outcomes of Patients With and Without HIV Hospitalised with COVID-19 in England During the Early Stages of the Pandemic: A Matched Retrospective Multicentre Analysis&nbsp;…</a><div class="gs_gray">M Lee, CJ Smith, S Douthwaite, S Fidler, N Fitzgerald, L Goodwin, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Ade32sEp0pkC" class="gsc_a_at">Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London</a><div class="gs_gray">YI Wan, VJ Apea, R Dhairyawan, ZA Puthucheary, RM Pearse, CM Orkin, ...</div><div class="gs_gray">medRxiv<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:MpfHP-DdYjUC" class="gsc_a_at">Increase in bone mineral density and weight in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG</a><div class="gs_gray">A Samarawickrama, L Hamzah, F Ibrahim, J Ainsworth, J Fox, Y Gilleece, ...</div><div class="gs_gray">HIV MEDICINE 21, 13-13<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:7Hz3ACDFbsoC" class="gsc_a_at">Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide versus comparators in cis-women and girls (living with HIV): an analysis of five clinical trials</a><div class="gs_gray">C Orkin, F Ajana, C Kityo, E Koenig, E Natukunda, B Gandhi-Patel, YP Liu, ...</div><div class="gs_gray">HIV MEDICINE 21, 18-19<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LdasjJ6CEcoC" class="gsc_a_at">Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results</a><div class="gs_gray">C Orkin, S Oka, P Philibert, C Brinson, AC Bassa, D Gusev, O Degen, ...</div><div class="gs_gray">HIV MEDICINE 21, 14-14<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:cK4Rrx0J3m0C" class="gsc_a_at">HIV-related admissions to a London specialist unit: who, what and why?</a><div class="gs_gray">S Parry, M Williamson, C Orkin, N Matin, R Dhairyawan</div><div class="gs_gray">HIV MEDICINE 21, 54-54<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:v1_lew4L6wgC" class="gsc_a_at">Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults</a><div class="gs_gray">C Orkin, P Sax, J Arribas, S Gupta, C Martorell, J Stephens, HJ Stellbrink, ...</div><div class="gs_gray">HIV MEDICINE 21, 18-18<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:BzfGm06jWhQC" class="gsc_a_at">Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background&nbsp;…</a><div class="gs_gray">D Bradshaw, I Abramowicz, S Bremner, Y Gilleece, S Fedele, S Kirk, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23, 76-77<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:43bX7VzcjpAC" class="gsc_a_at">Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results</a><div class="gs_gray">R D'Amico, C Orkin, E Bernal Morell, D Tan, H Katner, Y Singh, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23, 10-12<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:zCSUwVk65WsC" class="gsc_a_at">Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)</a><div class="gs_gray">V Chounta, S Wu, O Upadhyay, S Griffith, C Harrington, C Orkin, ...</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 23, 24-24<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ALROH1vI_8AC" class="gsc_a_at">Effet de la doravirine sur le poids et l’indice de masse corporelle chez les adultes VIH-1 débutant un traitement antirétroviral</a><div class="gs_gray">P Mariot, C Orkin, R Elion, M Thompson, J Rockstroh, Z Xu, E Martin, ...</div><div class="gs_gray">Médecine et Maladies Infectieuses 50 (6), S189<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:QD3KBmkZPeQC" class="gsc_a_at">Decline in HCV incidence in HIV Positive MSM–progress to HCV Micro-elimination in the UK?</a><div class="gs_gray">L Garvey, G Cooke, C Smith, C Stngone, I Ghosh, S Dakshina, L Jain, ...</div><div class="gs_gray">Oxford University Press (OUP)<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:6yz0xqPARnAC" class="gsc_a_at">ETHICAL: Ethnic Disparities In COVID-19 Admissions in east London</a><div class="gs_gray">YI Wan, V Apea, R Dhairyawan, C Orkin, RM Pearse, JR Prowle</div><div class="gs_gray">Queen Mary University of London, Critical Care and Preoperative Medicine&nbsp;…<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:2tRrZ1ZAMYUC" class="gsc_a_at">Enrolling pregnant women with HIV into clinical trials</a><div class="gs_gray">C Orkin, SL Goddard</div><div class="gs_gray">The Lancet HIV 7 (5), e302-e303<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:BJbdYPG6LGMC" class="gsc_a_at">Oncedaily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis (vol 70, ciz124, 2019)</a><div class="gs_gray">C Orkin, JM Molina, Lombaard</div><div class="gs_gray">CLINICAL INFECTIOUS DISEASES 70 (2), 360-360<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:kVjdVfd2voEC" class="gsc_a_at">Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide</a><div class="gs_gray">K Andreatta, R Acosta, M D'Antoni, D Porter, S Chang, R Martin, ...</div><div class="gs_gray">SEXUAL HEALTH 17 (5), XXIII-XXIII<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ubry08Y2EpUC" class="gsc_a_at">Erratum: Oncedaily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: An integrated efficacy analysis (Clinical Infectious Diseases</a><div class="gs_gray">C Orkin, JM Molina</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:48xauSegjOkC" class="gsc_a_at">Gender disparities in international COVID-19 clinical trial leadership</a><div class="gs_gray">M Cevik, SA Haque, J Manne, K Kuppalli, PE Sax, MS Majumder, C Orkin</div><div class="gs_gray">medRxiv<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:gVv57TyPmFsC" class="gsc_a_at">DRIVE-AHEAD Trial's Results and the Need for a More Appropriate Comparator Drug Reply</a><div class="gs_gray">EA Martin, C Hwang, C Orkin</div><div class="gs_gray">CLINICAL INFECTIOUS DISEASES 69 (10), 1832-1833<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ZzlSgRqYykMC" class="gsc_a_at">Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older</a><div class="gs_gray">HJ Stellbrink, FA Post, D Podzamczer, J Arribas, E Cua, JM Molina, ...</div><div class="gs_gray">HIV MEDICINE 20, 138-138<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:GFxP56DSvIMC" class="gsc_a_at">EACS 2019-Abstract Book</a><div class="gs_gray">R Quercia, C Orkin, R D'Amico, J Mrus, S Wu, A Cutrell, K Chow, J Polli, ...</div><div class="gs_gray">HIV MEDICINE 20, 3-3<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:umqufdRvDiIC" class="gsc_a_at">Reply to Lanzafame et al</a><div class="gs_gray">EA Martin, C Hwang, C Orkin</div><div class="gs_gray">Clinical Infectious Diseases<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:f2IySw72cVMC" class="gsc_a_at">Does less equal more yet?</a><div class="gs_gray">C Orkin</div><div class="gs_gray">The Lancet HIV 6 (7), e412-e413<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:SpbeaW3--B0C" class="gsc_a_at">B/F/TAF versus ABC/DTG/3TC or DTG+ F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results</a><div class="gs_gray">D Podzamczer, HJ Stellbrink, C Orkin, A Pozniak, J Arribas, E Koenig, ...</div><div class="gs_gray">HIV MEDICINE 20, 18-18<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:3fE2CSJIrl8C" class="gsc_a_at">Epidemiology and natural history of HIV</a><div class="gs_gray">P Khan, S Parry, C Orkin</div><div class="gs_gray">Tutorial Topics in Infection for the Combined Infection Training Programme, 413<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:uDGL6kOW6j0C" class="gsc_a_at">Reply to Lanzafame et al</a><div class="gs_gray">C Hwang, C Orkin</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Ri6SYOTghG4C" class="gsc_a_at">1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated&nbsp;…</a><div class="gs_gray">JK Rockstroh, SR Bhagani, C Orkin, R Soto-Malave, K Lacombe, Z Zhang, ...</div><div class="gs_gray">Open Forum Infectious Diseases 5 (suppl_1), S569-S570<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:evX43VCCuoAC" class="gsc_a_at">543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+ Ritonavir (DRV+ r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART&nbsp;…</a><div class="gs_gray">M Thompson, C Orkin, JM Molina, J Gatell, P Sax, P Cahn, K Squires, ...</div><div class="gs_gray">Open Forum Infectious Diseases 5 (suppl_1), S201-S202<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Y5dfb0dijaUC" class="gsc_a_at">1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single&nbsp;…</a><div class="gs_gray">J Eron, C Orkin, D Cunningham, F Pulido, F Post, S De Wit, E Lathouwers, ...</div><div class="gs_gray">Open Forum Infectious Diseases 5 (suppl_1), S65-S65<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:GnPB-g6toBAC" class="gsc_a_at">Mental health and HIV: what we all need to know</a><div class="gs_gray">C Orkin, F Lampe, C Izambert, L Waters</div><div class="gs_gray">JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:k_IJM867U9cC" class="gsc_a_at">Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study</a><div class="gs_gray">ME Vazquez, J Rockstroh, K Lacombe, C Orkin, A Luetkemeyer, D Wyles, ...</div><div class="gs_gray">International Journal of Infectious Diseases 73, 372<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:GtLg2Ama23sC" class="gsc_a_at">HIV-related medical admissions to an HIV specialist inpatient unit: quality standards and outcomes</a><div class="gs_gray">M Krutikov, S Parry, L Drury, N Matin, C Orkin</div><div class="gs_gray">HIV MEDICINE 19, S102-S103<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Se3iqnhoufwC" class="gsc_a_at">TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection</a><div class="gs_gray">M Martinello, M Cerrone, S Bhagani, E Gane, C Orkin, G Cooke, GJ Dore, ...</div><div class="gs_gray">HIV MEDICINE 19, S151-S152<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LkGwnXOMwfcC" class="gsc_a_at">Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus&nbsp;…</a><div class="gs_gray">C Orkin, JM Molina, J Gallant, E Negredo, J Gathe, J Eron, E van Landuyt, ...</div><div class="gs_gray">HIV MEDICINE 19, S32-S32<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:F9fV5C73w3QC" class="gsc_a_at">LATE BREAKER ABSTRACT</a><div class="gs_gray">C Orkin, MD Kathleen Squires, MD Jean-Michel Molina, P Sax</div><div class="gs_gray">Open Forum Infectious Diseases 1 (S1), S759-766<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:VL0QpB8kHFEC" class="gsc_a_at">Protease inhibitors in anti-retroviral therapy: past, present and future</a><div class="gs_gray">C Orkin</div><div class="gs_gray">INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 50, S14-S14<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Fu2w8maKXqMC" class="gsc_a_at">Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer, on behalf of the EMERALD study group</a><div class="gs_gray">C Orkin, JM Molina, E Negredo, JR Arribas, J Gathe, JJ Eron, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:1sJd4Hv_s6UC" class="gsc_a_at">Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: a retrospective analysis of sexual health&nbsp;…</a><div class="gs_gray">TJ Pasvol, C Orkin</div><div class="gs_gray">Sexually transmitted infections 93 (5), 326<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:fQNAKQ3IYiAC" class="gsc_a_at">Routine blood-borne virus testing for HIV, hepatitis B and hepatitis C in the emergency department: the'new normal'?</a><div class="gs_gray">S Parry, S Ullah, G Foster, K Ahmad, W Tong, C Orkin, S Balasegaram, ...</div><div class="gs_gray">HIV MEDICINE 18, 5-6<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:YFjsv_pBGBYC" class="gsc_a_at">Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT)</a><div class="gs_gray">M McNulty, C Orkin, C Smith, N Marshall, L Swaden, F Burns</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:-f6ydRqryjwC" class="gsc_a_at">Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir&nbsp;…</a><div class="gs_gray">C Orkin, E DeJesus, M Ramgopal, G Crofoot, P Ruane, A LaMarca, ...</div><div class="gs_gray">HIV MEDICINE 18, 21-21<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:hkOj_22Ku90C" class="gsc_a_at">O124 [LINE SEPARATOR] Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF&nbsp;…</a><div class="gs_gray">C Orkin, E DeJesus, M Ramgopal, G Crofoot, P Ruane, A LaMarca, ...</div><div class="gs_gray">Journal of the International Aids Society 19<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:NaGl4SEjCO4C" class="gsc_a_at">O125 [LINE SEPARATOR] Long‐term (96‐week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV‐infected&nbsp;…</a><div class="gs_gray">F Raffi, C Orkin, A Clarke, L Slama, J Gallant, E Daar, M Yan, M Abram, ...</div><div class="gs_gray">Journal of the International Aids Society 19<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:r0BpntZqJG4C" class="gsc_a_at">P248 [LINE SEPARATOR] TURQUOISE‐I part 2: safety and efficacy of ombitasvir+ paritaprevir/r±dasabuvir with or without RBV in patients with HIV‐1 and HCV GT1 or GT4 co‐infection</a><div class="gs_gray">J Rockstroh, C Orkin, R Viani, D Wyles, A Luetkemeyer, A Lazzarin, ...</div><div class="gs_gray">Journal of the International Aids Society 19<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:S16KYo8Pm5AC" class="gsc_a_at">Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial</a><div class="gs_gray">A Rodger, F Lampe, W Burman, A Gruhlich, G Friedland, W El-Sadr, ...</div><div class="gs_gray">Journal of the International AIDS Society 19 (Supplement 5), 124-125<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:kw52XkFRtyQC" class="gsc_a_at">WEAB0304LB [LINE SEPARATOR] TURQUOISE‐I Part 2: safety and efficacy of ombitasvir+ paritaprevir/r±dasabuvir with or without RBV in patients with HIV‐1 and HCV GT1 or GT4 co&nbsp;…</a><div class="gs_gray">JK Rockstroh, C Orkin, RM Viani, D Wyles, A Luetkemeyer, A Lazzarin, ...</div><div class="gs_gray">Journal of the International Aids Society 19<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_kc_bZDykSQC" class="gsc_a_at">Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa</a><div class="gs_gray">J Hakim, K Maitland</div><div class="gs_gray">International AIDS Society<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:eq2jaN3J8jMC" class="gsc_a_at">P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults</a><div class="gs_gray">C Orkin, B Rjinders, C Stephan, M McKellar, S Kiertiburanakul, J Arribas, ...</div><div class="gs_gray">Sexually Transmitted Infections 92 (Suppl 1), A34-A34<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:L8Ckcad2t8MC" class="gsc_a_at">O028 Low proportion of men who have sex with men (MSM) tested for hepatitis C despite high prevalence in 2 genito-urinary medicine (GUM) clinics</a><div class="gs_gray">T Pasvol, P Khan, A Thiagarajan, S Dakshina, L Sarner, C Orkin</div><div class="gs_gray">Sexually Transmitted Infections 92 (Suppl 1), A11-A11<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:dBIO0h50nwkC" class="gsc_a_at">Early virological response did not predict high levels of sustained virological response at 12 weeks (SVR12) in HIV/HCV-co-infected patients treated with directly acting agent&nbsp;…</a><div class="gs_gray">A Umaipalan, A Jayakumar, M Patel, E Wallis, G Baily, C Orkin</div><div class="gs_gray">Hiv Medicine 17<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:rmuvC79q63oC" class="gsc_a_at">The transfer times and outcomes of a tertiary in-patient HIV ward: P170</a><div class="gs_gray">S Marwaha, S Dakshina, A Umaipalan, T Pasvol, G Baily, C Orkin</div><div class="gs_gray">Hiv Medicine 17<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:tzM49s52ZIMC" class="gsc_a_at">Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults: P12</a><div class="gs_gray">C Orkin, A Clarke, J Gallant, E Daar, F Raffi, S Antonucci, Y Mingjin, ...</div><div class="gs_gray">Hiv Medicine 17<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:iH-uZ7U-co4C" class="gsc_a_at">Is there a role for a network-wide Kaposi sarcoma clinic in 2015? A review of transfers and clinical outcomes: P161</a><div class="gs_gray">S Dakshina, R Rieu, T Richards, C Cottrill, C Orkin</div><div class="gs_gray">Hiv Medicine 17<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:R3hNpaxXUhUC" class="gsc_a_at">P010 [LINE SEPARATOR] Improved safety and efficacy of TAF versus TDF single‐tablet regimen in HIV‐1 treatment‐naïve women through week 48</a><div class="gs_gray">E Koenig, C Orkin, A Clarke, D Podzamczer, B Clotet, C Callebaut, ...</div><div class="gs_gray">Journal of the International Aids Society 19<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:7PzlFSSx8tAC" class="gsc_a_at">Routine HIV testing in critical care: P127</a><div class="gs_gray">A Umaipalan, S Dakshina, P Khan, N Bunker, C Orkin</div><div class="gs_gray">Hiv Medicine 17<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ZeXyd9-uunAC" class="gsc_a_at">Should HIV testing week be blood-borne-virus testing week?</a><div class="gs_gray">C Orkin, E Wallis</div><div class="gs_gray">The Lancet HIV 2 (12), e510-e511<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:tuHXwOkdijsC" class="gsc_a_at">NtRTI sparing in patients at risk of bone disease</a><div class="gs_gray">C Orkin, A Umaipalan</div><div class="gs_gray">The Lancet HIV 2 (11), e452-e453<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:sNmaIFBj_lkC" class="gsc_a_at">High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4, and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study</a><div class="gs_gray">J Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ...</div><div class="gs_gray">Journal of the International Aids Society 18<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:q3oQSFYPqjQC" class="gsc_a_at">Disease progression in HIV-1 controllers; uptake and outcome of antiretroviral therapy: P27</a><div class="gs_gray">J Deayton, E O'Sullivan, Á McKnight, K Groves, D Bibby, D Clark, C Orkin, ...</div><div class="gs_gray">Hiv Medicine 16<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:XiSMed-E-HIC" class="gsc_a_at">Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co‐infected patients with HCV GT1‐4 infection: the PHOTON‐1 and‐2 Trials</a><div class="gs_gray">J Santana, J Rockstroh, M Puoti, M Rodriguez‐Torres, D Dieterich, ...</div><div class="gs_gray">Journal of the International Aids Society 18<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ldfaerwXgEUC" class="gsc_a_at">Post chemotherapy liver dysfunction and reactivation of Hepatitis B (HBV) and C (HCV) in an HIV-infected cohort: P93</a><div class="gs_gray">E Wallis, A Umaipalan, S Flanagan, S Montoto, C Orkin</div><div class="gs_gray">Hiv Medicine 16<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4X0JR2_MtJMC" class="gsc_a_at">Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human&nbsp;…</a><div class="gs_gray">S Flanagan, A Umaipalan, G Baily, C Orkin</div><div class="gs_gray">Journal of AIDS and HIV Research 7 (3), 33-35<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LPtt_HFRSbwC" class="gsc_a_at">8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015).</a><div class="gs_gray">KM Pate, C Pohlmeyer, V Walker-Sperling, J Foote, K Najarro, C Cryer, ...</div><div class="gs_gray">Wiley<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_5tno0g5mFcC" class="gsc_a_at">BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015</a><div class="gs_gray">N Ahmed, B Angus, M Boffito, M Bower, D Dunn, S Edwards, C Emerson, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:6ZxmRoH8BuwC" class="gsc_a_at">8th IAS Conference on HIV Pathogenesis, Treatment &amp; Prevention 19â 22 July 2015, Vancouver, Canada</a><div class="gs_gray">KM Pate, C Pohlmeyer, V Walker‐sperling, J Foote, K Najarro, C Cryer, ...</div><div class="gs_gray">International AIDS Society<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:u_35RYKgDlwC" class="gsc_a_at">P1247: Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital-should we be screening for HCV in ED attendees?</a><div class="gs_gray">C Orkin, E Leach, S Flanagan, E Wallis, GR Foster, M Ruf, CY Tong</div><div class="gs_gray">Journal of Hepatology, S825<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Wp0gIr-vW9MC" class="gsc_a_at">Noduloulcerative skin lesions in an HIV-positive man: an increasingly common presentation of an ancient disease: BI04</a><div class="gs_gray">M Krupiczojc, P Goldsmith, R Cerio, C Orkin, E Williams, C Harwood</div><div class="gs_gray">British Journal of Dermatology 171, 101-102<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:foquWX3nUaYC" class="gsc_a_at">Opt-out HIV testing in adult critical care units (vol 383, pg 1460, 2014)</a><div class="gs_gray">J Thornhill, G Mandersloot, R Bath, C Orkin</div><div class="gs_gray">LANCET 383 (9930), 1720-1720<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:hCrLmN-GePgC" class="gsc_a_at"># TestMeEast@ EuroHIVTestingWeek: a celebrity-endorsed, newsworthy NHS campaign across six hospitals to test 2500 patients (500/day) based in outpatients (OPD) and emergency&nbsp;…</a><div class="gs_gray">R Bath, R O'Connell, M Lascar, R Ferrand, N Matin, I Basnett, V Apea, ...</div><div class="gs_gray">Hiv Medicine 15<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:maZDTaKrznsC" class="gsc_a_at">STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a&nbsp;…</a><div class="gs_gray">E Wilkins, G Moyle, C Orkin, M Fisher, M Johnson, J Arribas, ...</div><div class="gs_gray">Hiv Medicine 15, 115-116<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:geHnlv5EZngC" class="gsc_a_at">Ninety-six-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF-subgroup analyses by baseline HIV-1 RNA and CD4 cells.: 95E.</a><div class="gs_gray">A Zolopa, J Rockstroh, C Orkin, HJ Stellbrink, S Walmsley, D Cooper, ...</div><div class="gs_gray">Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy 33 (10)<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:0KyAp5RtaNEC" class="gsc_a_at">HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA</a><div class="gs_gray">R Coutinho, M Flook, A Pria, S Gandhi, K Bailey, P Fields, K Cwynarski, ...</div><div class="gs_gray">HAEMATOLOGICA 98, 129-129<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:yD5IFk8b50cC" class="gsc_a_at">BHIVA Guidelines for the treatment of management of coinfection with HIV-1 and hepatitis viruses 2013</a><div class="gs_gray">E Wilkins, M Nelson, MD Awoyemi, DE Barnes, S Bhagani, G Brook, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:lmc2jWPfTJgC" class="gsc_a_at">Project “Test the Hospital”</a><div class="gs_gray">E Williams, R Bath, N Vaid, S Tillett, G Mandersloot, N Poole, J Saunders, ...</div><div class="gs_gray">Hiv Medicine 14, 47-47<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:CHSYGLWDkRkC" class="gsc_a_at">Opt-out HIV testing within intensive care in a large urban hospital: an innovative testing initiative</a><div class="gs_gray">S Tariq, R Bath, S Tillett, J Saunders, A Nori, G Mandersloot, C Orkin</div><div class="gs_gray">Hiv Medicine 14, 46-46<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:IWHjjKOFINEC" class="gsc_a_at">Cross-sectional analysis of invasive pneumococcal disease in a London HIV positive cohort</a><div class="gs_gray">J Thornhill, E Wallis, S Cho, P Khan, A Sivaramakrishnan, A Amin, ...</div><div class="gs_gray">Hiv Medicine 14, 67-67<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:5nxA0vEk-isC" class="gsc_a_at">In an ageing HIV positive cohort with mixed gender and sexuality, is bone mineral density impaired?: P37</a><div class="gs_gray">A Hartley, C Annesley, K Davies, C Orkin, A Williams</div><div class="gs_gray">Hiv Medicine 14<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:roLk4NBRz8UC" class="gsc_a_at">Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera (R)) in hepatitis C-HIV coinfection</a><div class="gs_gray">F Cresswell, A Gothard, M Cevik, G Haidari, H Alexander, I Katsarolis, ...</div><div class="gs_gray">ANTIVIRAL THERAPY 18, A61-A61<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:mVmsd5A6BfQC" class="gsc_a_at">AUTHOR INDEX: Journal of the International AIDS Society</a><div class="gs_gray">M Cohen, C Perno, W El‐Sadr, JM Molina, M Saag, J Lundgren, ...</div><div class="gs_gray">Journal of the International AIDS Society 15, 18447<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:a9-T7VOCCH8C" class="gsc_a_at">TUAE0104: HIV cure strategies: how good must they be to improve on current antiretroviral therapy?</a><div class="gs_gray">T Kyrychenko, G Dubynska, T Koval, I Kaidashev, V Korshenko, K Rono, ...</div><div class="gs_gray">Journal of the International AIDS Society 15, 18439<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:aqlVkmm33-oC" class="gsc_a_at">HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era</a><div class="gs_gray">C Orkin, S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson, ...</div><div class="gs_gray">Hiv Medicine 13<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4vMrXwiscB8C" class="gsc_a_at">SpR Trek: the next generation: P15</a><div class="gs_gray">A Williams, B Goh, C Orkin</div><div class="gs_gray">Hiv Medicine 13<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:-FonjvnnhkoC" class="gsc_a_at">The first 9 months: the lost to follow up (LTFU) clinic is born. A sustained approach to re-engaging patients: P210</a><div class="gs_gray">R Dhairyawan, S Lowe, B Ncube, A Jones, S Strachen, V Apea, C Orkin</div><div class="gs_gray">Hiv Medicine 13<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:_Re3VWB3Y0AC" class="gsc_a_at">Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir&nbsp;…</a><div class="gs_gray">E DeJesus, C Orkin, J Rockstroh, JM Molina, K White, X Wei, A Plummer, ...</div><div class="gs_gray">Hiv Medicine 13<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:tkaPQYYpVKoC" class="gsc_a_at">Incidence of rash in the 96-week analysis of the pooled, Phase III, randomised, double-blind ECHO and THRIVE trials</a><div class="gs_gray">C Orkin, J Arribas, S Hodder, HJ Stellbrink, S Vanveggel, H Deckx, ...</div><div class="gs_gray">Hiv Medicine 13, 50-50<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4fKUyHm3Qg0C" class="gsc_a_at">HIV research trials versus standard clinics for antiretroviral (ARV) naïve patients: the outcomes differ but do the patients?: P208</a><div class="gs_gray">A Williams, A Uthayakumar, C De Souza, L Murthen, J Hand, V Apea, ...</div><div class="gs_gray">Hiv Medicine 13<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:qxL8FJ1GzNcC" class="gsc_a_at">Pooled Week 96 efficacy and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV; TMC278) versus efavirenz (EFV) in treatment-naïve&nbsp;…</a><div class="gs_gray">C Orkin, C Cohen, JM Molina, I Cassetti, P Chetchotisakd, A Lazzarin, ...</div><div class="gs_gray">Hiv Medicine 13, 68-69<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Br1UauaknNIC" class="gsc_a_at">Track B Clinical Science</a><div class="gs_gray">T Kyrychenko, G Dubynska, T Koval, I Kaidashev, V Korshenko, K Rono, ...</div><div class="gs_gray">Journal of the International AIDS Society 15 (Suppl 3)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:dQ2og3OwTAUC" class="gsc_a_at">ÉPREUVE DE LECTURE CRITIQUE D’ARTICLE Drs Nadia Nathan et Pierre Loulergue</a><div class="gs_gray">S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson, M Shanyinde, ...</div><div class="gs_gray">J Clin Oncol 30, 4111-4116<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:SdhP9T11ey4C" class="gsc_a_at">Blinded by love: Ocular syphilis as the initial manifestation of HIV: Category: Clinical lesson</a><div class="gs_gray">J Dua, A Nori, E Elliot, B Goh, C Orkin</div><div class="gs_gray">Journal of Infection 63 (6), e119<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:0EnyYjriUFMC" class="gsc_a_at">HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era</a><div class="gs_gray">S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson, M Shanyinde, ...</div><div class="gs_gray">Blood 118 (21), 3646<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:epqYDVWIO7EC" class="gsc_a_at">Will earlier diagnosis of HIV infection in late presenters reduce the frequency of serious opportunistic infections? Response</a><div class="gs_gray">L Waters, M Fisher, J Anderson, C Wood, V Delpech, T Hill, J Walsh, ...</div><div class="gs_gray">HIV Medicine 12 (7), 450-451<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:cFHS6HbyZ2cC" class="gsc_a_at">Authors' response to Drs Scourfield, Jackson and Nelson</a><div class="gs_gray">L Waters, M Fisher, J Anderson, C Wood, V Delpech, T Hill, J Walsh, ...</div><div class="gs_gray">Hiv Medicine 12 (7), 450-451<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:ODE9OILHJdcC" class="gsc_a_at">First contact: exploring relationships between HIV clinics, primary care, geography and HIV diagnoses in North East London</a><div class="gs_gray">S Longwill, A Nori, C Orkin, B O’Connell, S Creighton, J Dorward, ...</div><div class="gs_gray">Hiv Medicine 12, 64-64<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:mNrWkgRL2YcC" class="gsc_a_at">Evaluation of a new clinic model: increasing enrolment into clinical trials without increasing staffing or costs</a><div class="gs_gray">E Draeger, K Smith, S Hogan, C Orkin</div><div class="gs_gray">Hiv Medicine 12, 19-20<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:k8Z6L05lTy4C" class="gsc_a_at">Does better tolerated antiretroviral therapy (ART) allow us to modernize post-exposure prophylaxis (PEP) services?: P6</a><div class="gs_gray">A Hartley, N Garrett, C Orkin, L Sarner, N Ault</div><div class="gs_gray">Hiv Medicine 12, 15-16<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:uWiczbcajpAC" class="gsc_a_at">Successful treatment of acute hepatitis C virus in a cohort of HIV-positive patients</a><div class="gs_gray">J Dorward, N Garrett, D Scott, M Buckland, C Orkin, G Baily</div><div class="gs_gray">HIV MEDICINE 12, 43-43<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:7T2F9Uy0os0C" class="gsc_a_at">Cutaneous Kaposi's sarcoma: a case of mistaken identity: P79</a><div class="gs_gray">J Dua, A Nori, C Cottrill, C Orkin</div><div class="gs_gray">Hiv Medicine 12<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:5ugPr518TE4C" class="gsc_a_at">Switching to a simplified single-tablet regimen (STR) of Atripla (ATR) from a two-or three-pill combination of the individual components (efavirenz [EFV], emtricitabine [FTC&nbsp;…</a><div class="gs_gray">G Moyle, C Orkin, M Fisher, S Taylor, J Ross, H Wang, C Simcock</div><div class="gs_gray">Hiv Medicine 12<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:JV2RwH3_ST0C" class="gsc_a_at">CHANGES IN PATIENT-REPORTED OUTCOMES DURING THE SENSE TRIAL: FIRST-LINE TREATMENT WITH 2 NRTIS PLUS ETRAVIRINE OR EFAVIRENZ</a><div class="gs_gray">A Castagna, A Lazzarin, G Carosi, M Andreoni, C Orkin, A Streinu-Cercel, ...</div><div class="gs_gray">INFECTION 39, S64-S64<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:VaXvl8Fpj5cC" class="gsc_a_at">Disease Progression Despite Suppressed Plasma Viral Load in Human Immunodeficiency Infected Viremic Controllers</a><div class="gs_gray">K Groves, D Bibby, D Clark, A Isaksen, J Deayton, J Anderson, C Orkin, ...</div><div class="gs_gray">AIDS RESEARCH AND HUMAN RETROVIRUSES 26 (10), A163-A163<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:b1wdh0AR-JQC" class="gsc_a_at">Routine investigation and monitoring of adult HIV-1-infected individuals</a><div class="gs_gray">D Asboe, C Aitken, M Boffito, A Fakoya, AM Geretti, P Kelleher, C Orkin, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:zLWjf1WUPmwC" class="gsc_a_at">Inter-clade dual HIV-1 infection in the UK-an emerging phenomenon: P60</a><div class="gs_gray">J Deayton, D Bibby, C Orkin, E O'Sullivan, A McKnight, D Clark</div><div class="gs_gray">Hiv Medicine 11<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:kh2fBNsKQNwC" class="gsc_a_at">Changes in patient-reported outcomes during the SENSE Trial: first-line treatment with 2 NRTIs plus etravirine or efavirenz</a><div class="gs_gray">C Orkin, A Streinu-Cercel, S Erscoiu, M Nelson, A Hill, Y van Delft, ...</div><div class="gs_gray">ANTIVIRAL THERAPY 15 (8), A69-A69<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:LI9QrySNdTsC" class="gsc_a_at">Outcomes of second-line ritonavir-boosted protease inhibitor (PI/r)-based ART after failure of a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART</a><div class="gs_gray">L Waters, D Asboe, A Pozniak, L Bansi, C Orkin, E Smit, E Fearnhill, ...</div><div class="gs_gray">HIV MED 11, 3-4<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:BqipwSGYUEgC" class="gsc_a_at">Switching from Kivexa+ efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study</a><div class="gs_gray">G Moyle, C Orkin, M Fisher, J Anderson, J Dhar, MH Wang, J Ewan</div><div class="gs_gray">Journal of the International AIDS Society 13 (Suppl 4), P80<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:NhqRSupF_l8C" class="gsc_a_at">An epidemiologic study to determine the prevalence of the HLA-B* 5701 allele among HIV-positive patients in Europe: PE18. 5/1</a><div class="gs_gray">C Orkin, J Wang, C Bergin, JM Molina, A Lazzarin, M Cavassini, S Esser, ...</div><div class="gs_gray">Hiv Medicine 10<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:EYYDruWGBe4C" class="gsc_a_at">P04-35. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients</a><div class="gs_gray">H Dreja, E O'Sullivan, C Pade, K Aubin, A Isaksen, C D'Souza, J Hand, ...</div><div class="gs_gray">Retrovirology 6 (3), 1-1<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:hFOr9nPyWt4C" class="gsc_a_at">P16-21. Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+ T-cell counts</a><div class="gs_gray">KC Groves, D Bibby, A Isaksen, J Deayton, J Anderson, C Orkin, AJ Stagg, ...</div><div class="gs_gray">Retrovirology 6 (3), 1-1<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:JoZmwDi-zQgC" class="gsc_a_at">Excellent immunological recovery following the intensive chemotherapy CODOX-M/IVAC, an effective therapy for HIV-associated Burkitt's lymphoma</a><div class="gs_gray">J Wilson, S Montoto, K Shaw, C Orkin, M Johnson, M Nelson, M Bower, ...</div><div class="gs_gray">HIV MEDICINE 10, 5-5<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:uLbwQdceFCQC" class="gsc_a_at">Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification</a><div class="gs_gray">X Couto-Parada, A Lee, I Ushiro-Lumb, J Anderson, G Baily, S Limb, ...</div><div class="gs_gray">Journal of the International AIDS Society 11 (1), 1-2<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:JQOojiI6XY0C" class="gsc_a_at">Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Assochited Burkitt's Lymphorna</a><div class="gs_gray">S Montoto, J Wilson, K Shaw, M Heath, A Wilson, C Orkin, C McNamara, ...</div><div class="gs_gray">BLOOD 112 (11), 1235-1236<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:pqnbT2bcN3wC" class="gsc_a_at">Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt’s Lymphoma</a><div class="gs_gray">S Montoto, J Wilson, K Shaw, M Heath, A Wilson, C Orkin, C McNamara, ...</div><div class="gs_gray">Blood, The Journal of the American Society of Hematology 112 (11), 3612-3612<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:MXK_kJrjxJIC" class="gsc_a_at">CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S ILYMPHOMA</a><div class="gs_gray">S Montoto, J Wilson, K Shaw, M Heath, A Wilson, C Orkin, C McNamara, ...</div><div class="gs_gray">HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 93, 393-393<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:YohjEiUPhakC" class="gsc_a_at">The efficacy and safety of darunavir/ritonavir (DRV/r) and etravarine (ETV) in a series of highly active anti-retroviral therapy (HAART) treatment experienced patients with or&nbsp;…</a><div class="gs_gray">R Varma, V Akyeampong, C Okoli, C Orkin</div><div class="gs_gray">Hiv Medicine 9, 20-21<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:TIZ-Mc8IlK0C" class="gsc_a_at">Frequency of N348I in diverse HIV-1 subtypes: P149</a><div class="gs_gray">K Forbes, D Bibby, D Clark, J Anderson, S Limb, S Obeyesekera, ...</div><div class="gs_gray">Hiv Medicine 9<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:XD-gHx7UXLsC" class="gsc_a_at">The efficacy and safety of Darunavir/ritonavir (DRV/r) with Etravarine (ETV) and Raltegravir (MK-0518), in combination, in a series of patients with triple class resistance to&nbsp;…</a><div class="gs_gray">R Varma, V Akyeampong, C Okoli, C Orkin</div><div class="gs_gray">Hiv Medicine 9<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:fEOibwPWpKIC" class="gsc_a_at">Retrospective descriptive cohort study of HIV/TB co-infection in a high income country and ethnically diverse urban HIV cohort 2004–07: outcomes, complications, morbidities&nbsp;…</a><div class="gs_gray">R O'Connell, R Varma, L Hijazi, S Limb, J Anderson, F Drobniewski, ...</div><div class="gs_gray">Hiv Medicine 9<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:O3NaXMp0MMsC" class="gsc_a_at">Non-Hodgkin Lymphoma-Clinical</a><div class="gs_gray">R Coutinho, M Flook, A Pria, S Gandhi, K Bailey, P Fields, K Cwynarski, ...</div><div class="gs_gray">18TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION STOCKHOLM, SWEDEN JUNE&nbsp;…<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:BrmTIyaxlBUC" class="gsc_a_at">Pharmacokinetics of a lopinavir/r (LPV/r) capsule to tablet switch when co-administered with non-nucleoside reverse transcriptase inhibitors (NNRTI), nevirapine (NVP) and&nbsp;…</a><div class="gs_gray">D Ladenheim, C Okoli, R Varma, C Orkin</div><div class="gs_gray">Hiv Medicine 8<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:08ZZubdj9fEC" class="gsc_a_at">Abacavir hypersensitivity testing: HLA-B* 57 allelic typing is necessary in an ethnically heterogeneous population P-149</a><div class="gs_gray">N Burlinson, S Hemmapour, C Orkin, P Sinnott</div><div class="gs_gray">Tissue Antigens 69 (5)<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:dfsIfKJdRG4C" class="gsc_a_at">Inter-individual variability of once daily boosted saquinavir (SQV/r)(Invirase®) in 18 HIV-1-infected patients on highly active antiretroviral therapy (HAART): P13</a><div class="gs_gray">C Okoli, D Ladenheim, R Varma, C Orkin</div><div class="gs_gray">Hiv Medicine 8<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:35r97b3x0nAC" class="gsc_a_at">Tipranavir/T20-containing salvage regimens highly effective and durable in heavily PI-treatment-experienced HIV-1-infected patients in clinical practice: P10</a><div class="gs_gray">R Gupta, C Loveday, U Kalidindi, M Lechelt, C Skinner, M Murray, ...</div><div class="gs_gray">Hiv Medicine 7<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:blknAaTinKkC" class="gsc_a_at">Tipranavir (Tip)/T-20 containing salvage regime in highly treatment experienced HIV-infected patients: P30</a><div class="gs_gray">U Kalidindi, M Lechelt, C Skinner, M Murphy, Y Gilleece, G Baily, ...</div><div class="gs_gray">Hiv Medicine 6<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:4JMBOYKVnBMC" class="gsc_a_at">Audit of virological and immunological outcome of a patient group on treatment with Tenofovir (TDF) and didanosine (ddI) plus Efavirenz (EFV) or Nevirapine (NVP): PA14</a><div class="gs_gray">K Forbes, M Murphy, C Skinner, G Baily, Y Gilleece, C Orkin</div><div class="gs_gray">Hiv Medicine 6, 58-59<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:oNZyr7d5Mn4C" class="gsc_a_at">Rituximab as retreatment for rituximab pretreated HIV-associated</a><div class="gs_gray">M Bower, T Powles, J Stebbing, S Montoto, M Nelson, B Gazzard, C Orkin, ...</div><div class="gs_gray">Annu Rev Cell Dev Biol 20, 781-810<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:g5m5HwL7SMYC" class="gsc_a_at">The association between nevirapine and abnormal liver function tests in a cohort setting: P11</a><div class="gs_gray">G Matthews, Y Gilleece, C Orkin, S Mandalia, G Salomov, M Nelson, ...</div><div class="gs_gray">Hiv Medicine 4 (3), 212-213<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:W5xh706n7nkC" class="gsc_a_at">Clinical issues</a><div class="gs_gray">D Hicks, SE Barton, C Orkin, B Gazzard</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:vRqMK49ujn8C" class="gsc_a_at">Both stavudine and zidovudine-based therapy is associated with gluteal subcutaneous adipocyte depletion</a><div class="gs_gray">J Morlese, N Qazi, C Orkin, D Datta, R Abbas, B Gazzard, N Francis, ...</div><div class="gs_gray">ANTIVIRAL THERAPY 7 (3), L22-L22<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:Dip1O2bNi0gC" class="gsc_a_at">Estimation of the prevalence of Delta F508 heterozygosity in HIV infected patients with Pseudomonas aeruginosa pulmonary infection</a><div class="gs_gray">C Orkin, J Morlese, A Buckingham, B Gazzard, D Asboe</div><div class="gs_gray">AIDS 14, S133-S133<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:PYBJJbyH-FwC" class="gsc_a_at">SHORT REPORT High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?</a><div class="gs_gray">C ORKIN, E LEACH, S FLANAGAN, E WALLIS, M RUF, GR FOSTER, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:nRpfm8aw39MC" class="gsc_a_at">Published Ahead-of-Print-Last Updated: December 16, 2020</a><div class="gs_gray">M Muchengeti, J Bohlius, TG Dhokotera, J Thornhill, C Orkin, A Waltmann, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:sJsF-0ZLhtgC" class="gsc_a_at">Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat&nbsp;…</a><div class="gs_gray">E Negredo, J Gathe, MD Erika Van Landuyt, JR Arribas, J Bailey, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:artPoR2Yc-kC" class="gsc_a_at">Once-Daily Dolutegravir Is Non-inferior to Raltegravir in Antiretroviral Naive Adults with HIV-1 Infection: 48 Week Results from the Randomized, Double-Blind Study SPRING-2</a><div class="gs_gray">F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Orkin, M Bloch, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:lvd772isFD0C" class="gsc_a_at">Study 1490 Results: HIV/HBV-Coinfected Treatment-Naïve Participants</a><div class="gs_gray">JK Rockstroh, PE Sax, ES Daar, S Walmsley, K Workowski, C Orkin, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:yMeIxYmEMEAC" class="gsc_a_at">Estimated glomerular filtration rate (eGFR) Slopes on Tenofovir Alafenamide (ESTA)</a><div class="gs_gray">F Ibrahim, L Campbell, A Bailey, S Stockwell, L Waters, C Orkin, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:HIFyuExEbWQC" class="gsc_a_at">or Low Baseline CD4 Count in 2 Phase 3 Randomized, Controlled Clinical Trials</a><div class="gs_gray">D Podzamczer, HJ Stellbrink, C Orkin, A Pozniak, J Arribas, E Koenig, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:OTTXONDVkokC" class="gsc_a_at">Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort</a><div class="gs_gray">J Hoy, E Florence, D Sedlacek, HJ Stellbrink, V Uzdaviniene, J Tomazic, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:5qfkUJPXOUwC" class="gsc_a_at">HIV transmission, the law and the work of the clinical team, 2010.</a><div class="gs_gray">M Poulton, J Anderson, Y Azad, J Chalmers, AM Geretti, M Nelson, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:UHK10RUVsp4C" class="gsc_a_at">HIV Transmission, the Law and the Work of the Clinical Team, January 2013.</a><div class="gs_gray">M Poulton, J Anderson, Y Azad, J Chalmers, AM Geretti, M Nelson, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:a0OBvERweLwC" class="gsc_a_at">Characterisation of V3 Envelope Determinants and their Correlation with Co-receptor Use from a Cohort of East London Patients Infected with HIV-1 Clade CRF02_AG</a><div class="gs_gray">R D’Amico, H Dreja, K Aubin, C Orkin, J Hand, C DeSouza, M Dittmar, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:isC4tDSrTZIC" class="gsc_a_at">Outcomes of second line antiretroviral therapy (ART) when switching from non-nucleoside reverse transcriptase inhibitor (NNRTI) to ritonavir-boosted protease inhibitor (PI/r).</a><div class="gs_gray">L Waters, D Asboe, A Pozniak, L Bansi, E Smit, C Orkin, E Fearnhill, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:bEWYMUwI8FkC" class="gsc_a_at">Cardiovascular Disease Risk Assessments and Fasting Lipid Changes in Virologically Suppressed Patients Randomized to Switch to Tenofovir Alafenamide versus Continuing Tenofovir&nbsp;…</a><div class="gs_gray">C Orkin, F Castelli, Y Yazdanpanah, J Rockstroh, C Brinson, G DiPerri, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=OB_eiO0AAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=OB_eiO0AAAAJ:qUcmZB5y_30C" class="gsc_a_at">Nick Freemantle, and Thomas Strack 1059 The Catch-22 of appraisals on the quality of observational studies</a><div class="gs_gray">RHH Groenwold, MM Rovers, T Shamliyan, RL Kane, S Dickinson, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr></tbody></table><div id="gsc_a_sp" class=""></div><div id="gsc_a_err" class="gs_alrt">The system can't perform the operation now. Try again later.</div></div><div id="gsc_lwp"><span id="gsc_a_nn">Articles 1–388</span><div id="gsc_bpf"><button type="button" id="gsc_bpf_more" class="gs_btnPD gs_in_ib gs_btn_flat gs_btn_lrge gs_btn_lsu" disabled=""><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Show more</span></span></button></div></div></form></div></div></div></div><div id="gs_ftr_sp" role="presentation"></div><div id="gs_ftr" role="contentinfo"><div id="gs_ftr_rt"><a href="/intl/en/scholar/about.html">Help</a><a href="//www.google.com/intl/en/policies/privacy/">Privacy</a><a href="//www.google.com/intl/en/policies/terms/">Terms</a></div></div></div></body></html>